OA16316A - Oxadiazole inhibitors of leukotriene production - Google Patents
Oxadiazole inhibitors of leukotriene production Download PDFInfo
- Publication number
- OA16316A OA16316A OA1201300028 OA16316A OA 16316 A OA16316 A OA 16316A OA 1201300028 OA1201300028 OA 1201300028 OA 16316 A OA16316 A OA 16316A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- phenyl
- methyl
- oxadiazol
- ethyl
- Prior art date
Links
- 150000002617 leukotrienes Chemical class 0.000 title description 19
- 230000002401 inhibitory effect Effects 0.000 title description 13
- 239000003112 inhibitor Substances 0.000 title description 9
- 238000004519 manufacturing process Methods 0.000 title description 5
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 193
- 239000011780 sodium chloride Substances 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- -1 -O-benzyl Chemical group 0.000 claims description 126
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 100
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- 239000001257 hydrogen Substances 0.000 claims description 39
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 35
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 33
- 125000000623 heterocyclic group Chemical group 0.000 claims description 29
- 150000002431 hydrogen Chemical group 0.000 claims description 24
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 22
- 125000004043 oxo group Chemical group O=* 0.000 claims description 22
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 21
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- 125000004193 piperazinyl group Chemical group 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000002757 morpholinyl group Chemical group 0.000 claims description 15
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 125000003386 piperidinyl group Chemical group 0.000 claims description 14
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 13
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000003282 alkyl amino group Chemical group 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 150000002825 nitriles Chemical class 0.000 claims description 10
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 10
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- 125000002883 imidazolyl group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 9
- 229910052717 sulfur Chemical group 0.000 claims description 9
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 8
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000005842 heteroatoms Chemical group 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000003566 oxetanyl group Chemical group 0.000 claims description 5
- 239000001301 oxygen Chemical group 0.000 claims description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 239000011593 sulfur Chemical group 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
- IIVWHGMLFGNMOW-UHFFFAOYSA-N 2-methylpropane Chemical group C[C](C)C IIVWHGMLFGNMOW-UHFFFAOYSA-N 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 121
- 201000010099 disease Diseases 0.000 abstract description 20
- 238000000034 method Methods 0.000 abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 164
- 239000000203 mixture Substances 0.000 description 130
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 125
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 90
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 88
- 230000015572 biosynthetic process Effects 0.000 description 86
- 238000003786 synthesis reaction Methods 0.000 description 85
- 230000002194 synthesizing Effects 0.000 description 85
- 238000006243 chemical reaction Methods 0.000 description 83
- 239000000243 solution Substances 0.000 description 83
- 235000019439 ethyl acetate Nutrition 0.000 description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 71
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 67
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 63
- 239000011541 reaction mixture Substances 0.000 description 61
- 238000003818 flash chromatography Methods 0.000 description 56
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 52
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 46
- 239000003153 chemical reaction reagent Substances 0.000 description 40
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 40
- 229910052681 coesite Inorganic materials 0.000 description 37
- 229910052906 cristobalite Inorganic materials 0.000 description 37
- 229910052904 quartz Inorganic materials 0.000 description 37
- 229910052682 stishovite Inorganic materials 0.000 description 37
- 229910052905 tridymite Inorganic materials 0.000 description 37
- 239000007787 solid Substances 0.000 description 34
- 239000012267 brine Substances 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000000377 silicon dioxide Substances 0.000 description 30
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 29
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 26
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 26
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- 101710009555 ALOX5AP Proteins 0.000 description 21
- 102100006689 ALOX5AP Human genes 0.000 description 21
- 239000002253 acid Substances 0.000 description 21
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 21
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 21
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 16
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 239000007832 Na2SO4 Substances 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 14
- 239000011734 sodium Substances 0.000 description 14
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 229910000029 sodium carbonate Inorganic materials 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 238000007792 addition Methods 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 239000003480 eluent Substances 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- BPQVMIDUTRJYSC-UHFFFAOYSA-N 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN=C(N)N=C1 BPQVMIDUTRJYSC-UHFFFAOYSA-N 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 8
- 108010093579 Arachidonate 5-Lipoxygenase Proteins 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-Bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 8
- 239000003643 water by type Substances 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 7
- 125000004429 atoms Chemical group 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 6
- 208000006673 Asthma Diseases 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atoms Chemical group C* 0.000 description 6
- 230000000875 corresponding Effects 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 5
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 5
- VNYSSYRCGWBHLG-AMOLWHMGSA-N Leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 5
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 5
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical group CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 5
- 201000001320 atherosclerosis Diseases 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000008079 hexane Substances 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000546 pharmaceutic aid Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrugs Drugs 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000003039 volatile agent Substances 0.000 description 5
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 description 4
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 description 4
- YNHIGQDRGKUECZ-UHFFFAOYSA-L Bis(triphenylphosphine)palladium(II) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 208000008787 Cardiovascular Disease Diseases 0.000 description 4
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 4
- 208000010125 Myocardial Infarction Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004027 cells Anatomy 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Substances CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 230000001404 mediated Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 230000002685 pulmonary Effects 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WWRCMNKATXZARA-UHFFFAOYSA-N 1-Isopropyl-2-methylbenzene Chemical compound CC(C)C1=CC=CC=C1C WWRCMNKATXZARA-UHFFFAOYSA-N 0.000 description 3
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 229940114079 Arachidonic Acid Drugs 0.000 description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N Arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 230000003143 atherosclerotic Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000003176 fibrotic Effects 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000004559 haa Nutrition 0.000 description 3
- 235000009424 haa Nutrition 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 230000002757 inflammatory Effects 0.000 description 3
- 125000002346 iodo group Chemical group I* 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229940011051 isopropyl acetate Drugs 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 3
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 3
- ZUVAACFIEPYYOP-UHFFFAOYSA-N methoxycyclopropane Chemical compound COC1CC1 ZUVAACFIEPYYOP-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- LKBDTZLABVUDEA-GFCCVEGCSA-N (2R)-2-(4-bromophenyl)-2-cyclopropylpropanenitrile Chemical compound C1([C@](C#N)(C)C=2C=CC(Br)=CC=2)CC1 LKBDTZLABVUDEA-GFCCVEGCSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-N,N-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 2
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- KRRTXVSBTPCDOS-UHFFFAOYSA-N 5-bromopyrazin-2-amine Chemical compound NC1=CN=C(Br)C=N1 KRRTXVSBTPCDOS-UHFFFAOYSA-N 0.000 description 2
- 101700025839 APOE Proteins 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N Bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102100017376 LTA4H Human genes 0.000 description 2
- OTZRAYGBFWZKMX-JUDRUQEKSA-N LTE4 Chemical compound CCCCCC=CCC=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O OTZRAYGBFWZKMX-JUDRUQEKSA-N 0.000 description 2
- UFPQIRYSPUYQHK-WAQVJNLQSA-N Leukotriene A4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(O)=O UFPQIRYSPUYQHK-WAQVJNLQSA-N 0.000 description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N Leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 2
- SRTHRWZAMDZJOS-UHFFFAOYSA-N Lithium hydride Chemical compound [H-].[Li+] SRTHRWZAMDZJOS-UHFFFAOYSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 229910002666 PdCl2 Inorganic materials 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N Trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N Trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- GTLDTDOJJJZVBW-UHFFFAOYSA-N Zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 101700070309 apoeb Proteins 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000000271 cardiovascular Effects 0.000 description 2
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 200000000018 inflammatory disease Diseases 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 2
- 125000004430 oxygen atoms Chemical group O* 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- CCRMAATUKBYMPA-UHFFFAOYSA-N trimethyltin Chemical compound C[Sn](C)C.C[Sn](C)C CCRMAATUKBYMPA-UHFFFAOYSA-N 0.000 description 2
- MEFKFJOEVLUFAY-UHFFFAOYSA-N (2,2,2-trichloroacetyl) 2,2,2-trichloroacetate Chemical compound ClC(Cl)(Cl)C(=O)OC(=O)C(Cl)(Cl)Cl MEFKFJOEVLUFAY-UHFFFAOYSA-N 0.000 description 1
- LCCZTROJRJFXNV-UHFFFAOYSA-N (2,6-difluoropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CC=C(F)N=C1F LCCZTROJRJFXNV-UHFFFAOYSA-N 0.000 description 1
- BWRWNUQAQPAYCK-RXMQYKEDSA-N (3R)-3-methoxypyrrolidine Chemical compound CO[C@@H]1CCNC1 BWRWNUQAQPAYCK-RXMQYKEDSA-N 0.000 description 1
- XIEMSKJTCLSVOS-HXBUSHRASA-N (3S)-1-[3-[1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]piperidin-3-ol Chemical compound N=1OC(N2C[C@@H](O)CCC2)=NC=1C(C=1C=CC(=CC=1)C=1C=NC(N)=NC=1)(C)C1CC1 XIEMSKJTCLSVOS-HXBUSHRASA-N 0.000 description 1
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- AHFYHVMKWIXPRN-UHFFFAOYSA-N 1,2-dimethyl-1$l^{3}-silinane Chemical compound CC1CCCC[Si]1C AHFYHVMKWIXPRN-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-Amino-2-propanol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- LTMJLQVOVVXULP-HSZRJFAPSA-N 1-[3-[(1S)-1-[4-(6-aminopyridin-3-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]piperidin-4-ol Chemical compound C1([C@](C)(C=2N=C(ON=2)N2CCC(O)CC2)C=2C=CC(=CC=2)C=2C=NC(N)=CC=2)CC1 LTMJLQVOVVXULP-HSZRJFAPSA-N 0.000 description 1
- KDLFPOINMLXLDB-UHFFFAOYSA-N 1-[3-[1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]azetidin-3-ol Chemical compound N=1OC(N2CC(O)C2)=NC=1C(C=1C=CC(=CC=1)C=1C=NC(N)=NC=1)(C)C1CC1 KDLFPOINMLXLDB-UHFFFAOYSA-N 0.000 description 1
- AAGDEJKTSVYQLC-UHFFFAOYSA-N 1-[3-[2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutan-2-yl]-1,2,4-oxadiazol-5-yl]azetidin-3-ol Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1N1CC(O)C1 AAGDEJKTSVYQLC-UHFFFAOYSA-N 0.000 description 1
- LVNCLSYCKRUBJV-UHFFFAOYSA-N 1-[3-[2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutan-2-yl]-1,2,4-oxadiazol-5-yl]piperidin-4-ol Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1N1CCC(O)CC1 LVNCLSYCKRUBJV-UHFFFAOYSA-N 0.000 description 1
- JJYBAICQGZQRFJ-UHFFFAOYSA-N 1-[3-[2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutan-2-yl]-1,2,4-oxadiazol-5-yl]piperidine-4-carboxamide Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1N1CCC(C(N)=O)CC1 JJYBAICQGZQRFJ-UHFFFAOYSA-N 0.000 description 1
- ADEWWZBXWCBWLE-UHFFFAOYSA-N 1-[4-[3-[2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutan-2-yl]-1,2,4-oxadiazol-5-yl]piperazin-1-yl]ethanone Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1N1CCN(C(C)=O)CC1 ADEWWZBXWCBWLE-UHFFFAOYSA-N 0.000 description 1
- WPWIFIPQWXVLAL-UHFFFAOYSA-N 1-[4-[3-[2-[4-(2-aminopyrimidin-5-yl)phenyl]propan-2-yl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-2-methylpropan-2-ol Chemical compound C1=NN(CC(C)(O)C)C=C1C1=NC(C(C)(C)C=2C=CC(=CC=2)C=2C=NC(N)=NC=2)=NO1 WPWIFIPQWXVLAL-UHFFFAOYSA-N 0.000 description 1
- LXQMHOKEXZETKB-UHFFFAOYSA-N 1-amino-2-methylpropan-2-ol Chemical compound CC(C)(O)CN LXQMHOKEXZETKB-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- KXODEDIOXQDDRS-UHFFFAOYSA-N 1-ethoxycarbonylcyclohexane-1-carboxylic acid Chemical compound CCOC(=O)C1(C(O)=O)CCCCC1 KXODEDIOXQDDRS-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- FJMQXAJQFNWGKL-UHFFFAOYSA-N 2,3-dihydro-1$l^{6}-benzothiepine 1,1-dioxide Chemical compound O=S1(=O)CCC=CC2=CC=CC=C12 FJMQXAJQFNWGKL-UHFFFAOYSA-N 0.000 description 1
- ZHXUWDPHUQHFOV-UHFFFAOYSA-N 2,5-dibromopyridine Chemical compound BrC1=CC=C(Br)N=C1 ZHXUWDPHUQHFOV-UHFFFAOYSA-N 0.000 description 1
- LKBDTZLABVUDEA-UHFFFAOYSA-N 2-(4-bromophenyl)-2-cyclopropylpropanenitrile Chemical compound C=1C=C(Br)C=CC=1C(C#N)(C)C1CC1 LKBDTZLABVUDEA-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-Bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- IVFORTAPFPHBDX-QFIPXVFZSA-N 2-[4-[3-[(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]acetic acid Chemical compound C1([C@@](C)(C=2N=C(ON=2)C2=CN(CC(O)=O)N=C2)C=2C=CC(=CC=2)C=2C=NC(N)=NC=2)CC1 IVFORTAPFPHBDX-QFIPXVFZSA-N 0.000 description 1
- XZNTUCFBQGMTJU-VWLOTQADSA-N 2-[4-[3-[(1R)-1-[4-(5-amino-6-methylpyrazin-2-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-N,N-dimethylacetamide Chemical compound C1=NN(CC(=O)N(C)C)C=C1C1=NC([C@](C)(C2CC2)C=2C=CC(=CC=2)C=2N=C(C)C(N)=NC=2)=NO1 XZNTUCFBQGMTJU-VWLOTQADSA-N 0.000 description 1
- KXQKCPIYJPBSDQ-MHZLTWQESA-N 2-[4-[3-[(1R)-1-cyclopropyl-1-[4-[2-(propan-2-ylamino)pyrimidin-5-yl]phenyl]ethyl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-N,N-dimethylacetamide Chemical compound C1=NC(NC(C)C)=NC=C1C1=CC=C([C@@](C)(C2CC2)C=2N=C(ON=2)C2=CN(CC(=O)N(C)C)N=C2)C=C1 KXQKCPIYJPBSDQ-MHZLTWQESA-N 0.000 description 1
- QOACSGKDKTVKEU-UHFFFAOYSA-N 2-[4-[3-[2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutan-2-yl]-1,2,4-oxadiazol-5-yl]piperazin-1-yl]ethanol Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1N1CCN(CCO)CC1 QOACSGKDKTVKEU-UHFFFAOYSA-N 0.000 description 1
- ZJNQCVXHXNHMJS-VWLOTQADSA-N 2-[[5-[3-[(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]pyrazin-2-yl]amino]-2-methylpropan-1-ol Chemical compound C1=NC(NC(C)(CO)C)=CN=C1C1=NC([C@](C)(C2CC2)C=2C=CC(=CC=2)C=2C=NC(N)=NC=2)=NO1 ZJNQCVXHXNHMJS-VWLOTQADSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- 125000001627 3 membered heterocyclic group Chemical group 0.000 description 1
- PAVNZLVXYJDFNR-UHFFFAOYSA-N 3,3-dimethyloxane-2,6-dione Chemical compound CC1(C)CCC(=O)OC1=O PAVNZLVXYJDFNR-UHFFFAOYSA-N 0.000 description 1
- RPYNKMZXEALWOJ-UHFFFAOYSA-N 3-(dichloromethyl)pyridine Chemical compound ClC(Cl)C1=CC=CN=C1 RPYNKMZXEALWOJ-UHFFFAOYSA-N 0.000 description 1
- CKQVPPGFGOPDIB-UHFFFAOYSA-N 3-[2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutan-2-yl]-N-(2-methoxyethyl)-1,2,4-oxadiazol-5-amine Chemical compound O1C(NCCOC)=NC(C(C)(C(C)C)C=2C=CC(=CC=2)C=2C=NC(N)=NC=2)=N1 CKQVPPGFGOPDIB-UHFFFAOYSA-N 0.000 description 1
- ANSLCZIPBJXBLH-UHFFFAOYSA-N 3-[2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutan-2-yl]-N-ethyl-1,2,4-oxadiazol-5-amine Chemical compound O1C(NCC)=NC(C(C)(C(C)C)C=2C=CC(=CC=2)C=2C=NC(N)=NC=2)=N1 ANSLCZIPBJXBLH-UHFFFAOYSA-N 0.000 description 1
- SPSSIVKMFBQIHX-UHFFFAOYSA-N 3-[2-[4-(5-methoxypyridin-3-yl)phenyl]-3-methylbutan-2-yl]-5-pyrazin-2-yl-1,2,4-oxadiazole Chemical compound COC1=CN=CC(C=2C=CC(=CC=2)C(C)(C(C)C)C=2N=C(ON=2)C=2N=CC=NC=2)=C1 SPSSIVKMFBQIHX-UHFFFAOYSA-N 0.000 description 1
- KBEIFKMKVCDETC-UHFFFAOYSA-N 3-iodooxetane Chemical compound IC1COC1 KBEIFKMKVCDETC-UHFFFAOYSA-N 0.000 description 1
- GICMHQJTKXNMGB-UHFFFAOYSA-N 4-(5-methoxy-1-benzofuran-2-yl)aniline Chemical compound C=1C2=CC(OC)=CC=C2OC=1C1=CC=C(N)C=C1 GICMHQJTKXNMGB-UHFFFAOYSA-N 0.000 description 1
- AMBPTXABQHXYPZ-UHFFFAOYSA-N 4-[3-[2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutan-2-yl]-1,2,4-oxadiazol-5-yl]-1-methylpiperazin-2-one Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1N1CCN(C)C(=O)C1 AMBPTXABQHXYPZ-UHFFFAOYSA-N 0.000 description 1
- DLVUNNJYFVYJOH-UHFFFAOYSA-N 4-[3-[2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutan-2-yl]-1,2,4-oxadiazol-5-yl]-N,N-dimethylpiperazine-1-carboxamide Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1N1CCN(C(=O)N(C)C)CC1 DLVUNNJYFVYJOH-UHFFFAOYSA-N 0.000 description 1
- UBNQGQIFYAIMAO-UHFFFAOYSA-N 4-fluoropyrimidin-2-amine Chemical compound NC1=NC=CC(F)=N1 UBNQGQIFYAIMAO-UHFFFAOYSA-N 0.000 description 1
- DXFMVOIWKXLAQF-UHFFFAOYSA-N 4-methoxypyridine-3-carboxylic acid Chemical compound COC1=CC=NC=C1C(O)=O DXFMVOIWKXLAQF-UHFFFAOYSA-N 0.000 description 1
- YFTAUNOLAHRUIE-UHFFFAOYSA-N 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N)N=C1 YFTAUNOLAHRUIE-UHFFFAOYSA-N 0.000 description 1
- MVYJDWRDPGXBJR-UHFFFAOYSA-N 5-[3-[2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutan-2-yl]-1,2,4-oxadiazol-5-yl]pyridine-2-carboxamide Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C1=CC=C(C(N)=O)N=C1 MVYJDWRDPGXBJR-UHFFFAOYSA-N 0.000 description 1
- SSJCEODENLRLQW-QHCPKHFHSA-N 5-[4-[(1R)-1-cyclopropyl-1-[5-(1-methylpyrazol-4-yl)-1,2,4-oxadiazol-3-yl]ethyl]phenyl]-3-methylpyridin-2-amine Chemical compound N1=C(N)C(C)=CC(C=2C=CC(=CC=2)[C@@](C)(C2CC2)C=2N=C(ON=2)C2=CN(C)N=C2)=C1 SSJCEODENLRLQW-QHCPKHFHSA-N 0.000 description 1
- WPPYCUHCEJKRHV-VWLOTQADSA-N 5-[4-[(1R)-1-cyclopropyl-1-[5-(5-piperazin-1-ylpyrazin-2-yl)-1,2,4-oxadiazol-3-yl]ethyl]phenyl]pyrazin-2-amine Chemical compound C1([C@@](C)(C=2N=C(ON=2)C=2N=CC(=NC=2)N2CCNCC2)C=2C=CC(=CC=2)C=2N=CC(N)=NC=2)CC1 WPPYCUHCEJKRHV-VWLOTQADSA-N 0.000 description 1
- GIAKDUVHUCIZGM-VWLOTQADSA-N 5-[4-[(1R)-1-cyclopropyl-1-[5-(5-piperazin-1-ylpyrazin-2-yl)-1,2,4-oxadiazol-3-yl]ethyl]phenyl]pyrimidin-2-amine Chemical compound C1([C@@](C)(C=2N=C(ON=2)C=2N=CC(=NC=2)N2CCNCC2)C=2C=CC(=CC=2)C=2C=NC(N)=NC=2)CC1 GIAKDUVHUCIZGM-VWLOTQADSA-N 0.000 description 1
- XGNYEXFSTQYDHC-SANMLTNESA-N 5-[4-[(1R)-1-cyclopropyl-1-[5-[1-(2-pyrrolidin-1-ylethyl)pyrazol-4-yl]-1,2,4-oxadiazol-3-yl]ethyl]phenyl]pyrimidin-2-amine Chemical compound C1([C@@](C)(C=2N=C(ON=2)C2=CN(CCN3CCCC3)N=C2)C=2C=CC(=CC=2)C=2C=NC(N)=NC=2)CC1 XGNYEXFSTQYDHC-SANMLTNESA-N 0.000 description 1
- WTWPAJHLGXZJNO-QGZVFWFLSA-N 5-[4-[(1R)-2,2-dimethyl-1-[5-(1-methylpyrazol-4-yl)-1,2,4-oxadiazol-3-yl]propyl]phenyl]pyrimidin-2-amine Chemical compound C1=NN(C)C=C1C1=NC([C@@H](C=2C=CC(=CC=2)C=2C=NC(N)=NC=2)C(C)(C)C)=NO1 WTWPAJHLGXZJNO-QGZVFWFLSA-N 0.000 description 1
- XZHYHEBYHZWYRX-OAQYLSRUSA-N 5-[4-[(2R)-3-methyl-2-[5-(1-methylpyrazol-4-yl)-1,2,4-oxadiazol-3-yl]butan-2-yl]phenyl]pyrimidin-2-amine Chemical compound N=1C([C@](C)(C(C)C)C=2C=CC(=CC=2)C=2C=NC(N)=NC=2)=NOC=1C=1C=NN(C)C=1 XZHYHEBYHZWYRX-OAQYLSRUSA-N 0.000 description 1
- PNISQLPSKBGABD-UHFFFAOYSA-N 5-[4-[1-cyclopropyl-1-[5-(4-methylsulfonylpiperidin-1-yl)-1,2,4-oxadiazol-3-yl]ethyl]phenyl]pyrimidin-2-amine Chemical compound N=1OC(N2CCC(CC2)S(C)(=O)=O)=NC=1C(C=1C=CC(=CC=1)C=1C=NC(N)=NC=1)(C)C1CC1 PNISQLPSKBGABD-UHFFFAOYSA-N 0.000 description 1
- OXUBLVRCCJXXEB-UHFFFAOYSA-N 5-[4-[1-cyclopropyl-1-[5-[1-(oxetan-3-yl)imidazol-4-yl]-1,2,4-oxadiazol-3-yl]ethyl]phenyl]pyrimidin-2-amine Chemical compound N=1OC(C=2N=CN(C=2)C2COC2)=NC=1C(C=1C=CC(=CC=1)C=1C=NC(N)=NC=1)(C)C1CC1 OXUBLVRCCJXXEB-UHFFFAOYSA-N 0.000 description 1
- NCZHUVWAELKGKY-UHFFFAOYSA-N 5-[4-[3-methyl-2-(5-piperidin-2-yl-1,2,4-oxadiazol-3-yl)butan-2-yl]phenyl]pyrimidin-2-amine Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C1CCCCN1 NCZHUVWAELKGKY-UHFFFAOYSA-N 0.000 description 1
- MJBPEFDFTIPDHN-UHFFFAOYSA-N 5-[4-[3-methyl-2-(5-pyridin-3-yl-1,2,4-oxadiazol-3-yl)butan-2-yl]phenyl]pyrimidin-2-amine Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C1=CC=CN=C1 MJBPEFDFTIPDHN-UHFFFAOYSA-N 0.000 description 1
- DFVILTXNRGZWJD-UHFFFAOYSA-N 5-[4-[3-methyl-2-[5-(1,3-thiazol-5-yl)-1,2,4-oxadiazol-3-yl]butan-2-yl]phenyl]pyrimidin-2-amine Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C1=CN=CS1 DFVILTXNRGZWJD-UHFFFAOYSA-N 0.000 description 1
- UUOYASFAZDXFTA-UHFFFAOYSA-N 5-[4-[3-methyl-2-[5-(1-methylcyclopropyl)-1,2,4-oxadiazol-3-yl]butan-2-yl]phenyl]pyrimidin-2-amine Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C1(C)CC1 UUOYASFAZDXFTA-UHFFFAOYSA-N 0.000 description 1
- YGDUMGMHNAABRG-UHFFFAOYSA-N 5-[4-[3-methyl-2-[5-(1H-pyrazol-5-yl)-1,2,4-oxadiazol-3-yl]butan-2-yl]phenyl]pyrimidin-2-amine Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C1=CC=NN1 YGDUMGMHNAABRG-UHFFFAOYSA-N 0.000 description 1
- SUNNVYJALWHELR-UHFFFAOYSA-N 5-[4-[3-methyl-2-[5-(3-methylsulfonylphenyl)-1,2,4-oxadiazol-3-yl]butan-2-yl]phenyl]pyrimidin-2-amine Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C1=CC=CC(S(C)(=O)=O)=C1 SUNNVYJALWHELR-UHFFFAOYSA-N 0.000 description 1
- TWOPBNAZLXLDLQ-UHFFFAOYSA-N 5-[4-[3-methyl-2-[5-(4-methyl-1,3-thiazol-5-yl)-1,2,4-oxadiazol-3-yl]butan-2-yl]phenyl]pyrimidin-2-amine Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C=1SC=NC=1C TWOPBNAZLXLDLQ-UHFFFAOYSA-N 0.000 description 1
- SCJKWODEODURAI-UHFFFAOYSA-N 5-[4-[3-methyl-2-[5-(4-propan-2-ylpiperazin-1-yl)-1,2,4-oxadiazol-3-yl]butan-2-yl]phenyl]pyrimidin-2-amine Chemical compound C1CN(C(C)C)CCN1C1=NC(C(C)(C(C)C)C=2C=CC(=CC=2)C=2C=NC(N)=NC=2)=NO1 SCJKWODEODURAI-UHFFFAOYSA-N 0.000 description 1
- OXJKZJKWLOZRGW-UHFFFAOYSA-N 5-[4-[3-methyl-2-[5-[4-(methylamino)piperidin-1-yl]-1,2,4-oxadiazol-3-yl]butan-2-yl]phenyl]pyrimidin-2-amine Chemical compound C1CC(NC)CCN1C1=NC(C(C)(C(C)C)C=2C=CC(=CC=2)C=2C=NC(N)=NC=2)=NO1 OXJKZJKWLOZRGW-UHFFFAOYSA-N 0.000 description 1
- IFSRFZMFVWYOPF-UHFFFAOYSA-N 5-bromo-3-(trifluoromethyl)pyrazin-2-amine Chemical compound NC1=NC=C(Br)N=C1C(F)(F)F IFSRFZMFVWYOPF-UHFFFAOYSA-N 0.000 description 1
- QLXASFJHUCKEHU-UHFFFAOYSA-N 5-bromo-3-fluoropyridin-2-amine Chemical compound NC1=NC=C(Br)C=C1F QLXASFJHUCKEHU-UHFFFAOYSA-N 0.000 description 1
- CRVPQFAORCSDMH-UHFFFAOYSA-N 5-bromo-6-chloropyrazin-2-amine Chemical compound NC1=CN=C(Br)C(Cl)=N1 CRVPQFAORCSDMH-UHFFFAOYSA-N 0.000 description 1
- KHPPOPZLVCZUPV-UHFFFAOYSA-N 5-bromo-N-methylpyridin-2-amine Chemical compound CNC1=CC=C(Br)C=N1 KHPPOPZLVCZUPV-UHFFFAOYSA-N 0.000 description 1
- UDQGIOYIJKRLFH-UHFFFAOYSA-N 5-bromo-N-methylpyrimidin-2-amine Chemical compound CNC1=NC=C(Br)C=N1 UDQGIOYIJKRLFH-UHFFFAOYSA-N 0.000 description 1
- CDWJPISSORTFRO-UHFFFAOYSA-N 5-bromo-N-tert-butylpyrimidin-2-amine Chemical compound CC(C)(C)NC1=NC=C(Br)C=N1 CDWJPISSORTFRO-UHFFFAOYSA-N 0.000 description 1
- VNYBIBSZZDAEOK-UHFFFAOYSA-N 5-bromopyridin-3-ol Chemical compound OC1=CN=CC(Br)=C1 VNYBIBSZZDAEOK-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- UJWBLRIYPWTJBI-UHFFFAOYSA-N 6-[3-[2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutan-2-yl]-1,2,4-oxadiazol-5-yl]-1-methylpiperidin-2-one Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C1CCCC(=O)N1C UJWBLRIYPWTJBI-UHFFFAOYSA-N 0.000 description 1
- BKLJUYPLUWUEOQ-UHFFFAOYSA-N 6-bromopyridin-2-amine Chemical compound NC1=CC=CC(Br)=N1 BKLJUYPLUWUEOQ-UHFFFAOYSA-N 0.000 description 1
- UAWMVMPAYRWUFX-UHFFFAOYSA-N 6-chloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1 UAWMVMPAYRWUFX-UHFFFAOYSA-N 0.000 description 1
- 101700075029 AIFM3 Proteins 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 101000169070 ALOX5AP Proteins 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 206010051895 Acute chest syndrome Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 210000000709 Aorta Anatomy 0.000 description 1
- 208000007474 Aortic Aneurysm Diseases 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 241000287523 Ara Species 0.000 description 1
- 241001127925 Arracacha virus A Species 0.000 description 1
- 206010003441 Asbestosis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- GZUXJHMPEANEGY-UHFFFAOYSA-N Bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
- 206010006475 Bronchopulmonary dysplasia Diseases 0.000 description 1
- QNVCTIPKJFKBIX-UHFFFAOYSA-N C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C1=CNC=N1 Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C1=CNC=N1 QNVCTIPKJFKBIX-UHFFFAOYSA-N 0.000 description 1
- GZIAUQTUQUHXNU-UHFFFAOYSA-N C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C=1C=NNC=1 Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C=1C=NNC=1 GZIAUQTUQUHXNU-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000272194 Ciconiiformes Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N Cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N Cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N Dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N Dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 210000003979 Eosinophils Anatomy 0.000 description 1
- 241000490229 Eucephalus Species 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229910004542 HfN Inorganic materials 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 101710022667 LTA4H Proteins 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N Lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 210000000138 Mast Cells Anatomy 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N Methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- RDPQRQMLPLKIBG-UHFFFAOYSA-N N-(1-acetylpiperidin-4-yl)-3-[2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutan-2-yl]-1,2,4-oxadiazole-5-carboxamide Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C(=O)NC1CCN(C(C)=O)CC1 RDPQRQMLPLKIBG-UHFFFAOYSA-N 0.000 description 1
- USVVENVKYJZFMW-UHFFFAOYSA-L N-carboxylatoiminocarbamate Chemical compound [O-]C(=O)N=NC([O-])=O USVVENVKYJZFMW-UHFFFAOYSA-L 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- OSSHODZPUWXYSV-UHFFFAOYSA-N N=1OC(C2=CNN=C2)=NC=1C(C=1C=CC(=CC=1)C=1C=NC(N)=NC=1)(C)C1CCC1 Chemical compound N=1OC(C2=CNN=C2)=NC=1C(C=1C=CC(=CC=1)C=1C=NC(N)=NC=1)(C)C1CCC1 OSSHODZPUWXYSV-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- BOWYQHCFTNADQJ-UHFFFAOYSA-N OC1=CN=NO1 Chemical compound OC1=CN=NO1 BOWYQHCFTNADQJ-UHFFFAOYSA-N 0.000 description 1
- 208000001797 Obstructive Sleep Apnea Diseases 0.000 description 1
- 101710019223 PGUG_02354 Proteins 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 101700059544 PTGR1 Proteins 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N Pathocidin Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N Potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N Potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N Potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N Pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 206010051739 Pulmonary sepsis Diseases 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 235000016976 Quercus macrolepis Nutrition 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010038683 Respiratory disease Diseases 0.000 description 1
- 206010039083 Rhinitis Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N Sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N Sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N Sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N Sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N Sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N Succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 108091005711 TGF-beta receptors Proteins 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- VPAYJEUHKVESSD-UHFFFAOYSA-N Trifluoroiodomethane Chemical compound FC(F)(F)I VPAYJEUHKVESSD-UHFFFAOYSA-N 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N Trimethylsilyl chloride Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046736 Urticarias Diseases 0.000 description 1
- 208000002365 Viral Bronchiolitis Diseases 0.000 description 1
- 241001446287 Xya Species 0.000 description 1
- 108060009635 YSP2 Proteins 0.000 description 1
- 229960004764 Zafirlukast Drugs 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- 240000003584 Ziziphus jujuba Species 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 230000003435 bronchoconstrictive Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 1
- MNKYQPOFRKPUAE-UHFFFAOYSA-N chloro(triphenyl)silane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 MNKYQPOFRKPUAE-UHFFFAOYSA-N 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- 231100000406 dermatitis Toxicity 0.000 description 1
- DMJZZSLVPSMWCS-UHFFFAOYSA-N diborane Chemical compound B1[H]B[H]1 DMJZZSLVPSMWCS-UHFFFAOYSA-N 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N ethanone Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- NEVHNBRNUWSFSB-UHFFFAOYSA-N ethyl 3-chloro-2,2-dimethylpropanoate Chemical compound CCOC(=O)C(C)(C)CCl NEVHNBRNUWSFSB-UHFFFAOYSA-N 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 102000028222 human ALOX5AP protein Human genes 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 1
- 125000005298 iminyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 108010072713 leukotriene A4 hydrolase Proteins 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- AZVCGYPLLBEUNV-UHFFFAOYSA-N lithium;ethanolate Chemical compound [Li+].CC[O-] AZVCGYPLLBEUNV-UHFFFAOYSA-N 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 239000012022 methylating agents Substances 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- XMWFMEYDRNJSOO-UHFFFAOYSA-N morpholine-4-carbonyl chloride Chemical compound ClC(=O)N1CCOCC1 XMWFMEYDRNJSOO-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 101700059820 oaz-1 Proteins 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- LKZAAHOOIJSWQR-UHFFFAOYSA-R palladium;triphenylphosphanium Chemical compound [Pd].[Pd].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 LKZAAHOOIJSWQR-UHFFFAOYSA-R 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- OCFVSFVLVRNXFJ-UHFFFAOYSA-N potassium hydride Inorganic materials [H-].[K+] OCFVSFVLVRNXFJ-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- TXJKATOSKLUITR-UHFFFAOYSA-N pyrazine-2-carbonyl chloride Chemical compound ClC(=O)C1=CN=CC=N1 TXJKATOSKLUITR-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- 239000004291 sulphur dioxide Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DAIVAVZRXSYXGR-UHFFFAOYSA-N tert-butyl 2-[3-[2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutan-2-yl]-1,2,4-oxadiazol-5-yl]piperidine-1-carboxylate Chemical compound C=1C=C(C=2C=NC(N)=NC=2)C=CC=1C(C)(C(C)C)C(N=1)=NOC=1C1CCCCN1C(=O)OC(C)(C)C DAIVAVZRXSYXGR-UHFFFAOYSA-N 0.000 description 1
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000000464 thioxo group Chemical group S=* 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JKNHZOAONLKYQL-UHFFFAOYSA-K tribromoindigane Chemical compound Br[In](Br)Br JKNHZOAONLKYQL-UHFFFAOYSA-K 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
Abstract
The present invention relates to compound of formula (I) :
Description
OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION
FIELD OF THE INVENTION
This invention relates to oxadiazoles that are useful as inhibitors of five lipoxygenase activating protein (FLAP) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of leukotrienes including asthma, allergy, rheumatoid arthritis, multiple sclerosis, inflammatory pain, acute chest syndrome and cardiovascular diseases including atherosclerosis, myocardial infarction and stroke. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
BACKGROUND OF THE INVENTION
Leukotrienes (LTs) and the bîosynthetic pathway from arachidonic acid leading to their production hâve been the targets of drug discovery efforts for over twenty years. LTs are produced by several cell types including neutrophils, mast cells, eosinophils, basophîls monocytes and macrophages. The first committed step in the întracellular synthesis of LTs involves oxidation of arachidonic acid by 5-lipoxygenase (5-LO) to LTA4, a process requiring the presence of the 18 kD intégral membrane protein 5-lipoxygenase-activating protein (FLAP) (D.K. Miller et al., Nature, 1990, 343, 278-281; R.A.F. Dixon et al., Nature, 1990, 343, 282-284). Subséquent metabolism of LTA4 leads to LTB4, and the cysteînyl LTs- LTC4, LTD4 and LTE4 (B. Samuelsson, Science, 1983, 220, 568-575). The cysteînyl LTs hâve potent smooth muscle constrictîng and bronchoconstricting effects and they stimulate mucous sécrétion and vascular leakage. LTB4 is a potent chemotactîc agent for leukocytes, and stimulâtes adhesion, aggregation and enzyme release. A
Much of the early drug discovery effort in the LT area was directed towards the treatment of allergy, asthma and other inflammatory conditions. Research efforts hâve been directed towards numerous targets in the pathway including antagonîsts of LTB4 and the cysteinyl leukotrienes LTC4, LTD4 and LTE4, as well as inhibîtors of 5-lipoxygenase (55 LO), LTA4 hydrolase and inhibîtors of 5-lipoxygenase activating protein (FLAP) (R.W.
Friesen and D. Riendeau, Leukotriene Biosynthesis Inhibîtors, Ann. Rep. Med. Chem., 2005, 40, 199-214). Years of effort in the above areas hâve yielded a few marketed products for the treatment of asthma including a 5-LO inhibitor, zileuton, and LT antagonîsts, montelukast, pranlukast and zafirlukast.
More recent work has împlicated LTs in cardiovascular disease, including myocardial infarction, stroke and atherosclerosis (G. Riccioni et al., J. Leukoc. Biol., 2008, 13741378). FLAP and 5-LO were among the components of the 5-LO and LT cascade found in atherosclerotic lésions, suggesting their involvement in atherogenesis (R. Spanbroek et 15 al., Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 1238-1243). Pharmacological inhibition of
FLAP has been reported to decrease atherosclerotic lésion size in animal models. In one study, oral dosing of the FLAP inhibitor MK-886 to apoE/LDL-R double knockout mice fed a high-fat diet from 2 months of âge to 6 months led to a 56% decrease in plaque coverage in the aorta and a 43% decrease in the aortic root (J. Jawien et al., Eur. J. Clin.
Invest., 2006, 36, 141-146). This plaque effect was coupled with a decrease in plaquemacrophage content and a concomitant increase in collagen and smooth muscle content which suggests a conversion to a more stable plaque phenotype. In another study, it was reported that administration of MK-886 via infusion to ApoE xCD4dnT[3RII mice (apoE KO mice expressing a dominant-negative TGF-beta receptor which effectively removes ali TGF-beta from the system) resulted in about a 40% decrease in plaque area in the aortic root (M. Back et al., Cire. Res., 2007, 100, 946-949). The mice were only treated for four weeks after plaque growth was already somewhat mature (12 weeks) thus raising the possîbility of therapeutically treating atherosclerosis via this mechanism. In a study examining human atherosclerotic lésions, it was found that the expression of FLAP,
5-LO and LT A4 hydrolase was significantly increased compared to healthy controls (H.
Qiu et al., Proc. Natl. Acad. Sci. U.S.A., 103, 21, 8161-8166). Similar studies suggest that inhibition of the LT pathway, for example by inhibition of FLAP, would be useful for the treatment of atherosclerosis (for reviews, see M. Back Curr. Athero. Reports, 2008 10,244-251 and Curr. Pharm. Des., 2009, 15,3116-3132).
In addition to the work cited above, many other studies hâve been directed towards understandîng the biological actions of LTs and the rôle of LTs in disease. These studies hâve implicated LTs as having a possible rôle in numerous diseases or conditions (for a review, see M. Peters-Golden and W.R. Henderson, Jr., M.D., N. Engl. J. Med., 2007, 357,1841-1854). In addition to the spécifie diseases cited above, LTs hâve been implicated as having a possible rôle in numerous allergie, pulmonary, fibrotic, inflammatory and cardiovascular diseases, as well as cancer. Inhibition of FLAP is also reported to be useful for treating rénal diseases such as diabetes-induced proteinuria (see for example J. M. Valdivieso et al., Journal of Nephrology, 2003, 16, 85-94 and A Montera et al., Journal of Nephrology, 2003, 16, 682-690).
A number of FLAP inhîbitors hâve been reported in the scientific literature (see for example J.F. Evans et al., Trends in Pharmacological Sciences, 2008, 72-78) and in U.S. patents. Some hâve been evaluated in clinîcal trials for asthma, including MK-886, MK591, and BAY X1005, also known as DG-031. More recently, the FLAP inhibitor AM103 (J.H. Hutchînson et al., J. Med. Chem. 52, 5803-5815) has been evaluated in clinîcal trials, based on its anti-inflammatory properties (D.S. Lorrain et al., J. Pharm. Exp. Ther., 2009, DOI: 10.1124/jpet. 109.158089). Subsequently, it was replaced by the back-up compound AM-803 (GSK-2190915) for the treatment of respiratory diseases. DG-031 has also been in clinîcal trials to evaluate its effect on biomarkers for myocardial infarction risk and showed a dose-dependent suppression of several biomarkers for the disease (H. Hakonarson et al., JAMA, 2005, 293, 2245-2256). MK.-591 was shown in a clinîcal trial to reduce proteinuria in human glomerulonephritis (see for example A. Guash et al., Kidney International, 1999, 56, 291-267).
However, to date, no FLAP inhibitor has been approved as a marketed drug. S
BRIEF SUMMARY OF THE INVENTION
The présent invention provides novel compounds which inhibit 5-lipoxygenase activating protein (FLAP) and are thus useful for treating a variety of dîseases and disorders that are mediated or sustained through the activity of leukotrienes, including allergie, pulmonary, fîbrotic, inflammatory and cardiovascular dîseases and cancer. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various dîseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
DETAILED DESCRIPTION OF THE INVENTION
In its first broadest embodiment, the présent invention relates to a cornpound of formula
I:
I wherein:
R1 and R2 are each independently hydrogen, Ci.7 alkyl or Cj.io carbocycle, with the proviso that both R1 and R2 are not hydrogen;
R3isa5-ll membered heteroaryl ring containing one to three heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl ring is optionally independently substituted with one to three groups selected from C|.s alkyl optionally substituted with one to three halogen atoms, Ci_s alkoxy, C1.3 hydroxy, halogen, hydroxy, -O-benzyl, oxo, cyano, amino, -NH-C3.6 carbocycle, C|.6 alkylamino and C1-3 dialkylamino; —
R4 is hydrogen, Cp3 alkyl, halogen or nitrile;
R5 is C].6 alkyl, C3 -jo carbocycle, 3-11 membered heterocycle, aryl, 5-11 membered heteroaryl, -C(O)-R6, hydroxy or —NR7R8, wherein each R5 is optionally independently substituted with one to three groups selected from R9, R10 and R11;
R6 is C3.g heterocycle or -NH-5-6 membered heterocycle, each optionally independently substituted with one to three groups selected from R9, R10 and R11 ;
R7and R8 are each independently hydrogen, 5-6 membered heterocycle optionally substituted with CT 6 alkyl, C3_i0 carbocycle optionally substituted with hydroxy or CT-r, alkyl;
R9, R10 and R11 are independently selected from (a)-H, (b)-OH, (c) halogen, (d)-CN, (e)-CF (f) Ci-ealkyl optionally substituted with one to three -OH, -N(R12)(R13) , 3-6 membered heterocycle, Ci-ôalkoxy, Ci-ealkoxy-O- Ci^alkyl, -CO2R12, -C(O)N(R12)(R13) or -S(O)nCi^aIkyl, (g) C!6alkoxy, (h) -N(R12)(R13), (i) -StOjnCr^alkyl, (j) -C02R12, (k) -C(O)N(RI2)(R13), (l) -S(O)2N(R,2)(Ri3), (m) a 3-10 membered heterocyclic group optionally substituted with one to three Ci_6 alkyl groups, (n’) oxo, X (o)-C(O)-Ci-, alkyl;
R12 and R13 are each independently selected from-H, -Cj^alkyl, C(O)C| 6alkyh and a 36 membered heterocyclic group, each of which is optionally independently substituted with one to three C^alkyl groups, -OH, Ci^alkoxy, -C(O)N(R14)(R15), -S(O)nC;_/,alkyl, CN, a 3-6 membered heterocyclic group, -OCj^alkyl, CF3, or;
R and R taken together with the nitrogen ring to which they are attached form a heterocyclyl ring optionally substituted with one to three -OH, CN, -OCi_6alkyl or oxo;
R14 and R15 are each independently selected from -H and -Ci-^alkyl;
n is 0,1 or 2;
or a pharmaceutically acceptable sait thereof.
In a second embodiment, the présent invention relates to a compound as described in the broadest embodiment above, wherein:
Rl and R2 are each independently hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert. butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl or cylohexyl, with the proviso that both R1 and R2 are not hydrogen;
R3 is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thienyl, furanyl or thiazolyl, wherein each heteroaryl ring is optionally independently substituted with one to three groups selected from Ci_3 alkyl optionally substituted with one to three halogen atoms, C[.3 alkoxy, C|.< hydroxy, halogen, hydroxy, -O-benzyk oxo, cyano, amino, -NHC3_6 carbocycle, Cj 6 alkylamino and Ci_3 dialkylamino;
or
R3 is pyridooxazinyl, dihydro-pyridooxazinyl, dihydro-pyrrolopyridinyl, pyrrolopyridinyl or pyrrolopyrazinyl, wherein each heteroaryl ring is optionally independently substituted with one to three groups selected from Cj.3 alkyl optionally substituted with one to three halogen atoms, Ci_3 alkoxy, Ci_3 hydroxy, halogen, hydroxy, -O-benzyl, oxo, cyano, amîno, -NH-C3.6 carbocycle, C1.3 alkylamino and Ci-3 dialkylamino;
R4 is hydrogen, methyl or fluoro;
R5 is methyl, ethyl, propyl, isopropyl, butyl, îsobutyl, /eri-butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, piperidînyl, piperazinyl, morpholinyl, thiomorpholinyl, azetidinyl, pyrrolidinyl, tetrahydropyranyl, pyrrolyl, thienyl, fiiranyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, triazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, isoquinolinyl, îndolyl, pyrrolopyridinyl, pyrrolopyrimidinyl, -C(O)-R6, hydroxy or NR7R8, wherein each R5 is optionally independently substituted with one to three groups selected from R9, R10 and R11;
R6 is piperidînyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl or -NHpîperadinyl each optionally independently substituted with one to three groups selected from R9, R10 and R11;
R7and R8 are each independently hydrogen, 5-6 membered heterocycle optionally substituted with methyl, C ^, carbocycle optionally substituted with hydroxy, or C1.5 alkyl;
R9, R10 and R11 are independently selected from (a)-H, (b)-OH, (c) halogen, (d)-CN, (e) -CF3î (f) Ci^alkyl optionally substituted with one to three -OH, -N(R12)(R1!) , 3-6 membered heterocycle, Ci-6alkoxy , Ci.6alkoxy-O- Ci.6alkyl, -CO2R , -C(O)N(R12)(R13) or -S(O)„Ci 6alkyl.
(g) Ci^alkoxy, S (h) -N(Ri2)(R13), (i) -S(O)nC^alkyl, (j) CO2R12, (k) -C(O)N(R12)(R13), (l) -S(O)2N(R12)(R13), (m) a 3-8 membered heterocyclic group optionally substituted with one to three Ci_6 alkyl groups, (n’) oxo, (oJ-CÎO^î alkyl;
R12 and R13 are each independently selected from -H, -Ci^alkyl, C(O)Ci <>alkyl, and a 3- membered heterocyclic group, each of which is optionally independently substituted with one to three Ci^alkyl groups, -OH, C| alkoxy, -C(O)N(R14)(R15), -S(O)nCi-6alkyl, CN, a 3-6 membered heterocyclic group, -OCt /,alkyl. CF3; or,
R12 and R13 taken together with the nitrogen ring to which they are attached can form a heterocyclyl ring optionally substituted with one to three -OH, CN, -0Cj_6alkyl or oxo;
R14 and R15 are each independently selected from -H and -Cj^alkyl;
n is 1 or 2;
or a pharmaceutically acceptable sait thereof.
In a third embodiment, the présent invention relates to a compound as described în any of the preceding embodiments above, wherein:
R1 and R2 are each independently hydrogen, methyl, ethyl, propyl, isopropyl, terf-butyl, cyclopropyl or cyclobutyl, with the proviso that both R and R are not hydrogen; or a pharmaceutically acceptable sait thereof.
In a fourth embodiment there is provided a compound of formula (I) as described in any of the preceding embodiments above, wherein:
R3 is pyridinyl, pyrazinyl, pyridazinyl or pyrimidinyl, wherein each heteroaryl ring is optionally independently substituted with one to two groups selected from Ci.3 alkyl optionally substituted with one to three halogen atoms, C1.3 alkoxy, C1.3 hydroxy, halogen, hydroxy, -O-benzyl, oxo, cyano, amino, -NH-C3.6 carbocycle, C].$ alkylamino and C1.3 dialkylamino; or
R3 is pyridooxazinyl, dîhydro-pyridooxazinyl, dihydro-pyrrolopyridinyl, pyrrolopyridinyl or pyrrolopyrazinyl;
or a pharmaceutically acceptable sait thereof.
In a fifth embodiment there is provided a compound as described in any of the preceding embodiments above, wherein:
R5 is methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, azetidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, thiazolyl, oxazolyl, îsoxazolyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, isoquinolinyl, -C(O)-piperizinyl, -C(O)piperidinyl, -C(O)-morpholînyl, -C(O)-NH-piperidinyl, hydroxy or -NR7R8, wherein each R5 is optionally independently substituted with one to three groups selected from R9, R10 and R11;
R7and R8 are each independently hydrogen, 5-6 membered heterocycle optionally substituted with methyl, C3.6 carbocycle optionally substituted with hydroxy or C1-C5 alkyl;
R9, Rlo and Rn are independently selected from (a) -H, (b) -oh, y (c) halogen, (d) -CN, (e) -CF3, (f) Ci^alkyl optionally substituted with one to three -OH, -N(R12)(R13) , morpholînyl, piperazinyl, C| f>alkoxy, Ci.3alkoxy-O- Ci.3alkyl, -CO2R12 or -C(O)N(RI3)(R13), (g) Ci_3alkoxy, (h) -N(R12)(R13), (i) -SiOKCj.ôalkyl, (j) -CO2R12, (k) -C(O)N(R12)(R13), (l) -S(O)2N(R12)(R13), (m) morpholînyl, piperazinyl, piperidinyl or oxetanyl each optionally substituted with a methyl group, (n’) oxo, (o) -C(O)-CH3;
R12 and R13 are each independently selected from -H and alkyl, wherein the alkyl group îs optionally substituted with one to three -OH, Ci-galkoxy, -C(O)N(R14)(R15) or S(O)nCi.6alkyl;
R14 and Rl5are each independently selected from -H and -C,^alkykn is 2;
or a pharmaceutically acceptable sait thereof.
In a sixth embodiment there is provided a compound of formula (I) as described in the second embodiment above, wherein:
R1 and R2 are each independently hydrogen, methyl, ethyl, propyl, isopropyl, im-butyl. cyclopropyl or cyclobutyl, with the proviso that both R1 and R2 are not hydrogen;
R3 is pyridinyl, pyrazinyl, pyridazinyl or pyrimidinyl, wherein each heteroaryl ring is optionally independently substituted with one to two groups selected from methyl, methoxy,-CH2OH, trifluoromethyl, bromo, chloro, fiuoro, hydroxy, -O-benzyl, oxo, cyano, amino, -NH-C3^ carbocycle, Cw alkylamino and Ci.3 dialkylamino; or R3 is pyridooxazinyl, dihydro-pyridooxazinyl, dihydro-pyrrolopyridinyl, pyrrolopyridinyl or pyrrolopyrazînyl;
R4 is hydrogen;
R5 is methyl, ethyl, propyl, isopropyl, butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, azetidînyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quînolinyl, isoquinolinyl, -C(O)-piperazinyl, -C(0)-morpholinyl, -C(O)-NHpiperidinyl, hydroxy or NRR*. wherein each Rs is optionally independently substituted with one to three groups selected from R9, R10 and R11;
R7and R8 are each independently hydrogen, piperidinyl optionally substituted with a methyl group, cyclohexyl optionally substituted with a hydroxy group, methyl or ethyl;
R9, R10 and R11 are independently selected from (a)-H, (b)-OH, (c) halogen, (d)-CN, (e)-CF (f) Ci-()alkyl optionally substituted with one to three -OH, -N(R12)(R13) , morpholinyl, piperazinyl, Ci.3alkoxy, Ci_3alkoxy-O- C].3alkyl, -CO2H or -C(O)N(R12)(R13), (g) Cr3alkoxy, (h) -N(RI2)(R!3), (i) -S(O)2Ci_2alkyl, (i)CO2R'\ (k) -C(O)N(R12)(R13), (l) -S(O)2N(Rl2)(R13), y (m) morpholinyl, piperazinyl, or oxetanyl each optionally substituted with a methyl group, (n’) oxo, (o) -C(O)-CH3;
R12 and R13 are each independently selected from -H and C].(,alkyl, wherein the alkyl group is optionally independently substituted with one to three -OH, Ci^alkoxy, C(O)N(R14)(R15), or -S(O)2C^alkyl;
R14 and R15are each independently selected from -H and -Ci ,;alkyl;
or a pharmaceutically acceptable sait thereof.
In a seventh embodiment there is provided a compound as described in the embodiment immediately above, wherein:
R1 is methyl,
R2 is selected from methyl, ethyl, isopropyl, ier/-butyl, cyclopropyl and cyclobutyl; or a pharmaceutically acceptable sait thereof.
In an eighth embodiment there is provided a compound as described in the sixth embodiment above, wherein:
R3 is selected from
or a pharmaceutically acceptable sait thereof.
In a ninth embodiment there îs provided a compound as described in the sixth embodiment above, wherein:
R5 is pyrazolyl optionally independently substituted with one to three groups selected from R9, R10 and R11 ;
or a pharmaceutically acceptable sait thereof.
In a tenth embodiment there is provided a compound as described in the sixth embodiment above, wherein:
R1 is methyl,
R2 is selected from methyl, ethyl, îsopropyl, tert-butyl, cyclopropyl and cyclobutyl;
R3 is selected from
R4 is hydrogen,
R5 is selected from
or a pharmaceutically acceptable sait thereof.
In an eleventh embodiment there is provided a compound as described in the tenth embodiment above, wherein:
R2 is cyclopropyl or cyclobutyl;
or a pharmaceutically acceptable sait thereof.
In a twelfth embodiment there is provided a compound as described in the tenth embodiment above, wherein:
R2 is selected from methyl, ethyl, îsopropyl and tert-butyl;
or a pharmaceutically acceptable sait thereof.
In a thirteenth embodiment there is provided a compound as described in the sixth embodiment above, wherein:
R3 is selected from
H
or a pharmaceutically acceptable sait thereof.
In a fourteenth embodiment there is provided a compound as described in the sixth embodiment above, wherein:
R3 is selected from
or a pharmaceutically acceptable sait thereof.
In a fîfteenth embodiment there is provided a compound as described in the tenth embodiment above, wherein:
R1 is methyl,
R2 is cyclopropyl;
R3 is selected from
R4 is hydrogen,
or a pharmaceutically acceptable sait thereof.
In a sixteenth embodiment there is provided a compound of formula I, wherein
R1 is methyl,
R2 is cyclopropyl;
R3 îs selected from
R4 is hydrogen, a'
R5 is selected from
or a pharmaceutically acceptable sait thereof.
The following are représentative compounds of the invention which can be made by the general synthetic schemes, the examples, and known methods in the art.
Table 1
Example | Structure | Name |
1 | 1 /° o | 2-(3-{2-[4-(5-methoxypyridin-3- yl)phenyl]-3-methylbutan-2-yl} - 1,2,4-oxadiazol-5-yl)pyrazine |
2 | <ννΝ' 1 T i 0 | 5-{4-[3-methyl-2-(5-phenyl-l,2,4oxadiazol-3-yl)butan-2yljphenyl} pyrimidin-2-amine |
3 | MU M N — Λ h2n'^n'X \Λ | 5-(4-{3-methyl-2-[5-(pyridin-3-yl)- 1,2,4-oxadiazol-3-yl]butan-2yl} phenyl)pyrimidin-2-amine |
4 | γ ηϊν^χ'νχ \Ύ Ν=/ | 5-(4- {3-methyl-2-[5-(6methylpyridin-3-yl)-1,2,4- oxadîazol-3-yl]butan-2- yl} phenyl)pyrimidin-2-ainine |
5 | Jk. ,.Ν jfjl > AV N=k H2N^rT —\~\ N=k | 5-(4-{3-methyl-2-[5-(2- methylpyridin-3-yl)-l,2,4- oxadiazol-3-yi]butan-2- yl} phenyl)pyrimidin-2-amine |
6 | ίΐΊΓ χθ Ίπ h2n n \ / N=k | [2-amino-5-(4-{3-methyl-2-[5(pyridin-3-yl)-l,2,4-oxadiazol-3yl]butan-2-yl} phenyl)pyridin-3 yljmethanol |
7 | ,<ÿ\ ,-N Av0 N'k_ H,kJ A N=k Cl | 5-(4-{2-[5-(6-chloropyridin-3-yl)l,2,4-oxadiazol-3-yl]-3methylbutan-2- yl} phenyl)pyrimidin-2-amine |
8 | z\ k/N fYA kk A N=/ o— | 5-(4-{2-[5-(6-methoxypyridin-3yl)-l,2,4-oxadiazol-3-yl]-3methylbutan-2- yl} phenyl)pyrimidin-2-amine |
9 | 1 II i s° n^AJ *=7 h2n^^n^ \3 N-< o | 5-(3- {2- [4-(2-aminopyrimldin- 5- yl)phenyl]-3-methylbutan-2-yl}l,2,4-oxadiazol-5-yl)pyridin-2(lH)one |
10 | HCA h2n^M °λ3 N=/ | 5-(4- [2-[5-(2-methoxypyridin-3- yl)-l ,2,4-oxadiazol-3-yl]-3methylbutan-2- yl} phenyl)pyrimidin-2-amine |
11 | rïr r a Q), | 5-(4-{2-[5-(4-methoxypyridin-3yl)-l,2,4-oxadiazol-3-yl]-3methylbutan-2- yl} phenyl)pyrimidin-2-amine |
12 | aX^n'' A Ύ h2n^n °=\ \ N—Z | 3-(3-{2-[4-(2-aminopyrimidin-5yl)phenyl]-3-methylbutan-2-yl}- 1,2,4-oxadîazol-5-yl)pyridin-2( 1H)- one |
13 | rîi r s° n^AJ nA Λ J /A hX n \ n —-o | 5-(4- [2-[5-(5-methoxypyridin-3yl)-l,2,4-oxadiazol-3-yl]-3methylbutan-2- yl} phenyl)pyrimîdin-2-amine |
14 | nA/ Λ J h2n n | u | x 1 ° N^/ A N / | 5-(4- [3-methyl-2-[5-( 1 -methyl-1Hpyrazol-3-yl)-1,2,4-oxadiazoi-3yl]butan-2-yl}phenyl)pyrimidin-2amine |
5-(4- (3-methyl-2-[5-( 1 -methyl-1 H- | ||||
pyrazol-4-yl)-1,2,4-oxadiazol-3- | ||||
AA | ||||
f T | o l / | yl]butan-2-yl} 1 phenyl)pyrimidin-2- | ||
15 | AA | n=7 | ||
A J h2n n | h VN 1 | amine | ||
5-(4-{(2R)-3-methyl-2-[5-(l- | ||||
N | methyl-1 H-pyrazol-3-yl)-1,2,4- | |||
A/ | ||||
1 1 | T 0 | oxadiazol-3-yl]butan-2- | ||
16 | N'A/ | AA | N==/ | yl} phenyl)pyrimidin-2-amine |
b | O N / | |||
h2n n | ||||
J | 5-(4-{(2S)-3-methyl-2-[5-(l- | |||
methyl-1 H-pyrazol-3-yl)-1,2,4- | ||||
AAA | A?’'» | |||
0 T | 1 ° | oxadiazol-3-yl]butan-2- | ||
17 | aJ h2n n | AA | n=A -O | yl} phenyl)pyrimidin-2-amine |
N / | ||||
5-(4-{3-methyl-2-[5-(l-rnethyl-lH- | ||||
AA/ | Αχ \ | pyrazol-5-yl)-1,2,4-oxadiazol-3- | ||
18 | n^A< | A | I O n=a | yl]butan-2-yl} phenyl)pyrimidin-2amine |
h2n n | —N\ A | |||
a |
19 | Γ J T ,° h2n'/^'n/ hnCI3 rr | 5-(4-{3-methyl-2-[5-(lH-pyrazol-5- yl)-1,2,4-oxadiazol-3-yl]butan-2yl} phenyl)pyrimidin-2-amine |
20 | aaa\ 1 o NzyU =/ A J Q h2n n hn \ | 5-(4-{2-[5-(lH-imidazol-2-yl)- l,2,4-oxadiazol-3-yl]-3methylbutan-2yl} phenyl)pyrimidin-2-amine |
21 | aaAam rT r x° JJ f N H | 5-(4-{l-cyclopropyl-l-[5-(lHpyrazol-4-yl)-l,2,4-oxadiazol-3yl]ethyl}phenyl)pyrimidin-2-amine |
22 | AA AA A 'A A \ 1 o n/AU -A η/Ά O N ! | 5-(4- {1-cyclopropyl-1 -[5-( 1 methyl- lH-pyrazol-4-yl)-1,2,4oxadîazol-3yljethyl} phenyl)pyrimidin-2-amine |
23 | nA Η,Ν'^ΝΓ HnQ t*T | 5-(4-{(2R)-3-methyl-2-[5-(lHpyrazol-5-yl)-1,2,4-oxadiazol-3yl]butan-2-yI} phenyl)pyrimîdin-2amine |
24 | Λ J HjN N | A.. γγ | C I 0 NiJ HN J N | 5-(4- {(2S)-3 -methyl-2-[5-(lH- pyrazol-5-yl)-l,2,4-oxadiazol-3yl]butan-2-yl}phenyl)pyrimidin-2amine | |
5-(4-(1 -cyclopropyl-1 - [ 5 - ( 1 H- | |||||
Mît | pyrazol-3 -yl)-1,2,4-oxadiazol-3 - | ||||
25 | N'’ | Ύ | AJ | l u nM | yI]ethyl}phenyl)pyrimidin-2-amine |
II | Y N | -o N H | |||
5-(4- {1 -cyclopropyl-1 -[5-( 1 methyl- lH-pyrazol-3-yl)-1,2,4- | |||||
Mr | N i 0 | oxadiazol-3- | |||
26 | n' Λ h2n | ίτ | •AJ | N=J b N / | yl]ethyl}phenyl)pyrimidin-2-amine |
5-(4- {1-cyclopropyl-1-(5-(1methyl-l H-pyrazol-5-yl)-1,2,4- | |||||
27 | NX | γ- | x 1 0 Νχ/ | oxadiazol-3 - yljethyl} phenyI)pyrimidin-2-amine | |
h2n^^ | Y N | -O N |
28 | I 0 HlNXX 7j tr I | 5-(4- {1 -cyclopropyl-1 -[5-( 1 methyl- lH-imidazol-4-yl)-1,2,4oxadiazol-3yl]ethyl} phenyl)pyrimidm-2-amîne |
29 | XÇ\ .tox AJ N=^/ H^N^^hT (S \ N=Z | 5-(4-{l-cyclopropyl-l-[5-(6methylpyridîn-3-yl)-l,2,4oxadiazol-3yljethyl} phenyl)pyrimidin-2-amine |
30 | r¥r xo N‘b A7^ b N ^0 | 5- [4-( 1 -cyclopropyl-1 - {5 - [ 1 -(2methoxyethyl)-1 H-pyrazol-4-yl]l,2,4-oxadiazol-3yl} ethyl)phenyl]pyrimidin-2-amine |
31 | —\A ΓΓ | 5-(4- {(2R)-3-methyl-2-[5-( 1 methyl-lH-pyrazol-5-yl)-l,2,4oxadiazol-3 -yl]butan-2- yl} phenyl)pyrimidin-2-amine |
32 | Az ιΓΥν Νκ° Ν^/ Η^Ν'^'Ν^ --Ν\<3 hF | 5-(4-{(2S)-3-methyl-2-[5-(l- methyl-1 H-pyrazol-5-yl)-1,2,4oxadîazol-3-yl]butan-2yl}phenyl)pyrimidin-2-amine | ||
33 | A AJ η2ν ν | Ί | /-Ν ' 'γΑ' X \ ° Ν==Ζ Ο VN ! | 5-(4- {1 -cyclobutyl- l-[5-(l -methyl- 1 H-pyrazol-4-yl)-1,2,4-oxadiazol- 3-yl]ethyi)phenyl)pyrimidin-2amine |
34 | Α A J η2ν ν | J | ΖΖ Ν 0 Ν==Ζ Ο VN Η | 5-(4- {1 -cyclobutyl-1-[5-( 1Hpyrazol-4-yl)-1,2,4-oxadiazol-3yl]ethyl }phenyl)pyrimidîn-2-amine |
35 | xJ η2ν ν | J | ζγ,-ΐγ f' Y Υ__^Ν Ν k ΗΟ | 1- {[5-(3-{ l-[4-(2-aminopyriniidin- 5-yl)phenyl]-l-cyclobutylethyl}- 1,2,4-oxadiazol-5-yl)pyrazin-2yljamino} -2-methylpropan-2-ol |
36 | Γγυν'ο A J /Λ H,N N N K N //NH —0 | 5- {4-[ 1 -cyclobutyl-1 -(5- {5-[(2methoxyethyl)amino]pyrazin-2-yl] l,2,4-oxadiazol-3yl)ethyl]phenyl}pyrimidin-2-amine |
37 | | T i o Ju q | 5-(4-{2-[5-(6-methylpyiïdm-3-yl)l,2,4-oxadiazol-3-yl]propan-2yl} phenyl)pyrimidin-2-amine |
38 | ^î\ AA r il A Η,Ν^Ν^ ζ^~\ n—/ N—. HA 0 \ | 5- [4-[ 1-cyclopropyl-l -(5- {6-[(2methoxyethyl)amino]pyridin-3-yl}- 1,2,4-oxadiazol-3yl)ethyl]phenyl} pyrimidin-2-amine |
39 | AA ^-n fY'O’ Ν^γ ++ N>—. H2N'^X'N<^ N—A 9Ί< HO | 1- {[5-(3-{ l-[4-(2-ammopyrimidin5-yl)phenyl]-l -cyclopropylethyl} - 1,2,4-oxadiazol-5-yl)pyridin-2- yl]amîno}-2-methylpropan-2-ol |
40 | . , Ν \ lî N~( η-,ν'^’Ά N—Z N—, H \ HO | 1- {[5-(3- {l-[4-(2-aminopyrimidin5-yl)phenyl]-1 -cyclopropylethyl} - 1,2,4-oxadiazol-5-yl)pyridin-2yl]amino}propan-2-ol |
41 | JA. /N ^jO^XL/0 ηχ^α N—7 N—. h¥ V o\ | 5-(4- {1 -cyclopropyl-1 -[5-(6- {[2(methylsulfonyl)ethyl] amino} pyridi n-3-yl)-l,2,4-oxadiazol-3yl]ethyl} phenyl )pyrimidin-2-amine |
42 | a¥¥n- i T 1 0 K nQ H \ λ | 5- {4-[ 1 -cyclopropyl-1 -(5- {5-[(2methoxyethyl)amino]pyrazin-2-yl} l,2,4-oxadiazol-3yl)ethyl]phenyl} pyrimidin-2-amine |
43 | AA γιΓ v 'ο Jp b. N | 5-(4-( l-cyclopropyl-1- [5-[ 1- (oxetan-3-yl)-lH-pyrazol-4-ylJ- l,2,4-oxadiazol-3- yl}ethyl)phenyl]pyrimidin-2-amine |
44 | rAAL·' ^XJ y0 Η,Ν-'Μ -θ «Λ —-T—OH | l-{[5-(3-(l-[4-(2-aminopyrimidin- 5-yl)phenyl]-1 -cyclopropyl ethyl} - 1,2,4-oxadiazol-5-yl)pyrazin-2- yl]amîno}-2-methylpropan-2-ol |
45 | Γ T T o n^A> Η,Ν'^'Ν^ f/ X y OH | 2- {[5-(3 - {l-[4-(2-ammopyrimidin- 5-yl)phenyl]-l -cyclopropylethyl} l,2,4-oxadiazol-5-yl)pyrazin-2yl]amino} -2-methylpropan-1 -ol |
46 | crVo N^JU -y Λ A K h2n n A H N / | 5-(4-{(2R)-3-methyl-2-[5-(l- methyl-1 H-pyrazol-4-yl)-1,2,4oxadiazol-3-yl]butan-2- yl}phenyl)pyrimidin-2-amine |
47 | Xz A h N I | 5-(4-{(2S)-3-methyl-2-[5-(l- methyl-1 H-pyrazol-4-yl)-1,2,4oxadiazol-3-yl]butan-2yl} phenyl)pyriinidin-2-amine |
48 | iAîYn'o Jd h N H | 5-(4-{(lR)-l-cyclopropyl-l-[5-(lHpyrazol-4-yl)-1,2,4-oxadiazoI-3yljethyl} phenyl)pyrimidin-2-amine |
49 | A/ JX h N H | 5-(4- {( l S)-1 -cyclopropyl-1 -[5-( 1Hpyrazol-4-yl)-1,2,4-oxadiazol-3yl]ethyl} phenyl)pyrimidin-2-amine |
50 | Ki N zAO h2n n V p N=/ NH Æ | l-{[5-(3-{(lR)-1-(4-(2aminopyrimidin-5-yl)phenyl]-1 cyclopropylethyl} -1,2,4-oxadiazol5-yl)pyrazin-2-yl]amino} -2methylpropan-2-ol |
51 | 4., (ΓΥυΝθ Ju Ίπ Ν==/ ΝΗ /ν0Η | l-{[5-(3-{(lS)-l-[4-(2- aminopyriniidin-5-yl)pheiiyl]-1 cyclopropylethyl)-l,2,4-oxadiazol5-yl)pyrazîn-2-yl]amino} -2methylpropan-2-ol |
52 | 5- [4-[( 1 R)-1 -cyclopropyl-1-{5-[1(2-methoxyethyl)-1 H-pyrazol-4yl]-1,2,4-oxadiazol-3yl}ethyl]phenyl}pyrimidin-2-amine | |
53 | 4, fl ν 0 Ν=/ η2ν^ν^ Ç}^ ° | 5- {4-[( 1 S)-1 -cyclopropyl-1 - [5-[ 1 (2-methoxyethyl)-1 H-pyrazol-4yl]-l,2,4-oxadiazol-3yl)ethyl]phenyl}pyrimidin-2-amine |
54 | fAo wA A J 4 HîN Ν 4,' | 5- [4-[( 1 R)-1-cyclopropyl-1 - {5-[ 1 (oxetan-3-yl)-lH-pyrazol-4-yl]1,2,4-oxadiazol-3 yl}ethyl]phenyl}pyrimidin-2-amme |
55 | A . CrV-o h2n n ' N Ao | 5-{4-[(lS)-l-cyclopropyl-l-[5-[l- (oxetan-3-yl)-1 H-pyrazol-4-yl]l,2,4-oxadiazol-3yl} ethyljphenyl} pyrimidin-2-amine |
56 | .Aa As A N=A NH A 0„ | 2-{[5-(3-{(lR)-l-[4-(2aminopyrimidin-5-yl)phenyl]-1 cyclopropylethyl} -1,2,4-oxadiazol5-yl)pyrazin-2-yl]amino} -2methylpropan-1 -ol |
57 | A\ ,n îi ί r o n=z AA A NH Χ,Η | 2-{[5-(3-{(lS)-l-[4-(2ammopyrimidin-5-yl)phenyl]-lcyclopropylethyl} -1,2,4-oxadiazol5-yl)pyrazîn-2-yl]amino}-2methylpropan-1 -ol |
58 | ΠτΛ „YJ NA A J A h2n n < n N / | 5-(4- (2,2-diinethyl-1 -[5-( 1 -methyl- 1 H-pyrazol-4-yl)-1,2,4-oxadiazol- 3 -yl]propyl} plienyl)pyrimidin-2amine |
59 | i T I ο + H2N N , CJn / N- 0 | 2-(4-(3- {l-(4-(2-aminopyrimidin-5yl)phenyl]-l -cyclopropylethyl} 1,2,4-oxadiazol-5-yl)-1 H-pyrazol- 1 -yl]-N,N-dimethylacetamide |
60 | JA. ,N fïr 'o JM b H « Y 0 | 2-(4-(3- {1 -(4-(2-aminopyrimidin-5yl)phenyl]-1 -cyclopropylethyl} 1,2,4-oxadiazol-5-yi)-1 H-pyrazoll-yl]-N-methylacetamide |
61 | -jO0° h N / | 5-(4-{(lR)-l-cyclopropyl-l-[5-(lmethyl- lH-pyrazol-4-yl)-1,2,4oxadiazol-3yl]ethyl}phenyl)pyrimidin-2-amine |
62 | 4./ <ννΝ' 1 T i ° AJ +1 Η,Ν N < « N / | 5-(4- {( 1 S)-1 -cyclopropyl-1-(5-(1methyl-1 H-pyrazol-4-yl)-1,2,4oxadiazol-3yljethyl} phenyl)pyrimidin-2-amine |
63 | 5-{4-[(2R)-2-{5-(l-(2- methoxyethyl)-lH-pyrazol-4-yl]- 1 l,2,4-oxadiazol-3-yl}-3- |
n X, v xJU -A h.nAt <fjj, N S °\ | methylbutan-2- yljphenyl} pyrimidin-2-amine | |
64 | A, [TYr% N^JU h2n^n^ N / ^0 | 5-{4-[(2S)-2-{5-[l-(2- methoxyethyl)-1 H-pyrazol-4-yI] l,2,4-oxadiazol-3-yl}-3methylbutan-2yljphenyl} pyrimidin-2-aniine |
65 | fil'/’ nx^A> X aJ K h2n N < H / | 5-(4-{(lR)-2,2-dimethyl-l-[5-(l- methyl-1 H-pyrazol-4-yl)-1,2,4oxadiazol-3yl]propyl} phenyl)pyrimidin-2amine |
66 | -4/ iiTr sa h N / | 5-(4- {(1 S)-2,2-dimethyl-1 -[5-( 1 methyl- lH-pyrazol-4-yl)-1,2,4oxadiazol-3yljpropyl} phenyl)pyrimidin-2amine |
67 | 5-(4-{2-methyl-l-[5-(l-inethyl-lH- pyrazol-4-yl)-l,2,4-oxadiazol-3- |
I o pJU Π2Ν H <fl N I | yl]propyl}phenyl)pyrimidin-2- amine | |
68 | zOrZx AI k AX b N / | 5-(4- {2-[5-( l -methyl-1 H-pyrazol-4- yl)-1,2,4-oxadîazol-3-yl]propan-2yl}phenyl)pyrimidm-2-amine |
69 | a4a n/QU »=/ h/V 0| N H | 5-(4-{2-[5-(lH-pyrazol-4-yl)-l,2,4oxadîazol-3-yl]propan-2yl]phenyl)pyrimidin-2-amme |
70 | XfX0 —/ «χΎΥ NH V HO X | 1 - {[5-(3 - (2-[4-(2-aminopyrimidin5-yl)phenyl]propan-2-yl} -1,2,4oxadiazol-5-yl)pyridin-2yljamino} -2-methylpropan-2-ol |
71 | AC .--ν Γ II κ° Α>^ ο Ν=Κ ΝΗ 0=/ Λ 0 χ | 5-(4-{2-[5-(6-{[2- (methylsulfonyl)ethyl] amino} pyridi n-3-yl)-l,2,4-oxadiazol-3yl]propan-2-yl}phenyl)pyrimidin2-amine |
72 | AC --Ν λ° KjA^hT ξ Ν=/ ΝΗ ΗΟ | 2-{[5-(3-{2-[4-(2-aminopyriimdin- 5-yl)phenyl]propan-2-yl} -1,2,4oxadiazol-5-yl)pyridin-2yljamino} -2-methylpropan-1 -ol |
73 | .^aGa ο n^aj < Α> A Ν—22/ ΝΗ κ ΗΟ λ | 1 -{[S-^-P-^-^-aminopyrimidinS-yljphenylJpropan^-yl} -1,2,4oxadiazol-5-yl)pyrazin-2 yl]amino}-2-methylpropan-2-ol |
74 | AC _--ν γΥγα ^Α^Α ν;Α γ\ Ν=/ ΝΗ ΗΟ | 2-{[5-(3-{2-[4-(2-aminopyrimidin- 5-yI)phenyl]propan-2-yl} -1,2,4oxadiazol-5-yl)pyrazin-2yljamino} -2-methylpropan-1 -ol |
75 | dd -N ΓιΓΤο N y HO | 1 -[4-(3 - {2-[4-(2-aminopyrimidin-5yl)phenyl]propan-2-yl}-1,2,4oxadiazol-5-yl)-lH-pyrazol-l-yl]2-methylpropan-2-ol |
76 | dd ^'N ί<^ 7Γ x [ ] I o N^ÂJ ”=( X^'f /J, N ..-.o | 5-[4-(2-{5-[l-(2-methoxyethyl)- 1 H-pyrazol-4-yl]-l ,2,4-oxadiazol- 3-yl}propan-2- yl)phenyl]pyrimidin-2-amine |
77 | Ν^,ΧΧ -=? η,ν^ν'' ^3, N H | 5-(4- { (2 R)-3-methyl-2-[5-( 1Hpyrazol-4-yl)-1,2,4-oxadiazol-3yl]butan-2-yl} phenyl)pyrîmidin-2amine |
78 | dd Ml rf x [ l o A <1 N H | 5-(4-{(2S)-3-methyl-2-[5-(lH- pyrazol-4-yl)-l ,2,4-oxadiazol-3yl]butan-2-yl} phenyl)pyrimidin-2amine |
79 | AC 11° ^yU -y »vZnx N V' _^-NH | 2-[4-(3-{2-[4-(2-aminopyrimidin-5yi)phenyl]propan-2-yl] -1,2,4oxadîazol-5-yl)-1 H-pyrazol-1 -yl]N-methylacetamide |
80 | ΜΑΜΆ h î t ïy-\ A J H?N N | 2-[(3-{2-[4-(2-aminopyrimidin-5- yl)phenyl]-3-methylbutan-2-yl} l,2,4-oxadiazol-5-yl)amino]ethanol |
81 | LA u ΓΎΎ yA XyLL A J h2n n | 5-[4-(2-{5-[(2- methoxyethyl)amino]-1,2,4oxadiazol-3-yl}-3-methylbutan-2yl)phenyl]pyrimidin-2-amine |
82 | yXï>M u HZN N | l-[(3-{2-[4-(2-aminopyrimidin-5- yI)phenyl]-3-methylbutan-2-yl} - 1,2,4-oxadiazol-5-yl)amino]-2- methylpropan-2-ol |
83 | ΑΖΑί r \ N—/ A—> N A ~ ° A J Η,Ν N | 5-(4-{3-methyl-2-[5-(piperazin-l - yl)-l,2,4-oxadiazol-3-yl]butan-2- yl} phenyl)pyrimidm-2-amine |
84 | AAAn lliv ° N^UU -a A J A κχ N /--N N-—' H | (3-{2-[4-(2-aminopyrimidin-5yl)phenyl]-3-methylbutan-2-yl}1,2,4-oxadiazol-5-yl)(piperazin-1 yl)methanone |
85 | AC {jO H2N^^A \_, ho—Ά 0 | 4-(3-{2-[4-(2-aminopyrimidin-5- yl)phenyl]-3-methylbutan-2-yl}- 1,2,4-oxadiazol-5-yl)-2,2dîmethylbutanoic acid |
86 | .uSuA-ca JA | N-(l -acetylpiperidin-4-yl)-3- {2-[4(2-aminopyrimidin-5-yl)phenyl]-3methylbutan-2-yl} -1,2,4oxadiazole-5-carboxamide |
87 | AC m jfyi yA xAU A .z/ | 5-{4-[3-methyI-2-(5-{[2- (methylsulfonyl)ethyl]amino} 1,2,4-oxadiazol-3-yl)butan-2yljphenyl} pyrimidm-2-amine |
88 | /O. JAC A AA A> x ^Jj M° A C oh h2n n | 3-{2-[4-(2-aminopyrimidin-5yl)phenyl]-3-methylbutan-2-yl} l,2,4-oxadiazol-5-ol |
89 | ΑΠΑ A J HjN N | 5-(4-{3-methyl-2-[5-(morpholin-4- yl)-1,2,4-oxadiazol-3-yl]butan-2yl} phenyl)pyriinidin-2-amine |
90 | ΠΑΜ0 N-X '—'0 | (3-{2-[4-(2-aniinopyrimidni-5yl)phenyl]-3-methylbutan-2-yl} l,2,4-oxadiazol-5-yl)(morpholin-4yl)methanone |
91 | /A À\ A ifYr 'o AU A A J A h2n n /N n-A | (3- [2-[4-(2-aminopyrimidin-5yl)phenyl]-3-inethylbutan-2-yl}- 1,2,4-oxadiazol-5-yl)(4methylpîperazin-1 -yl)methanone |
92 | ^AX a A TA, oz | 3-(3- {2-[4-(2-aminopyrimidin-5yl)phenyl]-3-methylbutan-2~yl} l,2,4-oxadiazol-5-yl)-3methylbutanoic acid |
93 | ifAAAAN\ A4 HjN N \ Γ™ O | 3-(3-{2-[4-(2-ammopyrimidin-5yl)phenyl]-3-methylbutan-2-yl}- 1,2>4-oxadiazol-5-yl)-2,2- dimethylpropanoîc acid |
94 | A x 0 nA //—0H oz | 3-(3-{2-[4-(2-amînopyrimidîn-5- yl)phenyl]-3-methylbutan-2-yl} - 1,2,4-oxadiazol-5-yI)propanoic acid |
95 | /7^ AA A iT \ i T I o fK Y 0 | l-(3-{2-[4-(2-aminopyrimîdin-5- yl)phenyl]-3-methylbutan-2-yl} - 1,2,4-oxadiazol-S- yl)cyclopropanecarboxylic acid |
96 | KC A ijl > fJA/V n=A Il J N—, H,N N / '—N \ | 5-(4-{3-methyI-2-[5-(4- methylpiperazin-1 -yl)-1.2.4- oxadîazol-3-yl]butan-2yl}phenyl)pyrimidin-2-amine |
97 | aXa l o Aaaa NZA” JF h N Y -Y | 2-(4-(3- {l-[4-(2-ammopyrimidîn-5yl)phenyl]-l-cyclobutylethyl}- 1,2,4-oxadîazol-5-yl)-1 H-pyrazol- 1 -yl]-N,N-dimethylacetainide |
2-[4-(3- {l -[4-(2-amînopyrimidin-5- | |||||
A | A\ ,N I 0 | yl)phenyl]-l-cyclobutyl ethyl}- | |||
98 | N'Y' | Y | N^=/ | 1,2,4-oxadiazol-5-yl)- lH-pyrazol- | |
AL b h2n n | <Ί N Y NH | 1 -yl]-N-methylaceÎamide | |||
5-[4-(l -cyclobutyl-1 - {5-[ 1 -(oxetan- | |||||
3-yl)-1 H-pyrazol-4-yl]-1,2,4- | |||||
99 | -O | T ° N=y | oxadiazol-3- | ||
A J h2n n | b N ύ | yl}ethyl)phenyl]pyrimidin-2-amine | |||
5-{4-[(lR)-l-cyclobutyl-l-{5-[l- | |||||
ιοο | A J h2n n | jO | N .'' JA l 0 nA p \ ^N N A | (2-methoxyethyl)-1 H-pyrazol-4- yl]-l ,2,4-oxadiazol-3yl}ethyl]phenyl}pyrimidîn-2-amine | |
5- {4-[( 1 S)-1 -cyclobutyl-1 - {5-[ 1 -(2- | |||||
A | / ><> X I 0 | methoxyethyl)-1 H-pyrazol-4-yl]- | |||
Ab | N=Y | l,2,4-oxadiazol-3- | |||
ΙΟΙ | JL <J h2n n | b X N rJ ....-O | yl}ethyl]phenyl}pyrimîdin-2-ainine |
102 | Γϊ i o /z>A^A wA AA^ b N /> | 5-{4-[(lR)-l-cyclobutyl-l-{5-[l- (oxetan-3-yl)-1 H-pyrazol-4-yl]- 1,2,4-oxadiazol-3- yl}ethyl]phenyl}pyrimidin-2-amine |
103 | Π xz\b\,N Tr J' x 1 T 1 o n^AJ n=Z H^n θ N ύ | 5- {4-[( 1 S)-1 -cyclobutyl-1 - {5-[ 1 (oxetan-3-yl)-1 H-pyrazol-4-yl]l,2,4-oxadiazol-3- yl} ethyl jphenyl} pyrimidin-2-amine |
104 | AAiA^ ° /z^AJ nA JJ h N V | 2-[4-(3-{(lR)-l-[4-(2- aminopyrimidin-5-yl)phenyl]-1 cyclobutyl ethyl}-1 f2,4-oxadiazol-5yl)-1 H-pyrazol-1 -yl]-N,Ndimethylacetamide |
105 | R, AA N V | 2-[4-(3-{(lS)-l-[4-(2- aminopyrimidin-5-yl)phenyl]-lcyclobutylethyl}-1,2,4-oxadiazol-5yl)-1 H-pyrazoi-1 -yl]-N,Ndimethylacetamide |
Z
106 | Η!Α9 Q tT V | 2-[4-(3-{2-[4-(2-aminopyrimidin-5yl)phenyl]-3-methyibutan-2-yl} l,2,4-oxadiazoI-5-yl)- ΙΗ-pyrazoll-yl]-N,N-dimethylacetamide |
107 | QÜ’Y'.n /-n ιΓΎυ OAk JL 2 ''OH η2ν ν | l-[4-(3-{(2R)-2-[4-(2aminopyrimidin-5 -yl)phenyl]-3methylbutan-2-yl}-l,2,4-oxadiazol5-yl)-lH-pyrazol-l -yl]-2methylpropan-2-ol |
108 | «ΑΧ Λ J Λη Η,Ν Ν | 1-(4-(3-{^Sj^-JA-P- aminopyrimîdin-S-yljphenylJ-Smethylbutan-2-yl} -1,2,4-oxadiazol5-yl)-1 H-pyrazol-1 -yl]-2methylpropan-2-ol |
109 | /¾. XC AV Q h- | tert-butyl 4-(3-(2-(4-(2amînopyrimidin-5-yl)phenyl]-3methylbutan-2-yl}-1,2,4-0 xadiazol5-yl)piperidine-l-carboxylate |
no | '—N \ H | 5-(4-{3-methyl-2-[5-(piperidin-4- yl)-1,2,4-oxadiazol-3 -yl]butan-2- yl] phenyl)pyrimidin-2-amine |
lll | 1 ι ° N^JU =/ η,ζύ Ού° A | tert-butyl 3-(3-{2-[4-(2aminopyrimidin-5-yl)phenyl]-3 methylbutan-2-yl} ~ 1,2,4-oxadiazol5-yl)pîperidine-l-carboxylate |
112 | X, ,N ΙΓΊΓ'^ /° °\ N:::< z>/ JJ θ J | tert-butyl 2-(3-{2-[4-(2aminopyrimidin-5 -yl)phenyl] -3 methylbutan-2-yl} -1,2,4-oxadiazol5-yl)piperidine-l-carboxylate |
113 | lixV'° jQ^A Y H2N N ξ NH | 5-(4- {3 -methyl-2-[5-(piperidin-3 yl)-l,2,4-oxadiazol-3-yl]butan-2yl} phenyl)pyrimidin-2-amine |
114 | Η,,Ν^Ύ^ Y | 5-(4-{3-methyl-2-[5-(pîperidin-2- yl)-1,2,4-oxadiazol-3-yl]butan-2yl}phenyl)pyrimidin-2-amine |
115 | A/0 HïfAA θ N 1 | 2-[4-(3-{(lR)-l-[4-(2- aminopyrimidin-5-yi)phenyl]-l cyclopropylethyl}-l,2,4-oxadiazol5-yl)-l H-pyrazol-1 -yl]-N,Ndimethylacetamide |
ll6 | 4 AA fjr > η,ν^Α <0 N 1 cArjA | 2-[4-(3-{(lS)-l-[4-(2- aminopyrimidîn-5-yl)phenyl]-1 cyclopropylethyl]-l,2,4-oxadiazol5-yl)-1 H-pyrazol-1 -yl]-N,Ndimethylacetamide |
ll7 | <JJ k A <5 | 5-(4-{3-methyl-2-[5-(lmethylcyclopentyl)-1,2,4- oxadiazol-3-yl]butan-2- yl} phenyl)pyrimîdin-2-amine |
118 | lYy H2N N | 5-(4- {3-methyl-2-[5-( 1 - methylcyclopropyl)-1,2,4- oxadiazol-3-yl]butan-2- yl} phenyl )pyrimidin-2-amine |
119 | A\ .^n 1 T 1 o n^aa a AA (X | 5- {4-[2-(5-cyclohexyl-1,2,4oxadiazol-3-yl)-3-methylbutan-2yljphenyl} pyrimidin-2-amine |
120 | 5-(4'{3-methyI-2-[5-(lmethylcyclohexyl)-1,2,4-oxadiazol3-yl]butan-2-yl} phenyl)pyrimidin2-amîne | |
121 | ΓμΑ N^/ h.A7^ h N 1 | 5-(4- {(1 R)-l -cyclobutyl-1 -[5-( 1 methyl-1 H-pyrazol-4-yl)-1,2,4oxadiazol-3- yl] ethyl} phenyl)pyrimidin-2-amine |
122 | X\ _X ΓΪΓ x o χχχ/ n;A a7^ h N 1 | 5-(4- {( 1 S)-1 -cyclobutyl-1 -[5-(lmethyl- lH-pyrazol-4-yl)-1,2,4oxadiazol-3yljethyl} phenyl)pyrimidîn-2-amine |
123 | rA/V' 11° NA JA 0 NH O \ | 5-{4-[(2R)-2-(5-{5-[(2methoxyethyl)amino]pyrazîn-2-yl}- 1,2,4-oxadiazol-3 - y 1) - 3 methylbutan-2yl]phenyl} pyrimidin-2-amine |
x
124 | HzNZ^N/ N=/ NH °\ | 5-{4-[(2S)-2-(5-{5-[(2- methoxyethyl)amino]pyrazin-2-yl} l,2,4-oxadiazol-3-yl)-3methylbutan-2yl]phenyl} pyrimîdin-2-amine |
125 | A J h2n n | 5-(3-{2-[4-(2-aminopyrimidin-5yl)phenyl]-3-methylbutan-2-yl}1,2,4-oxadîazol-5-yl)pyridine-2carboxamide |
126 | rrVyQ joa HjN N | 5-(4- {2-[5-( 1 H-imidazol-4-yl)- 1,2,4-oxadiazol-3-yl]-3methylbutan-2yl}phenyl)pyrimidin-2-amine |
127 | “o'VX aJ w h2n n | 5-(4- {2-[5-(îsoquinolin-4-yl)-1,2,4oxadiazol-3-yl]-3-methylbutan-2yl} phenyl)pyrîmidm-2-amine |
128 | aJ h2n n | 5-(3-{2-[4-(2-aminopyrimidin-5yl)phenyl]-3-methylbutan-2-yl} 1 f2,4-oxadiazol-5-yl)pyridine-2carbonitrile |
129 | N-o | 5-(4- {3-methyl-2-[5-(pyrimidin-5- yl)-1,2,4-oxadiazol-3-yl]butan-2yl} phenyl)pyrimidin-2-ainine |
130 | Aîyo Η,Ν'^^γΧ | 5-(4-{3-methyl-2-[5-(l,3-thiazol-5- yl)-1,2,4-oxadiazol-3-yl]butan-2yl} phenyl)pyrimidin-2-amine |
131 | mUk N-o N - Λ J h2n n | 5-(4-{3-methyl-2-[5-(4-methyl-l,3thiazol-2-yl)-1,2,4-oxadiazol-3 yl]butan-2-yl} phenyl)pyrîmidin-2amine |
132 | ffiVO /'χχ/Α'.ζ ζ O Λ J H,N n | 5-(4-{3-methyl-2-[5-(l,3-oxazol-5- yl)-1,2,4-oxadiazol-3-yl]butan-2yl} phenyI)pyrimidin-2-amine |
133 | zxzXzn Λ^’ΐ «γΟΧγ Η2Ν'·^ΧκΧ | 5-(4- {2-(5-(3,5-dim ethyl-1Hpyrazol-4-yl)-l,2,4-oxadiazol-3-yl]3-methylbutan-2- yl} phenyl)pyrimidÎn-2-amine |
134 | /OxA H f η Ύ y-\ Ν^γΑ> — H/l | 5-(4-{2-[5-(ethylamino)-1,2,4oxadiazol-3-yl]-3-methylbutan-2yl}phenyl)pyrimidin-2-amine |
135 | _dYv€><-> jj | 5-[4-(3-methyl-2-[5-[6-(moipholin- 4-yl)pyridin-3-yl]-l,2,4-oxadiazol- 3-yl}butan-2-yl)phenyl]pyrimidin- 2-amine |
136 | /Aa A F A J HZN N | 5-[4-(3-methyl-2-{5-[6(trifluoromethyl)pyridin-3-yl]l,2,4-oxadiazol-3-yl}butan-2yl)phenyl]pyrimidîn-2 -amine |
137 | Αύ-ο N^0 Z N vf A J h2n n | 5-(4-{3-methyl-2-[5-(pyrazin-2-yl)l,2,4-oxadiazol-3-yl]butan-2yl} phenyl)pyrimidin-2-amine |
138 | nVyO ν^α> n~° vA J h2n n | 5-(4-{3-methyl-2-[5-(tetrahydro2H-pyran-4-yl)-1,2,4-oxadiazol-3yl]butan-2-yl} phenyl)pyr imidin-2amine |
139 | rorvù æJU nA n | 5-(4-{3-methyl-2-[5-(l,3-thîazol-2- yl)-1 f2,4-oxadiazol-3-yl]butan-2yl} phenyl)pyrimidin-2-amine |
140 | ,aA Η2Ν'·'Χ·|'Γ | 5-(4- {3-methyl-2-[5-(4-methyl-l ,3oxazol-5-yl)-1,2,4-oxadiazol-3yl]butan-2-yl} phenyl)pyrimidin-2amine |
141 | Αχχ(Αν Κν ffiH J XJ X 8 A J h2n n | 5-(4- {3-methyl-2-[5-(4-methyl-1,3thiazol-5-yl)-1,2,4-oxadiazol-3 yl]butan-2-yl} phenyl )pyrimidin-2amîne |
142 | Λ J HaN N | 2-(4-(3- {2-(4-(2-aminop yrimidin-5 yl)phenyl]-3-methylbutan-2-yl}- 1,2,4-oxadiazol-5-yl)-1 H-pyrazol- l-yl]-N-methylacetamide |
143 | zK\/An /=N nAaC<x A J h2n n | 5-(4-{2-[5-(6-methyIpyridin-3-yl)- l,2,4-oxadiazol-3-yl]butan-2- yl} phenyl)pyrimidin-2-amine |
144 | / A JAKAaC Ix Η,Ν N | 5-{4-[3-methyl-2-(5-{l-(2- (morpholin-4-yl)ethylJ-1 H-pyrazol- 4-yl} -1,2,4-oxadiazol-3-yl)butan-2yljphenyl }pyrimidin-2-ainine |
145 | __/ o \/ V—OH AVA XJ X <) A J h2n n | l-(3-{2-[4-(2-aminopyrimidin-5- yl)phenyl]-3-methylbutan-2-yl} - 1,2,4-oxadiazol-5 yl)cyclohexanecarboxylic acid |
146 | zr\ AC -N /=?N Aj ocaJ h2n n | 5-(4-{3-methyl-2-[5-(lH-pyrazol-4- yl)-1,2,4-oxadiazol-3-yl]butan-2yl}phenyl)pyrimidin-2-amine |
147 | 5-(4-{3-methyl-2-[5-(pyridazin-4- yl)-1,2,4-oxadiazol-3-yl]butan-2- yl] phenyl)pyrimidin-2-amine |
x
n | ||
148 | ytW AJ Η,Ν N | 5-[4-(3-methyl-2-{5-[3- (methylsulfonyl)phenyl]-1,2,4- oxadiazol-3-yl}butan-2- yl)phenyl]pyrimidin-2-amine |
149 | \S^° aJ η2ν n | 5-[4-(3-methyl-2-{5-[2- (methylsulfonyl)phenylj-1,2,4- oxadiazol-3-yl} butan-2- yl)phenyl]pyrimidin-2-amine |
150 | _cArO A J h2n n | 5-(4-{3-methyI-2-[5-(l- methylpiperidin-4-yl)-1,2,4- oxadiazol-3-yl]butan-2- yI}phenyi)pyrimidin-2-amine |
151 | .uAiKr-' A J HjN N | 5-(4-{2-[5-(6-aminopyridin-3-yl)l,2,4-oxadiazol-3-yi]-3methylbutan-2- yl} phenyl )pyrimidin-2-amine |
152 | L> Z=N ΓΥ» aCA aj^ h2n n | 5-(4- {3-methyl-2-[5-(2- methylpyrimidin-5-yl)-l,2,4- oxadiazol-3-yl]butan-2- yl}phenyl)pyrimidin-2-amine |
153 | XL) ' HtH N | 5-(4- {2-[5-(2,4-dim ethyl-1,3thiazoI-5-yl)-1,2,4-oxadiazol-3-yl]3-methylbutan-2- yl} phenyl)pyrimîdin-2-amine |
154 | ,-AU -A aJ h2n n | 5-(3- {2-[4-(2-aminopyrimidin-5yl)phenyl]-3 -methylbutan-2-yl} 1 ,,2,4-oxadiazol-5-yl)pyrimidin2(lH)-one |
155 | îïWa pA> A ^- h2n tA | 5-(4-{2-[5-(2-methoxypyrimidin-5yl)-l,2,4-oxadiazol-3-yl]-3methylbutan-2- yl} phenyl)pyrimidin-2-amine |
156 | rpry-A N-o aJ HjN N | 5- {4-[2-(5-cyclopropyl-1,2,4oxadiazoi-3-yl)-3-methylbutan-2- yljphenyl} pyrimidin-2-amine |
157 | / no jaVa-CX Z%% ri η,ιΥΆ | 3-(3-{2-[4-(2-aminopyrimidin-5- yl)phenyl]-3-methylbutan-2-yl] 1,2,4-oxadiazol-5-yi)-6methylpyridin-2-ol |
158 | ΑχΑό A O c°x | 5-[4-(2- {5-[ 1 -(2-methoxyethyl)- 1 H-pyrazol-4-yl]-l ,2,4-oxadiazol- 3-yl} -3 -methylbutan-2- yl)phenyI]pyrimidîn-2-amine |
159 | .jW A J H2N N | 1 -[4-(3-{2-[4-(2-amînopyrimidin-5yl)phenyl]-3 -methylbutan-2-yi} - 1,2,4-oxadiazol-5-yl)-1 H-pyrazol- 1 -yl]-2-methylpropan-2-ol |
160 | NpAJ «v n·^' vA O’^'OH | 2-[4-(3-{2-[4-(2-aminopyrimidin-5yl)phenyl]-3-methylbutan-2-yl} 1,2,4-oxadiazol-5 -yl)-1 H-pyrazoIl-yl]-2-methylpropanoîc acid |
161 | {44Γ”” a~44\^ n^AM -oz v\o A 4 v HZN N | 5-[4-(3-methyl-2-{5-[l-(oxetan-3yl)-1 H-pyrazol-4-yl]-1,2,4oxadiazol-3 -yl} butan-2yl)phenyl]pyrimidin-2-amîne |
162 | II A0 h2n^A fA N=/ N—. H \ ^-o \ | 5-{4-[2-(5-{5-[(2- methoxyethyl)amino]pyrazin-2-yl} - 1,2,4-oxadiazol-3-yl)-3methylbutan-2yljphenyl }pyrimidin-2-ainine |
163 | .Ai H.N \ Q \ | 5-[4-(3-methyl-2- {5-[5-(4methylpiperazîn-1 -yl)pyrazin-2-yl]l,2,4-oxadiazol-3-yl}butan-2yl)phenyl]pyrimidin-2-amine |
164 | X d / N. o „A- ---L/-» h°A | 3 -[4-(3 - [2-[4-(2-aminopyrimidin-5 yl)phenyl]-3-methylbutan-2-yl}- 1,2,4-oxadiazol-5-yl)- lH-pyrazol- l-yl]-2,2-dimethylpropanoic acid |
165 | îAvA A* | 6-(3- {2-[4-(2-aminopyrimidin-5yl)phenyl]-3-methylbutan-2-yl} l,2,4-oxadiazol-5-yl)-lmethylpyridin-2( 1 H)-one |
166 | jCt^VA) nAV /Ao aJ H;N N | 6-(3- [2-[4-(2-aminopyrimidin-5yl)phenyl]-3 -methylbutan-2-yl} - 1,2,4-oxadiazol-5-yl)-1 - methylpiperidin-2-one |
167 | m-o ETA AJ h2n n | 6-(3- [2-[4-(2-aminopyrimidin-5yl)phenyl]-3-methylbutan-2-yl} l,2,4-oxadiazol-5-yl)piperidm-2one |
168 | LA i|*| \ ΝΧγΥζ N— JL J /Ά h2n n / \ r° o | 5-(4- {1 -[5-( 1,1 -Dioxo-1 lambdaôthiomorpholin-4-yl)- [1,2,4]oxadiazol-3-yl]-1,2dimethyl-propyl) -phenyl)pyrimidin-2-ylamine |
169 | MM H fYY \ A y AJ /M hX n f \ N y0 | 1 -[4-(3- {1 -[4-(2-Amino-pyrimidin5-yl)-phenyl]-1,2-dimethylpropyl} -[ 1,2,4]oxadiazol-5-yl)pîperazin-1 -yl]-ethanone |
170 | ,χΑ C '---N \ «r 0 | 5-(4- {l-[5-(4-Methanesulfonylpiperazin-1 -yl)-[ 1,2,4]oxadiazol-3yl]-1,2-dimethyl-propyl} -phenyl)pyrimidin-2-ylamine |
171 | x^JLa h n t y-\ M-OZ \ Ax r | N-(3- {l-[4-(2-Amino-pyrimidm-5yl)-phenyl]-1,2-dimethyl-propyl} [l,2,4]oxadiazol-5-yl)-N',N'diinethyl-ethane-1,2-diamine |
172 | γΧΧ Η2Ν Ν Ν ' A | 2-[4-(3-{(R)-I-(4-(6-Amino- pyridin-3-yl)-phenyl]-1 cyclopropyl-ethyl} - [ 1,2,4]oxadiazol-5 -yl)-pyrazol-1 yl]-N,N-dimethyl-acetamide |
173 | H3N n X '^Τ^ΟΗ | 1 -(4-(3- {(R)-1 -[4-(6-Amino- pyridin-3-yl)-phenyl]-1 cyclopropyl-ethyl}- [1,2,4]oxadiazol-5-yl)-pyrazol-1 - yl]-2-methyl-propan-2-ol |
174 | ιΧΧ ηΧ ν' A Ν ” X | 1 -(4-(3- {(R)-1 -[4-(2-Amino- pyrimidin-5-yl)-phenyl]-1 cyclopropyl-ethyl} - [ 1,2,4]oxadiazol-5-yl)-pyrazol-1 - yl]-2-methyl-propan-2-ol |
175 | ^-Ν ΛΠ, Ν Ί ^ΟΗ | 1-(4-(3-{(R)-1-[4-(5-Amino- pyrazîn-2-yl)-phenyl]-1 cyclopropyl-ethyl} - [1,2,4]oxadiazol-5-yl)-pyrazol-1 - yl]-2-methyl-propan-2-ol |
176 | Η/1 N V?N Ν 1 <Α/ 1 | 2-(4-(3- {(R)-1 -(4-(5-Aminopyrazin-2-yl)-phenyl]-1 cyclopropyl-ethyl}[l,2,4]oxadiazol-5-yl)-pyrazol-lyl]-N,N-dimethyl-acetamide |
177 | xr7 b N 1 1 | 2-[4-(3-{(R)-l-[4-(5-Amino-6- methyl-pyrazin-2-yl)-phenyl]-1 cyclopropyl-ethyl} - [ 1,2,4]oxadiazol-5-yl)-pyrazol-1 - yl]-N,N-dimethyl-acetamide | |
178 | fl X° xA A N 1 X'-.'' | 2-(4-(3-{(R)-1-(4-(6-Amino-5methyl-pyridin-3 -yl)-phenyl]-1 cyclopropyl-ethyl}- [ 1,2,4]oxadiazol-5-yl)-pyrazol-1- yl]-N,N-dimethyl-acetamîde | |
179 | 7<\ bb < V γΥ x l o AA H’N N X Y N 1 | ^OH | 1 -(4-(3- {(R)-1 -[4-(6-Amino-5methyl-pyridin-3 -yl)-phenyl]-1 cyclopropyl-ethyl} [l,2,4]oxadiazol-5-yl)-pyrazol-lyl]-2-methyl-propan-2-ol |
180 | bb N Ί | ^OH | 1-(4-(3-( (R)-1-(4-(5-Amino-6- methyl-pyrazin-2-yl)-phenyl]-1 cyclopropyl-ethyl} - [ 1,2,4]oxadiazol-5-yl)-pyrazol-1 - yI]-2-methyl-propan-2-ol |
181 | xbr Y x χ°Υ h5n N X ,r>r N | 5-(4- {(R)-1 -Cyclopropyl-1 -(5-(1 methyl-1 H-pyrazol-4-yl)[ 1,2,4]oxadiazol-3-yl]-ethyl} phenyl)-pyridin-2-ylamine |
182 | AA AU uz A b C 1 | 5-[4-((R)-1 -Cyclopropyl-1 - {5-[ 1 (2-dimethylamino-ethyl)-1Hpyrazol-4-yl]-[l,2,4]oxadiazol-3yl} -ethyl)-phenyl]-pyrimidin-2ylamine |
183 | f^TT Ύ=^ x f 11 i o /AU “Æ N 4- x X | 5-[4-((R)-l -Cyclopropyl-1 - [5-[ 1 (2-methoxy-ethyi)-1 H-pyrazol-4yl]-[ 1,2,4]oxadiazol-3-yl} -ethyl)phenyl]-pyridin-2-ylamine |
184 | Xb h2n n K;. N | 5-(4- {(R)-1 -Cyclopropyl-1 -[5-( 1 methyl-lH-pyrazol-4-yl)[ 1 ^/IJoxadiazol-S-ylJ-ethyl} phenyl)-pyrazin-2-ylamine |
185 | i^iïT x° A A H2N N N | 5-(4- {(R)-1 -Cyclopropyl-1 -[5-( 1 methyl-lH-pyrazol-4-yl)[ 1,2,4]oxadiazol-3-yl]-ethyl} phenyl)-3-methyl-pyridin-2ylamine |
186 | XC N T A T'A \ pïJVA Ab /A h,n n / \ '----N ? OH | 2-[4-(3- {1 -[4-(2-Amino-pyrimidin5-yl)-phenyl]-1,2-dîmethylpropyl} -[ 1,2,4]oxadiazol-5-yl)piperazin-l-yl]-ethanol |
187 | x/A N ' | 5-(4- {(R)-1-Cyclopropyl-1 -(5-( 1 methyl-1 H-pyrazol-4-yl)[ 1,2,4]oxadiazol-3-yl]-ethyl} phenyl)-3-methyl-pyrazin-2ylamine |
188 | xr14 “ \ 0 \ | 5-[4-((R)-l-Cyclopropyl-l-(5-(1(2-methoxy-ethyl)-1 H-pyrazol-4yl]-[l,2,4]oxadiazol-3-yl}-ethyl)phenyl]-3 -methyl-pyridin-2yl amine |
189 | x4 % \ O | 5-(4-( (R)-1 -Cyclopropyl-1-(5-(1(2-methoxy-ethyl)-lH-pyrazol-4yl]-[ 1,2,4]oxadiazol-3-yl} -ethyl)phenyl]-3 -methyl-pyrazin-2ylamine |
190 | xvvN^ 1 T 1 o η,νΆα /A ΚΓ NH, | 5-[4-((R)-1 - (5-[ 1 -(2-Amino-ethyl)lII-pyrazol-4-yl]-[l,2,4]oxadiazol3-yl}-l-cyclopropyl-ethyl)-phenyl]pyrimidin-2-ylamine |
191 | h2n N 5¾. .N. V 1 \ | 5-[4-((R)-l-Cyclopropyl-1-(5-(1(2-methoxy-ethyl)-1 H-pyrazol-4yl]-[ 1,2,4]oxadiazol-3-yl} -ethyl)phenyl]-pyrazîn-2-ylamine |
192 | A «=( '---N nh; 0 | 4-(3-(1 -[4-(2-Amino-pynmidin-5yl)-phenyl]-1,2-dimethyl-propyl} [l,2,4]oxadiazol-5-yl)-piperazine- 1 -carboxylic acid amide |
193 | <>AJ «-</ \_j y-\ AJ N | 2-(4-(3- {l-^-^-Amino-pyrimidin- S-ylj-phenyl]- 1,2-dimethylpropyl}-[1,2,4]oxadiazol-5-yl)piperazin-1 -yl]-N,N-dimethyIacetamide |
194 | aj o tr V Λ 0 ! | 2-(4-(3- {(R)-1 -[4-(2-Aminopyrimidin-5-yl)-phenyl]-1 cyclopropyl-ethyl} [l,2,4]oxadiazol-5-yl)-pyrazol-lyl]-N-(2-methoxy-ethyl)-N-methylacetamide |
195 | i) O '---N H | 5-(4-{(R)-l-Cyclopropyl-l-[5(3,4,5,6-tetrahydro-2H[ 1,2']bipyrazinyl-5'-yl)- [ 1,2,4]oxadiazol-3-yl]-ethyl} phenyl)-pyrazin-2-ylamine |
196 | aJ H;N N | G | A ^-N ><x x T /° y N----< o ---N H | 5-(4- {(R)-1 -Cyclopropyl-1 -[5(3,4,5,6-tetrahydro-2H[ 1,2’]bipyrazinyl-5'-yl)- [ 1,2,4]oxadîazol-3-yl]-ethyl} phenyl)-pyrimidin-2-ylamine |
1 A AC - N | 2-(4-(3-{(R)-l-[4-(2-Amino-6-oxo- | |||
0 | X >X \ | |||
f | 1 o | 1,6-dihydro-pyrimidin-5-yl)- | ||
/Y/ | J N=X | |||
197 | HtX AJ h2m n | h | phenyl]-1 -cyclopropyl-ethyl} - [1,2,4]oxadiazol-5-yl)-pyrazol-1 - | |
1 f Ÿ o | yl]-N,N-dimethyl-acetamide | |||
(AV | 2-[l-(3-{l-[4-(2-Amino-pyrimidin- | |||
198 | JU | 5-yl)-phenyl]-1,2-dimethyl- | ||
AJ | A | propyl] -[ 1,2,4]oxadiazol-5-yl)- | ||
C z OH | piperidin-4-yl]-propan-2-ol | |||
4-(3- {1 -[4-(2-Amino-pyrimîdin-5- | ||||
ιίΎ | \x x 1 0 | yl)-phenyl]-1,2-dimethyl-propyl] - | ||
199 | AA | [ 1,2,4]oxadiazol-5-yI)-piperazîn-2- | ||
A\ HZN N | CA k---N H | one |
200 | Γίϊ Νχ° Η2Ν'Χ^'ν’/ ΟΗ | 1 -(3 - {1 - [4-(2-Amino-pyrimidin-5 yl)-phenyl]-1,2-dimethyl-propyl} [ 1,2,4]oxadiazol-5-yl)-azetidin-3-ol |
201 | ΑΑ _-Ν ίι χ° II νη „ΑΑ | 5-(4-( 1,2-DimethyI-l-{5[(tetrahydro-pyran-4-ylmethyl)amino]-[ 1,2,4]oxadiazol-3-yl} propyl)-phenyl] -pyrimidin-2ylamine |
202 | ρ<γ\ A J ζΝ~\ η£ν ν < | 4-(3 - {1 - [4-(2-Amino-pyrimidin-5yl)-phenyl]-1,2-dimethyl-propyl} [ 1,2,4]oxadiazol-5-yl)-1 -methylpiperazin-2-one |
203 | ^Αγ-Vz Η,Ν^Ν^ Ο Λοη | l-(3-{l-[4-(2-Amino-pyrimidîn-5yl)-phenyl]-1,2-dîmethyl-propyl} [l,2,4]oxadiazol-5-yl)-3-methylazetidin-3-ol |
204 | AC Αύ \ ^JU Αο Λ J Ν---, N Q | 5- {4-[ 1 -Cyclopropyl-1 -(5pyrrolidin-l-yl-[l,2,4]oxadiazol-3yl)-ethyl]-phenyl} -pyrimidîn-2ylamîne |
205 | TA x Λ j -X H2N^ Y / A OH | 1 -(3- {1 -[4-(2-Amino-pyrimîdin-5yl)-phenyl]-1 -cyclopropyl-ethyl] [l,2,4]oxadiazol-5-yl)-pîperidin-4ol |
206 | aOK p° «2νΆ b N | 5-(4-{l-Cyclopropyl-l-[5-(3oxetan-3-yl-3H-imidazol-4-yl)- [l,2,4]oxadiazol-3-yl]-ethyl}- phenyl)-pyrimidin-2-ylamîne |
207 | rrVo naAJ Λ J A HjAl C JJ N fi | 5-(4- {1 -Cyclopropyl-1 -[5-( 1 oxetan-3-yl-1 H-imidazol-4-yl)- [ 1,2,4]oxadiazol-3-yl]-ethyl} phenyl)-pyrimidin-2-ylamine |
208 | l o .^yU =( h,Y Q /r 0 0 | 5-(4- {1 -[5-(4-Methanesulfonylpiperidin-l-yl)-[l,2,4]oxadiazol-3yl]-l ,2-dimethyl-propyl] -phenyl)pyrimidin-2-ylainine |
209 | HO | [ 1 -(3- {1 -[4-(2-Amino-pyrimidin-5yl)-phenyl]-1,2-dimethyl-propyl] [ 1,2,4]oxadiazol-5-yl)-pîperidin-4yl]-methanol |
210 | χΎ3- N^/ O '---N H | 5-(4-{(R)-l-Cyclopropyl-l-[5- (3,4,5,6-tetrahydro-2H- [ 1,2']bipyrazinyl-5'-yl)- [ 1,2,4]oxadiazol-3-yl]-ethyI} - phenyl)-pyridin-2-ylamine |
211 | Πο-νΑ» yj y Η,Ν N | 1 -[4-(3- {l-[4-(2-Amino-pyrimidin- 5-yl)-phenyl]-1,2-dimethylpropyl) -[ 1,2,4]oxadiazol-5-yl)piperazin-1 -yl]-2-methyl-propan-2ol |
212 | (Γίγ'ο J *=( /Λ H2N N < \ 1 OH | 2-[ 1 -(3- {1 -[4-(2-Amîno-pyrimidin5-yl)-phenyl]~ 1,2-dim ethylpropyl}-[l,2,4]oxadiazol-5-yl)piperidin-4-yl]-ethanoi |
213 | h2n | 1 -(3- {1 -[4-(2-Amino-pyrimidin-5yl)-phenyl]-1,2-dimethyl-propyl} [ 1,2,4]oxadiazol-5-yl)-piperidine-4carboxylic acid amide |
214 | A il 'Ί 1' A Ύ k'j ύ o '-----N H | 5-(4- {(S)-1-Cyclopropyl-1-[5(3,4,5,6-tetrahydro-2H[ 1,2']bipyrazinyl-5'-yl)- [l,2,4]oxadiazol-3-yl]-ethyl}phenyl)-pyrazin-2-ylamine |
215 | „VJ -A V o N r~^ o | 5-[4-((R)-1 -Cyclopropyl-1 - {5-[ 1 (2-pyrrolîdin-1 -yl-ethyl)- 1Hpyrazol-4-yl]-[ 1,2,4]oxadiazol-3yl)-ethyl)-phenyl]-pyrimidîn-2ylamine |
216 | 1 -(3-{ l-[4-(2-Amino-pyrimidin-5yl)-phenyl]-l,2-dîmethyl-propyl} [ 1,2,4]oxadiazol-5-yl)-4-methylpiperidin-4-ol | |
217 | ~Y 1 N-----1 v. y / v h2n n î \ NH / | 5-(4- {1,2-Dîmethyl-1 -[5-(4methylamino-piperidin-1 -yl)[ 1,2,4]oxadiazol-3-yl]-propyl} phenyl)-pyrimidin-2-ylamîne |
218 | Α^Α y | Q | l ° Q N-- / | 5-(4- {l-[5-(4-Dimethylaminopiperidin-l-yl)-[l,2,4]oxadiazol-3yl]-l,2-dimethyl-propyl} -phenyl)pyrimidin-2-ylamîne |
AAx | l -(3- {l -(4-(2-Amino-pyrimidin-5- | |||
219 | nAAi aJ | U | XA O | yl)-phenyl]-1,2-dimethyl-propyl} - [l,2,4]oxadiazol-5-yl)-piperidine-4- |
H:N N | A °h o | carboxylic acid | ||
n | ''K rX^\ o | 2-(4-(3-{(R)-1-(4-(2-Amino- | ||
AA/ aJ H,N N | AJ | pyrimidm-5-yl)-phenyl]-1 - | ||
<A | cyclopropyl-ethyl} - | |||
220 | \ N N 0 / | [ 1,2,4]oxadiazol-5-yl)-pyrazol-1 - | ||
r | yl]-1 -((R)-3-methoxy-pyrrolidin-1 - | |||
-N P | yl)-ethanone | |||
0 \ |
221 | n^zCj -Z H.H'Z'' N V ...0 0 \ | 2-(4-(3- {(R)-1 -[4-(2-Amino- pyrimidin-5-yl)-phenyl]-1 cyclopropyl-ethyl}- [1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]~ 1 ~((S)-3-methoxy-pyrrolidin-1 yl)-ethanone |
222 | q nh2 | 5-(4- {1 -[5-(4-Animo-piperidin-1 yl)-[ 1,2,4]oxadiazoI-3 -yl]-1,2dimethyl-propyl} -phenyl)pyrimidin-2-ylamine |
223 | ZZ (j a z ^ZaZa n’ < Λ J ”~A H2N N / A OH | l-(3-{(R)-l-[4-(2-Amino- pyrimidin-5-yl)-phenyl]-1,2dimethyl-propyl}-[l,2,4]oxadiazol5-yl)-piperidin-4-ol |
224 | Z. Z ZZ zZ x° N— θ OH | 1-(3-{(S)-1-(4-(2-Amino- pyrimidin-5-yl)-phenyl]-1,2dimethyl-propyl}-(l,2,4]oxadiazol5-yl)-piperidin-4-ol |
225 | ΑΧ l o K^AA A/ OH | 1 -(3- {1 -[4-(2-Ainino-pyrimidin-5yl)-phenyl]-l,2-dimethyl-propyl} - [ 1,2,4]oxadiazol-5-yl)-2-methylpropan-2-ol |
226 | Xï Y' a AX^ çv 0Ay | 2-[4-(3-{(R)-l-Cyclopropyl-l-[4- (2-methylamino-pyrimîdin-5-yl)phenyl]-ethyl}-[l,2,4]oxadîazol-5- yl)-pyrazol-1 -yl]-N,N-dîmethylacetamide |
227 | x ]^OH | 1 -(3- {(R)-1 -[4-(2-Aminopyrimidin-5-yl)-phenyl]-l ,2dimethyl-propyl}-[l,2,4]oxadiazol5-yl)-4-methyl-piperidin-4-ol |
228 | π x° [i n—\ H;m A CZ/> T | l-(3-{(S)-l-[4-(2-Amino- pyrimidin-5-yl)-phenyl]-1,2dimethyl-propyl}-[l,2,4]oxadiazol- 5-yl)-4-methyl-piperidin-4-ol |
229 | \ ιΓ aJ > η2ν ν /° | 5-(4- {I -(5-(2-Methoxy- ethoxymethyl)-[ 1,2,4]oxadiazol-3yl]-l,2-dimethyl-propyl}-phenyl)pyrimidin-2-ylamine |
230 | ΓγνΝ'ο ν-^ΑΑ -4 Ο Ν V ΝΗ | 2-(4-(3- {(R)-1 -[4-(2-Aminopyrimidin-5-yl)-phenyl]-1 cyclopropyl-ethyl}- ( 1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N-methyl-acetamide |
231 | <ι fijr ο N^JU ~4 ηΑΑ Ο Ν V ΝΗ | 2-(4-(3- {(S)-1 -[4-(2-Aminopyrimidin-5-yl)-phenyl]-1 cyclopropyl-ethyl}( 1,2,4]oxadiazol-5-yl)-pyrazol-1 yiJ-N-inethyl-acetamide |
232 | /ÿ\ Α \ rîir χθ Ν-χγ-Μ -Α aJ > η2ν ν < 0 / | 5-(4- {l-[5-(2-Methoxy-ethyl)- [ 1,2,4]oxadiazol-3-yl]-1,2dimethyl-propyl} -phenyl )pyrimidin-2-ylamine |
233 | O pJJ Y Q OH | l-(3-{(R)-l-[4-(2-Aminopyrimidin-5-yi)-phenyl]-1 cyclopropyl-ethyl} [ 1,2î4]oxadiazol-5-yi)-piperidin-4ol |
234 | 4 zQ X/° Λ J X h2n n / \ OH | l-(3-{(S)-l-[4-(2-Aminopyrimidm-5-yl)-phenyl]-lcyclopropyl-ethyl} [ 1,2)4]oxadiazol-5-yl)-piperidin-4ol |
235 | A A /j. H/J N X OH | 8-(3- {l-[4-(2-Amino-pyrimidin-5yl)-phenyl]-1,2-dimethyl-propyl} [l,2,4]oxadiazol-5-yl)-8-azabicyclo[3.2.1 ]octan-3-ol |
236 | if Z 0 \ 0 .,/Qf γ J| J NH Η,Ν'^^Ν’^ / Ç N--Z Z | 5-(4- {1,2-Dimethyl-1 -[5-(l -methylpiperidîn-4-ylamino)[l,2,4]oxadiazol-3-yl]-propyl}phenyl)-pyrimidin-2-ylamine |
237 | /J. A\ -N zyU A NH ' 0 HO | 4-(3- {l -[4-(2-Amino-pyrimidin-5yl)-phenyl]-l,2-dimethyl-propyl}[ l ,2,4]oxadiazol-5-ylamino)cyclohexanol |
238 | Ας, ΓθΗ | ] -(3- {1 -(4-(2-Amino-pyrimidin-5yl)-phenyl]-1 -cyclopropyl-ethyl} [ 1,2,4]oxadiazol-5-yl)-4-methylpiperidin-4-ol |
239 | œAj K Ί | 2-(4-(3- {1 -Cyclopropyl-1 - [4-(3,4dihydro-2H-pyrido[3,2- b][l ,4]oxazin-7-yl)-phenyl]-ethyl} ( 1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N,N-dimethyl-acetamide |
240 | i /VV“' .LU 4 JA h 0Xr | 2-(4-(3- {l-[4-(2-Amino-4-methylpyrimidin-5-yl)-phenyl]-1 cyclopropyl-ethyl} - ( 1,2,4]oxadîazol-5-yl)-pyrazol-1 yl]-N,N-dimethyl-acetamide |
241 | ΓΊίΟ5 çcA U “ 1 y·'»'' | 2-(4-(3- {1 -Cyclopropyl-1 -(4-(2,3 dihydro-1 H-pyrrolo[2,3-b]pyridin- 5-yl)-phenyl]-ethyl} - [ 1,2,4]oxadiazol-5-yl)-pyrazol-l - yl]-N,N-dimethyl-acetamide |
242 | Γ ιΓ χ° ATM À Η A Q 1 | 2-(4-(3- {1-Cyclopropyl-1 -[4-( 1Hpyrrolo[2,3-b]pyridin-5-yl)phenyl]-ethyl} -( 1,2,4]oxadiazol-5yl)-pyrazol-l-yl]-N,N-dimethylacetamide |
243 | μΑ η3ν ν 1 Ν1 °^ϊ | 2-(4-(3- {1 -[4-(6-Amino-5-fluoropyridin-3-yl)-phenyl]-1cyclopropyl-ethyl}- [ 1,2,4]oxadiazol-5-yl)-pyrazol-1 yI]-N,N-dimethyl-acetamide |
244 | LA ^-ν ΜίΓ'ο χτΜ Η;Ν Ν ' Ν 1 | 2-(4-(3-( 1-(4-( 6- Amîno-2-methylpyridin-3-yl)-phenyl]-1 cyclopropyl-ethyl} - ( 1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N,N-dimethyl-acetamide |
245 | gyJg. Γ II ' /° Μ 1 Ν A A 1 0 | 2-(4-(3-(l-[4-(5-Amino-3-methylpyrazîn-2-yl)-phenyl]-lcyclopropyl-ethyl} - ( 1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N,N-dimethyl-acetamide |
246 | /A A A AAA ΛΑ à Η,Ν Z 4 A 1 Zs | 2-(4-(3-(1 -(4-(6-Amino-5- trifluoromethyl-pyridin-3-yl)- phenyl]-1 -cyclopropyl-ethyl] [ 1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N,N-dimethyl-acetamide |
247 | N 1 OAnx- 1 | 2-(4-(3-(1-Cyclopropyl-l-[4-(5H- pyirolo[2,3-b]pyrazin-2-yl)phenyl]-ethyl]-[1,2,4]oxadiazol-5yl)-pyrazol- l-yl]-N,N-dimethylacetamide |
248 | '/a HSN N / \ OH | 1 -(3- {1 -(4-(6-Amino-pyridin-3-yl)phenyl]-1 -cyclopropyl-ethyl] - [ 1,2,4]oxadiazol-5-yl)-piperidin-4ol |
249 | Ax H VA 0Az 1 | 2-(4-(3- {1 -Cyclopropyl-1-(4-(2ethylamino-pyrimidin-5-yl)phenyl]-ethyl] -( 1,2,4]oxadiazol-5- yl)-pyrazol-1 -yl]-N,N-dim ethyl acetamide |
250 | A \V H V N 1 | 2-(4-(3-{1-Cycloprop yl-1-(4-(2cyclopropylamino-pyrimidin-5-yl)phenyl]-ethyl]-[l,2,4]oxadiazol-5- yl)-pyrazol-l-yl]-N,N-dimethylacetamide |
251 | Hbi I | .N I 0 nA A 1 oAZ 1 | 2-[4-(3- {1 -Cyclopropyl-1 -(4-(6methylamîno-pyridin-3 -yl)phenyl]-ethyl}-[lf2,4]oxadiazol-5yl)-pyrazol-l-yl]-N,N-dîmethylacetamide | ||
rx N | XX | ||||
rXY | JA ' X' \ | 2-(4-(3- {1 -(4-(2-Amino-pyrimidin- | |||
252 | O N | x) | l /° N^/ 0 ? OH | 5-yl)-phenyl]-1 -cyclopropyl-ethyl) - ( 1,2,4]oxadiazol-5-yl)-piperazin-1- yl]-ethanol | |
5-(4- {1 -Cyclopropyl-1-(5-( 1 - | |||||
253 | rAr | ' '(C X 1 ° | methyl-1 H-pyrazol-4-yl)- | ||
A | aj | n=a | ( 1,2,4]oxadiazol-3-yl]-ethyl) - | ||
N H | AJ N | A | phenyl)-lH-pyrrolo[2,3-b]pyridme | ||
2-(4-(3- {(R)-1-Cyclopropyl-1 -(4- | |||||
XY' | Lx | (3,4-dîhydro-2H-pyrido[3,2- | |||
254 | C | XJ | y | b]( 1,4]oxazîn-7-yl)-phenyl]-ethyl} - | |
r/ H | 4 A N 1 1 | [ 1,2,4]oxadiazol-5-yl)-pyrazol-1 - | |||
yl]-N,N-dimethyl-acetamide | |||||
2-(4-(3- {(S)-1 -Cyclopropyl-1 -[4- | |||||
χγ | L/ | (3,4-dihydro-2H-pyrido(3,2- | |||
255 | C | XJ | A | b]( l,4]oxazin-7-yl)-phenyl]-ethyl) - | |
H | 4 A N 1 «A/ 1 | ( 1,2,4]oxadiazol-5-yl)-pyrazol-1 - | |||
yl]-N,N-dimethyl-acetamide |
256 | ça | 5-(4- {1 -Cyclopropyl-1 -[5-( 1 methyl-1 H-pyrazol-4-yl)[l,2,4]oxadiazol-3-yl]-ethyl}phenyl)-2,3 -dihydro-1Hpyrrolo [2,3 -bjpyridine |
257 | . r; γΧ χ YU Α/ Xk b Ar | 2-[4-(3-{(R)-l-[4-(2-Amiïio-4- rnethyl-pyrirnidin-5-yl)-phenyl]-1 cyclopropyl-ethyl}- [ 1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N,N-dimethyl-acetamide |
258 | A ,Α^Ο'Ο’ ^A»'' AA 1 1 | 2-[4-(3-{(S)-l-[4-(2-Amino-4- methyl-pyrimidin-5-yl)-phenyl]-1 cyclopropyl-ethyl} [l,2,4]oxadiazol-5-yl)-pyrazol-lyl]-N,N-dimethyl-acetamide |
259 | l O K^AA ~=< H.AA q °=T~ o | 5-(4- {1 -Cyclopropyl-1 -[ 5-(4methanesulfonyl-piperidin-1 -yl)- [ 1,2,4]oxadiazol-3-yl]-ethyl} phenyl)-pyrimidin-2-ylamine |
260 | 2 '----N \ | N-(3-{ l-[4-(2-Amino-pyrimidin-5yl)-phenyl]-1,2-dimethyl-propyl} [l,2,4]oxadiazol-5-yl)-N,N’,N’trimethyl-ethane-1,2-diamine |
261 | A A /—\ h2n n / \ '---N λ | 5-(4- {1 -[5-(4-tert-Butyl-piperazinl-yl)-[l ,2,4]oxadiazol-3-yl]-l ,2dimethyl-propyl} -phenyl)pyrimidin-2-ylamine |
262 | JA Ay x° nAJ a A A N—λ OH | 1-(3-(1 -[4-(2-Amino-pyrimidin-5 yl)-phenyl]-1,2-dimethyl-propyl} [ 1,2,4]oxadiazol-5-yl)-piperidin-4ol |
263 | A/ ><N'· AA H?i N '/VA V° | 5-(4- {(R)-1 -Cyclopropyl-1 -[5-( 1 oxetan-3-yl-lH-pyrazol-4-yl)[l,2,4]oxadiazol-3-yl]-ethyl}phenyl)-pyridin-2-ylamine |
264 | JA _-N ÎiJ^ X° N'Y/ 'Y N \ A J A HjN N / \ '---N A | 5-(4- (1 -[5-(4-Isopropyl-piperazin1 -y l)-[ 1,2,4]oxadiazol-3-yl]-1,2dimethyl-propyl}-phenyl)pyrimidin-2-ylamine |
265 | A\ /À Afr /Y Y Η,Ν N νΑΛ v° | 5-(4-{(R)-l-Cyclopropyl-l-[5-(loxetan-3-yl-lH-pyrazoI-4-yl)[l,2,4]oxadiazol-3-yl]-ethyl}phenyl)-pyrazin-2-ylamine; compound with trifluoro-acetic acid |
/
266 | b «a AA A X---N K | 5-(4- {1 -[5-(4-Cyclopropylpiperazin-1 -yl)-[ 1,2,4]oxadiazol-3yl]-1,2-dimethyl-propyl} -phenyl)pyrimidm-2-ylamine |
267 | 4 f'A’ ,,^AJ a AU -h Ν==/ O '---N H | 5-(4-{(S)-l-Cyclopropyl-l-[5(3,4,5,6-tetrahydro-2H[l,2’]bipyrazinyl-5'-yl)- [ 1,2,4]oxadiazol-3-yl]-ethyi} - phenyl)-pyrimidin-2-ylamine |
268 | A rA/AV I II l o JA À A C > O x---N H | 5-(4-{(S)-l-Cyclopropyl-l-[5(3,4,5,6-tetrahydro-2H[ 1,2’]bipyrazinyl-5'-yl)- [l,2,4]oxadiazol-3-yl]-ethyl}phenyl)-pyridin-2-ylamîne |
269 | .Λ. A A ίΎΥχ° n^A4 -a AU /-} K | 4-(3-( 1 -[4-(2- Amino-pyrimidin-5yl)-phenyl]-1,2-dimethyl-propyl} [ 1,2,4]oxadiazol-5-yl)-pîperazine- 1-carboxylic acid dimethylamide |
270 | „aA c o--- | 5-(4- {1 -[5-(4-Methoxy-piperidin-1 yl)-[ 1,2,4 Joxadiazol-3-yl]-1,2dimethyl-propyl} -phenyl)pyrimidin-2-ylamine |
271 | x .X ίτ γΧ λ o AU À N Z | 5-(4- {(R)-l -Cyclopropyl-1 -[5-(l cyclopropyl-1 H-pyrazol-4-yl)[l,2,4]oxadiazol-3-yl]-ethyl}phenyl)-pyrimidin-2-ylamine |
272 | aJ Η,Ν N | [4-(3- {1 -[4-(2-Amino-pyrimidm-5yl)-phenyl]-l,2-diniethyl-propyl] [ 1,2,4]oxadiazol-5-yl)-piperazin-1 yl]-acetic acid |
273 | X \ | 2-(4- {1 -Cyclopropyl- l-[5-(lmethyl-1H-pyrazol -4-y ) ) - [ 1,2,4]oxadiazol-3-yl]-ethyl}phenyl)-5H-pyrrolo[2,3 -bjpyrazine |
274 | ζ^Α\γΝ χ ta c OH | 1 -(3- {1 -[4-(2- Amino-pyrimidin-5yl)-phenyl]-1 -cyclopropyl-ethyl} [ 1,2,4]oxadiazol-5-yl)-azetidin-3-ol |
275 | t Aa „w γ A çî, ^0 | 2-[4-(3- {l -[4-(2-Amino-4-fluoropyrimidin-5-yl)-phenyl]-1 cyclopropyl-ethyl} - [ 1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N,N-dimethyl-acetamide |
276 | h2 AA^^γ [Y | 1-(3-(1- [4-(2-Amino-pyrimidin-5yl)-phenyl]-l-cyclopropyl-ethyl}[l,2,4]oxadiazol-5-yl)-3-methylazetidin-3-ol |
277 | cxJ À < N NH2 <Yn | 2-[4-(3- {1 -[4-(2-Amino-6-fluoropyridin-3-yl)-phenyl]-lcyclopropyl-ethyl}- [ 1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N,N-dimethyl-acetamide |
278 | A7’! H=N N F <( « N V -A | 2-[4-(3-{l-[4-(6-Amino-2-fluoropyridin-3-yl)-phenyl]-lcyclopropyl-ethyl} - [1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N,N-dimethyl-acetamide idin-3-yl)-phenyl]-1 -cyclopropyl-et hyl}-[l,2,4]oxadiazol-5-yl)-pyrazol -1 -yl]-N,N-dimethyl-acetamide |
279 | aAV H V ^-N N1 1 | 2-[4-(3- {(R)-1 -Cyclopropyl-1 -[4(2-isopropylamino-pyrimîdin-5-yl)phenyl]-ethyl} -[ 1,2,4]oxadiazol-5yl)-pyrazol-l-yl]-N,N-dimethylacetamide |
280 | iVVN' V Ί N X À 1 A oA | 2-[4-(3-{(R)-l-Cyclopropyl-l-[4- (6-methylamino-pyridin-3-yl)phenyl]-ethyl}-[l,2,4]oxadiazol-5yl)-pyrazol-l-yl]-N,N-dimethylacetamide |
281 | i / i l 1 o ArA x 1 o<=X | 2-[4-(3- {(R)-1 -[4-(6-Amino-5tri fluorom ethyl-pyridîn-3 -yl)phenyl]-1 -cyclopropyl-ethyl} [ 1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N.,N-dimethyl-acetamide |
282 | x I l 1 o pAJ 4 A J /v h2n n / \ OH | 1 -(3- {(R)-1 - [4-(6-Amino-pyridin3-yl)-phenyl]-l-cyclopropyl-ethyl}[ 1,2,4]oxadiazoi-5-yl)-piperidin-4ol |
/
283 | 4 I l o pXJ y A J Λ H2N N / \ OH | 1 -(3 - {(S)-1 -[4-(6-Amino-pyridin-3 yl)-phenyl]-1 -cyclopropyl-ethyl} [ 1,2,4]oxadiazol-5-yl)-piperidin-4ol |
284 | ’v. N 1 1 | 2-[4-(3- {(R)-1 -Cyclopropyl-1 - [4(2,3-dihydro-1 H-pyrrolo[2,3b]pyridin-5-yl)-phenyl]-ethyl}[ 1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N,N-dimethyl-acetamide |
285 | AL N 1 f444 1 | 2-[4-(3-{(R)-l-[4-(5-Amino-3methyl-pyrazin-2-yl)-phenyl] -1 cyclopropyl-ethyl} [ 1,2,4]oxadiazol-5-yI)-pyrazol-1 yl]-N,N-dîmethyl-acetamide |
286 | Zr/A N A A N \ | 3-(4- {1 -Cyclopropyl-1 -[5-( 1 methyl-1 H-pyrazol-4-yl)[l,2,4]oxadiazol-3-yl]-ethyl}phenyl)-5 -methoxy-pyridine |
287 | ^-N Îl x° Νζζζχ^ΑΑ J Il n—i h’n z 0 HO* | (R)-l-(3-{l-[4-(2-Amino- pyrimidin-5-yl)-phenyl]-1cyclopropyl-ethyl}- [ 1,2,4]oxadiazol-5-yl)-piperidin-3ol |
288 | ifXv Νχ° Il N----\ X θ ho' | (S)-1-(3-( l-[4-(2-Aminopyrimidin-5-yl)-phenyl]-1 cyclopropyl-ethyl} [ 1,2,4]oxadiazol-5-yl)-piperidîn-3ol |
289 | î/f XyU A H/< H Fl 1 | 2-(4-(3-{l-[4-(5-Amino-6- trifluoromethyl-pyrazin-2-yl)- phenyl]-1 -cyclopropyl-ethyl} [ 1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N,N-dimethyl-acetamide |
290 | F fiXo V h. N A | 3-Benzyloxy-5-(4- {1 -cyclopropyl- 1 -[5-(l -methyl-1 H-pyrazol-4-yl)[l,2,4]oxadiazol-3-yl]-ethyl}phenyl)-pyridîne |
291 | /X AA < Af \ 1 o Y î H=N N X N1 AKA' 1 | 2-(4-(3-{(R)-l-[4-(6-Amino-5- fluoiO-pyridin-3-yl)-phenyl]-1 cyclopropyl-ethyl} - [ 1,2,4]oxadiazol-5-yl)-pyrazol-l - yl]-N,N-dimethyl-acetamide |
292 | Ay JFJ ..N [ I o jxJ $ N 1 A | 2-(4-(3-{(R)-1-[4-(6-Amino-2- methyl-pyridin-3-yl)-phenyl]-lcyclopropyl-ethyl} - [1,2,4]oxadiazol-5-yl)-pyrazol-1 - yll-NjN-dimethyl-acetamide |
293 | i Æv nAA> -A h,An1 Π N | 2-(4-(3-{(R)-1-(4-(2-Amino-4fluoro-pyrimidin-5-yl)-phenyl] -1 cyclopropyl-ethyl} - [ 1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N,N-dimethyl-acetamide |
294 | Γ]^Νο Y\/U Nk h/AL <T»n Ço | 2-(4-(3- {(R)-1-(4-(5-Amino-6cyano-pyrazin-2-yl)-phenyl]-1 cyclopropyl-ethyl} - ( 1,2,4]oxadiazol-5-yl)-pyrazol-l - yl]-N,N-dimethyl-acetamide |
295 | A- F ç -x | 2-(4-(3- {1-(4-(5-Amino-3-cyanopyrazin-2-yl)-phenyl]-1 cyclopropyl-ethyl} - [ 1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N,N-dimethyl-acetamide |
296 | Av. vc j h2n n^n | 2-(4-(3 - {1 -(4-(6-Amino-2-cyanopyridin-3 -yl)-phenyl] -1 cyclopropyl-ethyl}- ( 1,2,4]oxadiazol-5-yl)-pyrazol-1 yl]-N,N-dimethyl-acetamîde |
297 | AA V\ V ,^,ίΓΧί’ JJ /~O-“ H,N N \---/ | 4-[(3- {1-(4-(2-Amîno-pyrimîdin-5yl)-phenyl]-1-cyclopropyl-ethyl} - [ 1,2,4]oxadiazol-5-yl)-methylamino]-cyclohexanol |
298
2-[4-(3-{(R)-1 -[4-(2-Amino-4fluoro-6-methyl-pyrimidin-5 -yl)phenyl]-l -cyclopropyl-ethyl} [ l ,2,4]oxadiazol-5-yl)-pyrazol-lyl]-N,N-dimethyl-acetamide
In one embodiment, the invention relates to any of the compounds depicted in Table 1 above or pharmaceutically acceptable salts thereof.
Représentative compounds of the invention show activity in the FLAP binding assay, described in the assessment of biological properties section, as shown in Table 2.
Table 2
Example | FLAP binding IC50 (nM) | Human Whole Blood IC50 (nM) |
1 | 57 | |
2 | 5.1 | 680 |
3 | 1.7 | 94 |
4 | 1.6 | 310 |
5 | 1.6 | 150 |
6 | 1.1 | 70 |
7 | 3.1 | 560 |
8 | 3.8 | 530 |
9 | 2.9 | 210 |
10 | 4.3 | |
11 | 1.9 | 89 |
12 | 3.3 | 290 |
13 | 3.6 | 460 |
14 | 4.6 | 140 |
15 | 2.0 | 46 |
16 | 2.5 | 110 |
17 | 24 | 510 |
18 | 3.3 | 320 |
19 | 5.8 | 260 |
20 | 10 | 3200 |
21 | 5.5 | 87 |
22 | 4.2 | 46 |
23 | 6.9 | 170 |
24 | 19 | 410 |
25 | 6.0 | 170 |
26 | 9.1 | 160 |
27 | 12 | 330 |
28 | 26 | 320 |
29 | 5.3 | 190 |
30 | 5.0 | 60 |
31 | 1.6 | 200 |
32 | 18 | 2500 |
33 | 6.6 | 210 |
34 | 3.7 | 160 |
35 | 3.2 | 360 |
36 | 3.2 | 170 |
37 | 7.4 | 250 |
38 | 2.2 | 97 |
39 | 2.1 | 110 |
40 | 2.3 | 100 |
41 | 2.2 | 170 |
42 | 1.5 | 25 |
43 | 2.5 | 30 |
44 | 2.2 | 150 |
45 | 3.1 | 140 |
46 | 1.6 | 33 |
47 | 7.7 | 360 |
48 | 6.8 | 190 |
49 | 19 | 680 |
50 | 1.3 | 95 |
51 | 3.9 | 140 |
52 | 2.4 | 26 |
53 | 27 | 450 |
54 | 2.6 | 27 |
55 | 11 | 200 |
56 | 2.4 | 79 |
57 | 6.8 | 150 |
58 | 11 | 190 |
59 | 1.1 | 76 |
60 | 4.0 | 140 |
61 | 1.3 | 15 |
62 | 18 | 350 |
63 | 1.1 | 14 |
64 | 16 | 410 |
65 | 75 | 1500 |
66 | 11 | 330 |
67 | 6.2 | 190 |
68 | 6.7 | 93 |
69 | 7.7 | 120 |
70 | 7.1 | 590 |
71 | 17 | 900 |
72 | 12 | 440 |
73 | 28 | 990 |
74 | 17 | 640 |
75 | 23 | 260 |
76 | 35 | 270 |
77 | 1.7 | 36 |
78 | 1.3 | 240 |
79 | 150 | 2200 |
80 | 23 | 350 |
81 | 11 | 180 |
82 | 13 | 220 |
83 | 26 | 1100 |
84 | 120 | 1700 |
85 | 48 | >5000 |
86 | 190 | >5000 |
87 | 41 | 970 |
88 | 51%inh@1000nM | >5000 |
89 | 13 | 270 |
90 | 63 | 1500 |
91 | 54 | 1300 |
92 | 110 | >5000 |
93 | 240 | >5000 |
94 | 350 | >5000 |
95 | 130 | >5000 |
96 | 7.5 | 150 |
97 | 8.8 | 170 |
98 | 12 | 570 |
99 | 3.9 | 200 |
100 | 2.3 | 110 |
101 | 280 | >5000 |
102 | 1.6 | 51 |
103 | 130 | 2700 |
104 | 6.1 | 130 |
105 | 490 | >5000 |
106 | 4.8 | 76 |
107 | 0.86 | 17 |
108 | 8.7 | 320 |
109 | 46 | 1500 |
110 | 190 | 2800 |
111 | 15 | 2900 |
112 | 190 | >5000 |
113 | 66 | 3100 |
114 | 21 | 1100 |
115 | 1.9 | 58 |
116 | 150 | 2000 |
117 | 31 | 1200 |
118 | 9.9 | 820 |
119 | 9.2 | 900 |
120 | 40 | 2100 |
121 | 2.6 | 91 |
122 | 140 | 3200 |
123 | 1.7 | 42 |
124 | 2.3 | 31 |
125 | 1.5 | 290 |
126 | 4.6 | 260 |
127 | 2.9 | 650 |
128 | 1.6 | 240 |
129 | 2 | 180 |
130 | 1.4 | 180 |
131 | 8.7 | |
132 | 2.8 | 330 |
133 | 1.6 | 190 |
134 | 8.3 | 190 |
135 | 1.4 | 250 |
136 | 5.4 | 320 |
137 | 2.8 | 77 |
138 | 15 | 760 |
139 | 4.4 | |
140 | 4.1 | 710 |
141 | 1.5 | 530 |
142 | 1.1 | 59 |
143 | 4.1 | 360 |
144 | 3.1 | 26 |
145 | 17 | 2500 |
146 | 1.3 | 46 |
147 | 2.7 | 86 |
148 | 14 | 610 |
149 | 58 | |
150 | 330 | 1800 |
151 | 2.3 | 100 |
152 | 3.3 | 270 |
153 | 4.6 | 180 |
154 | 3,3 | |
155 | 1.9 | 81 |
156 | 15 | |
157 | 3.3 | 760 |
158 | 3.4 | 55 |
159 | 4.6 | 83 |
160 | 9.0 | >5000 |
161 | 2.0 | 36 |
162 | 2.3 | 41 |
163 | 0.74 | 30 |
164 | 1.4 | 2700 |
165 | 2.1 | 89 |
166 | 26 | 2400 |
167 | 46 | 4300 |
168 | 21 | 390 |
169 | 14 | 370 |
170 | 14 | 310 |
171 | 220 | 1900 |
172 | 1.1 | 66 |
173 | 2.4 | 31 |
174 | 1.2 | 19 |
175 | 2.2 | 39 |
176 | 1.2 | 73 |
177 | 8.9 | 66 |
178 | 2.2 | 180 |
179 | 4.6 | 49 |
180 | 2.9 | 29 |
181 | 3.3 | 51 |
182 | 3.1 | 14 |
183 | 5.5 | 39 |
184 | 2.0 | 23 |
185 | 1.9 | 28 |
186 | 20 | 150 |
187 | 17 | 23 |
188 | 48 | 51 |
189 | 13 | 49 |
190 | 5.9 | 230 |
191 | 5.9 | 17 |
192 | 23 | 740 |
193 | 18 | 230 |
194 | 6.0 | 96 |
195 | 4.6 | 280 |
196 | 2.2 | 180 |
197 | 16 | >5000 |
198 | 7.5 | 280 |
199 | 32 | 690 |
200 | 15 | 250 |
201 | 13 | 200 |
202 | 46 | 350 |
203 | 15 | 130 |
204 | 13 | 150 |
205 | 11 | 68 |
206 | 23 | 310 |
207 | 92 | 700 |
208 | 13 | 250 |
209 | 8.2 | 100 |
210 | 4.4 | 190 |
211 | 12 | 230 |
212 | 12 | 86 |
213 | 14 | 330 |
214 | 12 | 450 |
215 | 3.6 | 28 |
216 | 7.7 | 34 |
217 | 90 | 1200 |
218 | 130 | 920 |
219 | 39 | >5000 |
220 | 8.5 | 210 |
221 | 6.2 | 150 |
222 | 130 | 1700 |
223 | 7.3 | 55 |
224 | 80 | 760 |
225 | 16 | 350 |
226 | 2.0 | 30 |
227 | 3.1 | 21 |
228 | 54 | 550 |
229 | 99 | 550 |
230 | 3.8 | 160 |
231 | 120 | 700 |
232 | 37 | 370 |
233 | 5.2 | 37 |
234 | 230 | 1000 |
235 | 29 | 780 |
236 | 89 | 1300 |
237 | 26 | 470 |
238 | 5.0 | 29 |
239 | 4.1 | 290 |
240 | 15 | 190 |
241 | 3.4 | 170 |
242 | 5.7 | 310 |
243 | 12 | 170 |
244 | 25 | 270 |
245 | 28 | 310 |
246 | 19 | 430 |
247 | 5.9 | 300 |
248 | 10 | 80 |
249 | 370 | >5000 |
250 | 470 | >5000 |
251 | 9.1 | 130 |
252 | 15 | 220 |
253 | 3.8 | 120 |
254 | 2.8 | 210 |
255 | 15 | 1800 |
256 | 4.5 | 51 |
257 | 7.3 | 150 |
258 | 430 | 2300 |
259 | 16 | 270 |
260 | 94 | 900 |
261 | 11 | 190 |
262 | 11 | 84 |
263 | 3.5 | 21 |
264 | 11 | 120 |
265 | 5.1 | 22 |
266 | 16 | 170 |
267 | 12 | 390 |
268 | 9.3 | 600 |
269 | 24 | 230 |
270 | 9.8 | 96 |
271 | 4.9 | 51 |
272 | 280 | >5000 |
273 | 6.1 | 56 |
274 | 40 | 200 |
275 | 11 | 220 |
276 | 28 | 260 |
277 | 64 | >5000 |
278 | 5.0 | 150 |
279 | 76 | >5000 |
280 | 3.0 | 35 |
281 | 5.0 | 160 |
282 | 6.5 | 44 |
283 | 16 | 920 |
284 | 4.7 | 200 |
285 | 7.0 | 190 |
286 | 16 | 2100 |
287 | 7.0 | 150 |
288 | 2.5 | 200 |
289 | 22 | 1000 |
290 | 22 | 2000 |
291 | 4.5 | 89 |
292 | 8.5 | 150 |
293 | 3.5 | 110 |
294 | 7.0 | 200 |
295 | 7.5 | 150 |
296 | 12 | 230 |
297 | 8.5 | 79 |
298 | 10 | 130 |
i i
i i
The invention also relates to pharmaceutical préparations, containing as active substance one or more compounds of the invention, or the pharmaceutically acceptable dérivatives thereof, optionally combined with conventional excipients and/or carriers.
Compounds of the invention also include their isotopically-labelled forms. An isotopically-labelled form of an active agent of a combination of the présent invention is îdentical to said active agent but for the fact that one or more atoms of said active agent 10 have been replaced by an atom or atoms having an atomic mass or mass number different from the atomic mass or mass number of said atom which is usually found in nature. Examples of isotopes which are readily available commercially and which can be incorporated into an active agent of a combination of the présent invention in accordance with well established procedures, include isotopes of hydrogen, carbon, nitrogen, oxygen, 15 phosphorous, fluorine and chiorine, e.g., 2H, 3H, 13C, 14C, ,5N, 18O, 17O, 31P, 32P, 35S, 18F, and 36C1, respectively. An active agent of a combination of the présent invention, a / prodrug thereof, or a pharmaceutically acceptable sait of either which contains one or more of the above-mentioned isotopes and/or other isotopes of other atoms is contemplated to be within the scope of the présent invention.
The invention includes the use of any compounds of described above containing one or more asymmetric carbon atoms may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Isomers shall be defined as being enantiomers and diastereomers. Ail such isomeric forms of these compounds are expressly included in the présent invention. Each stereogenîc carbon may be in the R or S configuration, or a combination of configurations.
Some of the compounds of the invention can exist in more than one tautomeric form.
The invention includes methods using ail such tautomers.
Ail terms as used herein in this spécification, unless otherwise stated, shall be understood in their ordînary meaning as known in the art. For example, “Cif) alkoxy” is a Ci-6 alkyl with a terminal oxygen, such as methoxy, ethoxy, propoxy, butoxy. Ail alkyl, alkenyl, and alkynyl groups shall be understood as being branched or unbranched where structurally possible and unless otherwise specified. Other more spécifie définitions are as follows:
The term “alkyl” refers to both branched and unbranched alkyl groups. It should be understood that any combination term using an “alk” or “alkyl” prefix refers to analogs according to the above définition of “alkyl”. For example, terms such as “alkoxy”, “alkythio” refer to alkyl groups linked to a second group via an oxygen or sulfur atom. “Alkanoyl” refers to an alkyl group linked to a carbonyl group (C=O).
In ail alkyl groups or carbon chains, one or more carbon atoms can be optionally replaced by heteroatoms such as O, S or N. It shall be understood that if N is not substituted then it îs NH. It shall also be understood that the heteroatoms may replace either terminal carbon atoms or internai carbon atoms within a branched or unbranched carbon chain. X
Such groups can be substituted as herein above described by groups such as oxo to resuit in définitions such as but not limited to: alkoxycarbonyl, acyl, amido and thioxo.
As used herein, “nitrogen” and “sulfur” include any oxidîzed form of nitrogen and sulfur and the quatemized form of any basic nitrogen. For example, for a -S-Cj_6 alkyl radical, unless otherwise specified, shall be understood to include -S(O)-Ci_6 alkyl and -S(O)2-CM alkyl.
The term C1.3hydroxy also means -Ci^alkyl-hydroxy or -C'i ;alkyl-OH.
The term “C3_to carbocycle” refers to a nonaromatic 3 to 10-membered (but preferably, 3 to 6-membered) monocyclic carbocyclic radical or a nonaromatic 6 to 10-membered fused bicyclic, bridged bicyclic, or spirocyclîc carbocyclic radical. The C3.10 carbocycle may be either saturated or partially unsaturated, and the carbocycle may be attached by any atom of the cycle which results in the création of a stable structure. Non-limiting examples of 3 to 10-membcred monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptanyl, cycloheptenyl, and cyclohexanone. Non-limiting examples of 6 to 10-membered fused bicyclic carbocyclic radicale include bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, and bicyclo[4.4.0]decanyl (decahydronaphthalcnyl). Non-limiting examples of 6 to 10-membered bridged bicyclic carbocyclic radicale include bicyclo [2.2.2]heptanyl, bicyclo[2.2.2]octanyl, and bicyclo[3.2.1]octanyl. Non-limiting examples of 6 to 10-membered spirocyclîc carbocyclic radicals include but are not limited to spiro[3,3]heptanyl, spiro[3,4]octanyl and spiro[4,4]heptanyl.
The term “Cé-io aryl” or “aryl” refers to aromatic hydrocarbon rings containing from six to ten carbon ring atoms. The term C^io aryl includes monocyclic rings and bicyclic rings where at least one of the rings îs aromatic. Non-limiting examples of C^jq aryls include phenyl, indanyl, indenyl, benzocyclobutanyl, dihydronaphthyl, tetrahydronaphthyl, naphthyl, benzocycloheptanyl and benzocycloheptenyl. X
The term “5 to 11 -membered heterocycle” refers to a stable nonaromatic 4-8 membered monocyclic heterocyclic radical or a stable nonaromatic 6 to 11-membered fused bicyclic, bridged bicyclic or spirocyclic heterocyclic radical. The 5 to 11-membered heterocycle consists of carbon atoms and one or more, preferably from one to four heteroatoms chosen from nitrogen, oxygen and sulfur. The heterocycle may be either saturated or partially unsaturated. Non-limitîng examples of nonaromatic 4-8 membered monocyclic heterocyclic radicals include tetrahydrofuranyl, tetrahydropyranyl, oxetanyl, azetidinyl, pyrrolidinyl, pyranyl, tetrahydropyranyl, dioxanyl, thiomorpholinyl, 1,1dioxo-A-thiomorpholinyl, morpholinyl, piperidinyl, piperazinyl, and azepinyl. Non10 limiting examples of nonaromatic 6 to 11-membered fiised bicyclic radicals include octahydroindolyl, octahydrobenzofuranyl, and octahydrobenzothiophenyl. Non-limiting examples of nonaromatic 6 to 11-membered bridged bicyclic radicals include 2azabicyclo[2.2.1]heptanyl, 3-azabicyclo[3.1.0]hexanyl, and 3-azabicyclo[3.2.1]octanyl. Non-limiting examples of nonaromatic 6 to 11-membered spirocyclic heterocyclic radicals include 7-aza-spiro[3,3]heptanyl, 7-spîro[3,4]octanyl, and 7-azaspiro[3,4]octanyl.
The term “5 to 11-membered heteroaryl” shall be understood to mean an aromatic 5 to 6membered monocyclic heteroaryl or an aromatic 7 to 11-membered heteroaryl bicyclic ring where at least one of the rings is aromatic, wherein the heteroaryl ring contains 1-4 heteroatoms such as N, O and S. Non-limiting examples of 5 to 6-membered monocyclic heteroaryl rings include furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, pyrazolyl, pyrrolyl, imidazolyl, tetrazolyl, triazolyl, thienyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazînyl, and purinyl. Non-limiting examples of 7 to 1125 membered heteroaryl bicyclic heteroaryl rings include benzîmidazolyl, quinolinyl, dihydro-2//-quino[iny!, isoquinoiinyl, quinazoiinyl, indazolyl, thieno[2,3-d]pyrimidinyl, indolyl, isoindolyl, benzofuranyl, benzopyranyl, benzodioxolyl, benzoxazolyl, pyridooxazinyl, dîhydro-pyridooxazinyl, dihydro-pyrrolopyridinyl, pyrroiopyridinyl, pyrrolopyrazinyl, and benzothiazolyl.
It will be understood that one to three carbon ring moieties in the each of the C3_io carbocyclic rings, the 5 to 11-membered heterocyclic rings, the nonaromatic portion of the bicyclic aryl rings, and the nonaromatic portion of the bicyclic heteroaryl rings can independently be replaced with a carbonyl, thiocarbonyl, or iminyl moiety, i.e., -C(=O)-, -C(=S)- and -C(=NR8)-, respectively, where R8 is as defined above.
The term “heteroatom” as used herein shall be understood to mean atoms other than carbon such as O, N, and S.
The term “halogen” as used in the présent spécification shall be understood to mean bromine, chlorine, fluorine or iodine. The définitions “halogenated”, “partially or fully halogenated”; partially or fully fluorinated; “substituted by one or more halogen atoms”, includes for example, mono, dî or tri halo dérivatives on one or more carbon atoms. For alkyl, a non-limiting example would be -CH2CHF2, -CF3 etc.
Each alkyl, carbocycle, heterocycle or heteroaryl, or the analogs thereof, described herein shall be understood to be optionally partially or fully halogenated.
The compounds of the invention are only those which are contemplated to be ‘chemîcally stable’ as will be appreciated by those skilled in the art. For example, a compound which would hâve a ‘dangling valency’, or a ‘carbanion’ are not compounds contemplated by the inventive methods disclosed herein.
The invention includes pharmaceutically acceptable dérivatives of compounds of formula (I). A pharmaceutically acceptable dérivative refers to any pharmaceutically acceptable sait or ester, or any other compound which, upon administration to a patient, is capable of providing (directly or indirectly) a compound useful for the invention, or a pharmacologically active métabolite or pharmacologically active residue thereof. A pharmacologically active métabolite shall be understood to mean any compound of the invention capable of being metabolized enzymatically or chemîcally. This includes, for example, hydroxylated or oxidîzed dérivative compounds of the invention.
Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulfiiric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfuric, tartane, acetic, citric, methanesulfonic, formic, benzoîc, malonîc, naphthalene-2-sulfuric and benzenesulfonic acids. Other acids, such as oxalic acid, while not themselves pharmaceutically acceptable, may be employed in the préparation of salts usefol as intermediates in obtaining the compounds and their pharmaceutically acceptable acid addition salts. Salts derived from appropriate bases include alkali métal (e.g., sodium), alkaline earth métal (e.g., magnésium), ammonium and N-(C |-C^ alkyl)4+ salts.
In addition, within the scope of the invention is use of prodrugs of compounds of the invention. Prodrugs include those compounds that, upon simple chemical transformation, are modified to produce compounds of the invention. Simple chemical transformations include hydrolysîs, oxidation and réduction. Specifically, when a prodrug is administered to a patient, the prodrug may be transformed into a compound disclosed hereinabove, thereby imparting the desired pharmacological effect.
The compounds of formula I may be made using the general synthetic methods described below, which also constitute part of the invention.
GENERAL SYNTHETIC METHODS
The invention also provides processes for making compounds of Formula (I). In all Schemes, unless specified otherwise, R1, R2, R3, R4 an^ R5 in the Formulas below shall hâve the meaning of R1, R2, R3, R4 and Rs in Formula (I) of the invention described herein above.
Optimum reaction conditions and reaction times may vary depending on the particular reactants used. Unless otherwise specified, solvents, températures, pressures, and other reaction conditions may be readily selected by one of ordinary skill în the art. Spécifie procedures are provided in the Synthetic Examples section. Typicalîy, reaction progress z may be monitored by thin layer chromatography (TLC) or LC-MS, if desired, and intermediates and products may be purified by chromatography on silica gel, recrystallization and/or préparative HPLC.
The examples which follow are illustrative and, as recognized by one skilled in the art, particular reagents or conditions could be modified as needed for individual compounds without undue expérimentation, Starting materials and intermediates used, in the Schemes below, are either commercially available or easily prepared from commercially available materials by those skilled in the art.
The compounds of Formula (I) may be synthesized according to Scheme 1:
Scheme 1
As illustrated in scheme 1, reaction of a compound of formula II with a boronic acid or the corresponding boronic acid ester shown in the above scheme, in a suitable solvent, în the presence of a suitable catalyst, provides a compound of formula (I). Ra and Rb are hydrogen or Ra and Rb together with the oxygen atoms to which they are attached form a 5-6 membered ring optionally substituted with 2-4 methyl groups.
Alternatively, reaction of a compound of formula II with a diborane, under standard reaction conditions, provides a compound of formula III. Coupling the intermediate of z' formula III with a halide or triflate R3X, in a suitable solvent, in the presence of a suitable catalyst, provides a compound of formula (I). X is chloro,bromo, triflate, or iodo.
The compounds of Formula (I) may be prepared according to Scheme 2:
R5COCI or
R5COOH
Scheme 2
As illustrated in scheme 2, réaction of a compound of formula IV with an acid chloride
R5COC1, in a suitable solvent, in the presence of a suitable base, provides a compound of formula (I).
Altematively, reaction of a compound of formula IV with an acid R5COOH, in a suitable solvent, in the presence of carbonyl diimidazole, or other suitable amide coupling reagent, provides a compound of formula (I).
The intermediate of formula Π may be synthesized as outlined in Scheme 3 : S
Scheme 3
As illustrated in scheme 3, reaction of a nitrile of formula V with a halide R*X, in a suîtable solvent, in the presence of a suîtable base such as sodium hydride or potassium tbutoxide, provides a substituted nitrile of formula VI, Further reaction of the intennediate of formula VI with a halide R2X, in a suîtable solvent, in the presence of a suîtable base, provides the corresponding disubstituted nitrile of formula VII. X is chloro, bromo, or iodo. Reaction of the compound of formula VII with hydroxylamîne, under standard reaction conditions, provides a compound of formula VIII. Réaction of the compound of formula VIII with an acid chloride R5COC1, in a suîtable solvent, in the presence of a suîtable base, provides a compound of formula II. Alternative!y, reaction of a compound of formula VIII with an acid R5COOH, in a suîtable solvent, in the presence of carbonyl diimidazole, or other suîtable amide coupiing reagent, provides a compound of formula 15 II.
Aitematively, reaction of a compound of formula VIII with a reagent such as carbonyldiimidazole provides a compound of formula II wherein Rs îs -OH. Further tranformation of this -OH may be carried out by procedures known in the art, to provide additional compounds of formula II.
100
Nitrile intermediate of formula VII may also be resolved via resolution techniques, known to one skilled in the art, to provide the enantiomers VIIA and VIIA’. Each of these enantiomers may be further converted to a compound of formula I by the reaction sequence shown above in scheme 3.
The intermediate of formula II may also be synthesized as shown in Scheme 4:
Scheme 4
As shown în scheme 4, réaction of a carbonyl compound of formula IX with a grignard reagent R2MgX, in a suitable solvent, provides a hydroxy compound of formula X. Conversion of the hydroxyl group in compound of formula X to a cyano group, using 15 standard procedures, provides a compound of formula VII. The compound of formula
VII is converted to the intermediate of formula II by the reactions shown in scheme 3. X in R2MgX is chloro, bromo or iodo.
The intermediate of formula IV may be synthesized according to Scheme 5:
As illustrated above in scheme 5, reaction of a nitrile of formula VII with a boronic acid or the corresponding boronic acid ester shown in the above scheme, in a suitable solvent, /
101 in the presence of a suitable catalyst, provides a compound of formula XI. Ra and Rb are hydrogen or Ra and Rb together with the oxygen atoms to which they are attached form a 5-6 membered ring optionally substituted with 2-4 methyl groups. Reaction of a compound of formula XI with hydroxylamine, under standard reaction conditions, provides a compound of formula IV.
The nitrile intermediate of formula VII may be synthesized according to Scheme 6:
Scheme 6
As illustrated în scheme 6, reaction of a ketone of formula XIII with methylating agent in the presence of a suitable base, in a suitable solvent, provides an enolether of formula XIV. Reaction of the enolether XIV with an oxidizing agent such as ozone, under suitable conditions, provides an ester of formula XV. Hydrolysis of the ester of formula XV, in a suitable solvent, in the presence of a suitable base, provides an acid of formula XII. This racemic acid may be resolved to provide the enantiomers XiïA and XIIA’. Altematively, the acid XII may be reacted with an organic base such as a primary or secondary amine, în a suitable solvent, to provide the corresponding sait. /
102
Reaction of a carboxylic acid of XII with a reagent such as ammonia, in a suitable solvent, provides an amide of formula XVII. Reaction of the amide of formula XVII with a suitable dehydrating agent, în a suitable solvent, provides a nitrile of formula VII. Non-limiting examples of bases useful in step (a) include potassium t-butoxide, sodium tbutoxide, lithium ΐ-butoxide, sodium hydride, potassium hydride, lithium hydride, sodium hexamethyldisilazide, potassium hexamethyldisilazide, lithium hexamethyldisilazide, sodium methoxide, potassium methoxide, lithium methoxide, sodium ethoxide, potassium ethoxide, lithium ethoxide, LD A, n-butyllithium, sec-butyllithium or t-butyllithium. Nonlimiting examples of solvents useful for step (a) include dimethylformamide, dichloromethane, ethyl acetate, hexane, heptane, acetonitrile, methyl tert-butyl ether, isopropyl acetate, toluene, and cyclopropylmethyl ether. Non-limiting examples of alkylating agents useful in step (a) include dimethyl sulfate, dimethyl carbonate, bromomethane, methyl trifluoromethanesulfonate and iodomethane. Non-limiting examples of silylating agents useful in step (a) include trimethylchlorosilane, tertbutyldimethylchlorosilane, triphenylchlorosilane, and triisopropylchlorosilane, triethylchlorosilane.
Non-limiting examples of solvents useful in step (b) include dimethylformamide, dichloromethane, ethyl acetate, hexane, heptane, acetonitrile, methyl tert-butyl ether, isopropyl acetate, toluene, and cyclopropylmethyl ether. Non-limiting examples of bases useful in step (b) include l,8-diazabicycloundec-7-ene (DBU), triethylamine, pyridîne, 4methylmorpholine, diisopropylethylamine and dimethylamine. Non-limiting examples of dehydrating agents usefiil in step (b) include acetic anhydride, methanesulfonyl chloride, trifluoroacetic anhydride, toluenesulfonyl chloride, sodium hypochlorite, calcium hypochlorite and tert-butyl hypochlorite.
Non-limiting examplcs of bases useful in step (c) include potassium hydroxide, sodium hydroxide, lithium hydroxide and césium hydroxide. Non-limiting examples of solvents usefiil in step (c) include methanol, methanol-water mixture, dimethylformamide, dichloromethane, ethyl acetate, hexane, heptane, acetonitrile, methyl tert-butyl ether, isopropyl acetate, toluene, and cyclopropylmethyl ether. /
103
The resolution of the racemic acid of formula ΧΠ described in optional step d) can be carried out using methods known in the art including, for example, fractional crystallization and chiral chromatography.
In one embodiment, the invention relates to a process of making intermediate acids XII, XII A or XIIA’ according to scheme 6 above. In another embodiment the invention relates to an intermediate acid of formula XII, XIIA or XIIA’
Compounds of formula I as well as întermediates prepared by the above methods may be further converted to additional întermediates or compounds of formula I by methods known in the art and exemplîfied in the Synthetic Examples section below.
SYNTHETIC EXAMPLES
The following are représentative compounds of the invention which can be made by the general synthetic schemes, the examples, and known methods in the art.
LCMS rétention time and observed m/z data for the compounds below is obtained by one of the following methods:
LC-MS Method A
Column | Agilent Zorbax Eclipse XDB-C8 5pm 4.6x150mm Ambient temperatur | |
Mobile phase | A = Formic acid (aq) 0.1% B = Formic acid (acetonitrile) 0.1% | |
Flow rate | 1.5 ml/min | |
Injection volume | 7uL | |
Detector | 200-600 nm | |
Gradient | Time (mins) | %B |
0 | 1 |
104
I ί J i
2 | 20 |
7 | 95 |
9 | 95 |
9.3 | 1 |
10 | 1 |
LC-MS Method B
Column | Agilent Zorbax C18 SB 3.5pm, 4.6x30mm Ambient température | |
Mobile phase | A = Formic acid (aq) 0.1 % B = Formic acid (acetonitrile) 0.1% | |
Flow rate | 2.5 ml/min | |
Injection volume | 7pL | |
Detector | 200-600 nm | |
Gradient | Time (mins) | %B |
0 | 5 | |
1.7 | 95 | |
2 | 95 | |
2.1 | 5 | |
2.3 | 5 |
LC-MS Method C
Column | Agilent SB-C18 l.Spm, 3x50mm Ambient température |
Mobile phase | A - Formic acid (aq) 0.1% B = Formic acid (acetonitrile) 0.1% |
Flow rate | 1.5 ml/min |
Injection volume | 3gL |
105 ί
Detector | 220 and 254 nm | |
Gradient | Time (mins) | %B |
0 | 5 | |
3.8 | 90 | |
4.5 | 100 |
LC-MS Method D
Column | Agilent SB-C18 l.Spm, 3x50mm column Ambient température | |
Mobile phase | A = Formic acid (aq) 0.1% B = Formic acid (acetonitrile) 0.1% | |
Flow rate | 1.5 ml/min | |
Injection volume | 3pL | |
Detector | 220 and 254 nm | |
Gradient | Time (mins) | %B |
0 | 12 | |
0.25 | 30 | |
0.3 | 40 | |
1.19 | 95 | |
1.75 | 100 |
LC-MS Method E
Column | Agilent SB-AQ Ι.δμιη, 3x50mm Ambient température |
Mobile phase | A = Formic acid (aq) 0.1 % B — Formic acid (acetonitrile) 0.1% |
Flow rate | 1.5 ml/min |
Injection volume | 3pL |
106
Detector | 220 and 254 nm | |
Gradient | Time (mins) | %B |
0 | 5 | |
0.25 | 50 | |
0.3 | 70 | |
1.3 | 90 | |
1.7 | 100 |
LC-MS Method F
Column | Waters Atlantis dC18 100 x 2.1mm, 3pm column 40 °C | |
Mobile phase | A - 0.1% Formic acid (water) B - 0.1% Formic acid (acetonitrile) | |
Flow rate | 0.6 ml/min | |
Injection volume | 3pL | |
Detector | 215nm (nominal) | |
Gradient | Time (mins) | %B |
0 | 5 | |
5 | 100 | |
5.4 | 100 | |
5.42 | 5 |
Synthetic Methods
The compounds of the invention may be prepared by the methods described below. Optimum reaction conditions and reaction times may vary depending on the particular reactants used. Unless otherwise specified, solvents, températures, pressures and other
107 reaction conditions may be readily selected by one of ordinary skill in the art. Spécifie procedures are provided in the Synthetic Examples section. Typically, reaction progress may be monitored by thin layer chromatography (TLC) or HPLC-MS if desired. Intermediates and products may be purified by chromatography on silica gel, 5 recrystallization and/or reverse phase HPLC. HPLC purification methods used anywhere from 0-100% acetonitrile in water and may contain 0.1% formîc acid, 0.1% TFA or 0.2% ammonium hydroxide and used one of the following columns:
a) Waters Sunfire OBD Cl8 5 μΜ 30x150 mm column
b) Waters XBridge OBD C18 5 μΜ 30x150 mm column
c) Waters ODB C8 5 μΜ 19x150 mm column.
d) Waters Atlantis ODB C18 5 μΜ 19x50 mm column.
e) Waters Atlantis T3 OBD 5 μΜ 30x100 mm column
f) Phenomenex Gemini Axia C18 5 μΜ 30x100 mm column
g) Waters SunFire C18 Prep OBD 5um 19 x 100 mm
h) Waters XBridge Prep C18 5 um 19 x 100 mm
Starting materials and reagents are either commercially avaîlable or may be prepared by one skilled in the art using methods described in the chemical lîterature.
Synthesis of Nitrile Intermediates:
Synthesis of 2-(4-bromo-phenyl)-2,3-dijnethylbutyronitrile X
108
To a solution of R-l (20.0 g, 0.102 mol) in DMF (300 mL) at 0 °C is added NaH (60% in oil suspension, 4.28 g, 0.107 mol) slowly. The mixture is then stirred for a further 15 minutes and 2-bromopropane (9.60 mL, 0.107 mol) is added. The reaction mixture is allowed to warm to room température, stirring contînued for 2 hours and then concentrated in vacuo. The residue is partitioned between CH2C12 and brine. The combined organics are dried with Na2SO4, filtered and concentrated in vacuo. The residue is purified by flash chromatography (SiO2, 0-15% EtOAc in heptane) to give 1-1 (21.3 g); m/z 238.3, 240.2 [M/M+2H]
1-1 (21.3 g, 89.6 mmol) is dissolved in DMF (300 mL). The mixture is cooled to 0 °C and NaH (60% in oil suspension, 3.76 g, 94.1 mmol) is added slowly. The mixture is then stirred for a further 15 minutes and methyl iodide (5.9 mL, 94.1 mmol) is added. The reaction mixture is stirred at 0 °C to room température for 2 hours and then concentrated m vacuo. The residue is partitioned between methylene chloride and brine. The combined organics are dried with Na2SC>4, filtered and concentrated in vacuo. The residue is purified by flash chromatography (SiO2, 0-15% EtOAc in hepatne) to give the tîtle intermediate (21.7 g); m/z 252.3, 254.3 [M/M+2H].
The following intermediates are synthesîzed in similar fashion from the approprîate reagents:
Intermediate | Structure |
1-3 | .Y |
Synthesis of 2-(4-bronio-phenyl)-2-cydopropylpropionitrile S
109
To a solution of R-2 (5.00 g, 22 mmol) in THF (30 mL) is added a solution of MeMgBr (l.OM in butyl ether, 27.0 mL). The solution is stirred for 30 min then treated with saturated aqueous NaHCO3. The mixture is partîoned between CH2CI2 and brine then organics are collected, dried with MgSO4, filtered, and concentrated to give R-3 (5.35 g).
To a solution of R-3 (5.35 g, 22.2 mmol) in CH2CI2 (100 mL) is added TMSCN (5.9 mL, mmol) and InBr3 (790 mg, 2.22 mmol). The reaction is stirred ovemîght then poured into 20% aqueous Na2CO3. The mixture is extracted with CH2CI2, dried with MgSO4, filtered, and concentrated in vacuo. The residue is purified by flash chromatography 10 (SiO2, 0-15% EtOAc in heptane) to give the title intermediate (3.82 g); ’H-NMR, 400
MHz, DMSO-iZdppm: 7.65 (2H)(d: J=12 Hz); 7.52 (2H)(d: J-12 Hz); 1.69 (3H) (s); 1.41 (IH) (m); 0.68 (IH) (m); 0.58 (2H)(m); 0.41 (IH) (m).
The following intermediates are synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M+H] |
1-5 | .X | 265.2 |
2-(4-Bromo-phenyl)-2-cyclopropylpropionitrile can also be prepared in the following manner:
To a solution of R-2 (309 g, 1.37 mol) in THF (3.0 L) îs added dropwise MeMgBr (3M in Et2O 1.37 L, 4.12 mol) at -78 °C. The mixture is stirred at -78 °C for 10 min and then at room température for 2 h. The reaction mixture is quenched with saturated aqueous '
110
NH4CI and extracted with EtOAc. The combined organic layers are washed with brine, dried over anhydrous Ni^SO-, and concentrated to afford the crude compound R-3 (330
g) which is used in the next step without further purification.
To a solution ofR-3 (330 g, 1.37 mol) in CH2C12 (2.4 L) is added dropwise BF3.EtO2 (198 g, 1.37 mol) at -78 °C. The mixture is stirred at the same température for 30 min. TMSCN (272 g, 2.74 mol) is added drop-wise at -78 °C. After addition, the mixture is allowed to stir at room température for 2 h. The reaction mixture is quenched with chilled water and the organic layer is separated. The aqueous phase is extracted with CH2C12. The organic layer is washed with brine, dried over anhydrus NajSCL and concentrated. The residue is purified by chromatography on silica gel with petroleum ether/EtOAc (50:1) to give the title intermediate (160 g).
Préparation of (R)-2-(4-bromo-phenyl)-2-cyclopropylpropionitrile (1-6) and (5)-2-(4 bromo-phenyI)-2-cyclopropylpropiomtriie (1-7)
Enantiomers 1-6 and 1-7 are prepared by resolution of 1-4 (150 g) on a ChiralPak AY-H 300x20mm SFC column (eluting 85:15 SF CO2:ethanol, 80 mL/min flow rate). The faster eluting isomer is determined to be 1-7; 1 H-NMR, 400 MHz, CDC13-ri6 ppm: 7.547.50 (2H)(m); 7.41-7.37 (2H)(m); 1.73 (3H) (s); 1.26-1.19 (1H) (m); 0.74-0.50 (4H) (m); the slower eluting isomer is 1-6; ’H-NMR, 400 MHz, CDC13-riô ppm: 7.54-7.50 (2H)(m); 7.41-7.37 (2H)(m); 1.73 (3H) (s); 1.26-1.19 (1H) (m); 0.74-0.50 (4H) (m).
Synthesis of 2-(4-hroino-phenyl)-3,3-dimethylbutyronitrile S
111
H
R-4 t-BuMgBr
To a solution of t-BuMgBr (l 10 mL, 1.0 M in THF) is added a solution of R-4 (10 g, 54 mmol) in THF (50 mL). The solution is stirred for 10 min then treated with saturated aqueous NaHCth. The mixture is partioned between methylene chloride and brine, the 5 organics are collected, dried with MgSOi, filtered, and concentrated. Purification of the crude by flash chromatography (SiO2, Heptane to 15% EtOAc in Heptane) gives a yellow solid that is further purified by slurrying in heptane to give after filtration R-5 (4.67 g).
To a solution of R-5 (4.63 g, 19.0 mmol) in CH3CN (100 mL) is added imîdazole (3.89 g, 57.1 mmol) followed by PhTBr? (24.1 g, 57.1 mmol). The mixture is heated at 40 °C for 10 6 h then cooled to 23 °C and partioned between EtOAc and satuared aquoues NalICO-,.
The organics are collected, washed with water, dried with MgSÛ4, filtered, and concentrated in vacuo. The residue is slurried in hepatane and resulting solid is filtered.
The filtrate is collected and volatiles are removed in vacuo. The residue is dissolved in DMSO (100 mL) and treated with NaCN (1.11 g, 22.7 mmol). The mixture is heated at 15 140 °C for 3h then cooled to 23 °C. The mixture is partioned between Et2O and water.
The organics are washed with water, dried with MgSO4, filtered, and concentrated. Purification of the crude by flash chromatography (SiO2, Hep to 15%EtOAc in Hep) yields the title intermediate (2.37 g) ’H-NMR, 400 MHz, CDC13 ppm: 7.59 (2H)(d: J-12 Hz); 7.33 (2H)(d: J-12 Hz); 4.26 (lH)(brs); 1.35 (9H)(s).
Synthesis of Carboxamidine Intermediates
Synthesis of 2-(4-bronio-pheny])-A-hydroxy-2.3-dimethylbutyraniidine
112
A solution of 1-2 (10.0 g, 40 mmol) în EtOH (50 mL) is treated with 50% aqueous hydroxylamine (50 mL). The reaction is heated at 80 °C overnight then concentrated in vacuo. The solid is filtered and washed with water then heptane. The solid is collected and triturated with EtOAc then filtered, collected, and dried to afford the title intermediate (10.4 g); m/z 285.4;287.2 [M/M+2H]
The following intermediates are synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z IM/M+2H] |
1-15 | rxvSiNH2 Br'Xz | Not available |
1-16 | XXz Br OH | 283.0/285.0 |
1-17 | Br-XX N'OH | 283.1/285.0 |
1-19 | A, /A\/nh 2 JU 1 BT OH | 283.1/285.0 |
Synthesis of 2-[4-(2-aminopyrimidin-5-yI)phenyl]-iV-hydroxy-2,3-dimethyl butanimidamide
113 i
A solution of 1-2 (2.00 g, 7.93 mmol), 2-aminopyrimidine-5-boronic acid pinacol ester (2.63 g, 11.9 mmol), and tetrakis(triphenylphosphîne)palladium(0) (459 mg, 0.397 mmol) in THF (20 mL) and saturated aqueous NibCCL (10 mL) is heated at 80 °C for 3 h. The 5 mixture is cooled to 23 °C then partioned between EtOAc and brine. The organics are collected, dried with MgSO4, filtered, and concentrated to give a residue that is purified by flash chromatography (SiOi, CH2CI2 to 3%MeOH in CH2CI2) to afford 1-20 (m/z 267.5 [M+H]).
The following intermediates were synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M+H] |
I-20A | h2n^4 | 264.0 |
I-20B | JÎjX Λ J H2N N | 265.1 |
I-20C | JJ J A Λ J h2n n | 267.0 |
114
I-20D | jfj^N | 253.1 |
I-20E | N A J H2N N | Not available |
I-20F | ,0,pJU | 281.7 |
1-20 îs dissolved in EtOH (30 mL) and treated with 50% aqueous hydroxylamine (12 mL). The reaction is heated at 80 °C for 48 h then cooied to 23 ’C and filtered through 5 Celite. The filtrate is partioned between EtOAc and water. The organics are collected, dried with MgSOt, filtered, and concentrated in vacuo. Purification of the crude by flash chromatography (S1O2, CH2CI2 to 10%MeOH in CH2C12) provides the title intermediate (1.56 g); m/z: 300.4 [M+H]
The following intermediates were synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M+H] |
1-22 | n-oh h2n^nx | 312.4 |
115
1-23 | AA %h h2n^n^ | 298.4 |
1-24 | ν.οη Λ J h2n N | Not available |
1-25 | pX™, AYX·' n oh h2n^A | 286.2 |
1-26 | pANH, ν'Ύχ·;; n-oh Λ J h2n n | 272.1 |
1-27 | fAA -CA/J %„ | Not available |
Synthesis of: (R)-2-]4-(2-amino-pyrimidin-5-yl)-phenyl)-2-cyclopropyl-N-hvdroxypropionamidine
To a mixture of 1-6 (18.5 g, 0.074 mol) in THF (300 mL) are added 5-(4,4,5,5tetramethyI-[l,3,2]dioxaborolan-2-yl)-pyrimidin-2-ylamine (19.6 g, 0.089 mol), tetrakis A
116 (triphenylphosphine)palladium (0) (8.5 g, 0.007 mol) and 2M Nî^COj (74 mL, 0.148 mol). The mixture is heated to 80 °C for 24 hours. The solution is cooled down to room température and is extracted with EtOAc and water. The combined organic layer is dried with \lgSO4 and is filtered. The filtrate is concentrated and the residue is re-suspended in CH2Ci2. The solid that precipitated out from the solution is collected by filtration. The solid is dried and is confirmed to be 1-28 (14.8 g); m/z 265.4 [M+H].
A suspension of 1-28 (14.8 g, 0.056 mol), KOH (15.7 g, 0.28 mol), and hydroxylamine solution in H2O (50% by weight) (34 mL, 0.56 mol) is stirred at 85 °C for 48 hours. The mixture is cooled and the solid is filtered and is dried to afford the title intermediate (12.5
g); m/z 298.4 [M+H], phenyl] -p ropionamidine
Synthesis of (R)-2-Cvclopropyl-N-hydroxv-2-|4-(2-methylainino-pyrimidin-5-yl)-
H__ \/ /
In a 5 ml microwave reaction vessel are combined 5-bromo-2-(methylamino)pyrimidine (451 mg, 2.39 mmol) and hexamethyldistannane (0.456 ml, 2.19 mmol) in toluène (5 ml). The mixture is degassed using argon after which tetrakis(triphenylphosphine) palladium (0) (115mg, 0.10 mmol) is added. The reaction is degassed once more, capped and warmed to 115°C for lh. Upon cooling to ambient température, 1-6 (500 mg, 1.99 mmol) is introduced along with tetrakis(triphenylphosphine) palladium (0) (115 mg, 0.10 mmol). The vessel is capped and warmed to 115°C over night. After this time the reaction is cooled and concentrated. The resulting solid is purifîed via flash chromatography (silica gel, 0-100% EtOAc/heptanes) to afford I-29bis (134 mg); m/z 279.4 [M+H].
To a suspension of I-29bis (134 mg, 0.481 mmol) in EtOH (3.2 ml) is added hydroxylamine solution in H2O (50% by weight) (1.18 mL, 19.24 mmol) is stirred at 85 °C for 72 hours. The mixture is cooled and concentrated, and diluted with water and λ'
117 ethyl acetate. White solid is filtered and is dried, organic is purified by flash chromatography and combined with solid to afford the tîtle intermediate, (110 mg); m/z 312.4 [M+H].
Synthesis of Aryl Bromide Intermediates
Synthesis of 3-[2-(4-bromophenyl)-3-methylbutan-2-yl]-5-cyclopropyl-l,2,4oxadiazole
Pyridine
A mixture of 1-14 (150 mg, 0.53 mmol) and cyclopropylcarbonyl chloride (60 mg, 0.58 mmol) in pyridine (2 mL) îs stirred at room température for 15 minutes before heating at 110 °C for 18 h. The réaction mixture is concentrated in vacuo, then partitîoned between CH2CI2 and saturated aqueous NaHCO3. The organics are dried with NiibSO.j, filtered and concentrated in vacuo to give the title intermediate (167 mg); m/z 336.0 [M+H].
The following intermediates are synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure |
1-31 | CH Q V-N 0 π Ύ H A V/ |
1-32 | BrJU |
118
Synthesis of
5-{3-[2-(4-bromophenyl)-3-methylbutan-2-yl]-l,2,4-oxadiazol-5yl}pyrimidine
To a solution of pyrimidine-5-carboxyiic acid (200 mg, 0.70 mmol) in pyridine (l.O mL) is added thionyl chloride (61 uL, 0.84 mmol). The mixture is stirred at room température for 15 minutes before 1-14 (91 mg, 0.74 mmol) is added. The resulting mixture is heated at 110 °C for 18 h then concentrated in vacuo. The residue îs partitîoned between EtOAc and saturated aqueous NalICOj, washed with brine, dried with Na2SO4, filtered, and concentrated in vacuo to give the title compound (236 mg); m/z 373.0, 375.0 [Μ, M+2H]
The following intermediates were synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z |
1-36 | iX h n JxJ Ν-χ Br | 361.0/363.0 [M/M+2H] |
X
119
1-37 | w | 422.0/424.0 [M/M+2H] |
1-38 | xAy+x Br | 397.0/399.0 [M/M+2H] |
1-39 | £ Tl HJ< N-o | 380.0 [M+2H] |
1-40 | il T yO JL AA N-o N ' Br u | 392.0/394.0 [M/M+2H] |
1-41 | T/AvA _ A/ N-0 | 362.0/364.0 [M/M+2H] |
1-42 | jrjjf aa^nh ΒγΑ<> N-o γ | 389.0/391.0 [M/M+2H] |
1-43 | âHwi ΒγΛΡ n-o a n | Not available |
1-44 | z°~Ï1 os >-Vn Brx> N-° r | Not available |
1-45 | AT><An /-n os H? Br--^.O «-o S | Not available |
120
1-46 | Br | cr | X.-N ii yN-o | /=N ib | 372.0/374.0 [M/M+2H] |
1-47 | Br | o | AXn « > N-o | ΛΝ A-nh | 361.0/363.0 [M/M+2H] |
1-48 | Br | jO | AAn N-o | r=N Ab | 374.0 [M+H] |
1-49 | Br' | n | Ύ y N-q | °a Ό | 450.0 [M+H] |
1-50 | Br' | .o | AL o A<An u A N-o | y° Ab | Not avaîlable |
1-51 | Br'' | cr | <L-N T y- N-O | _/ N | 393.0 [M+H] |
1-52 | i Br | b | \.N Y y- N-O | cy | 388.0 [M+H] |
1-53 | Br | XJn h y N-o | Ar | 388.0 [M+H] | |
1-54 | BX | O | ?Cn T x) N-o | /Y A-N | 407.0 [M+H] |
I2l
1-55 | AX | M | 390.0 [M+H] |
1-56 | N-ci | 404.0 [M+H] | |
1-57 | a | HO Sytr | 403.0 [M+H] |
1-58 | a | 372.4/374.5 [M/M+2H] |
Synthesis of 3-[l-(4-bromo-phenyl)-l-cycIopropyI-ethyl]-5-(lH-pyrazol-4-yl)-[l,2,4] oxadiazole
1,1'-Carbonyldiimidazoie (4.9 g, 30.7 mmol) is added to a mixture of lH-pyrazole-4carboxylic acid (3.4 g, 30.7 mmol) in 1,4-dioxane (150 ml). The mixture is stirred at 50°C for 30 minutes, 1-16 is added and the reaction mixture is heated at 85°C for 48 hours. The reaction mixture is cooled to room température, poored into a solution of saturated NalICOi and extracted with EtOAc. The organic layers are dried over MgSO4, 10 filtered and concentrated to afford the crude product that is purified via flash chromatography (SiO2, 0-6% MeOH/CH2C12) to afford the title intermediate (6.9 g); m/z 359,361 [Μ, M+2H]. z
122
The following întermediates are synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z |
1-60 | r il r θ N W A. Xi H N N-N H | 388.4 [M+H] |
Synthesis of 3- [(R)-l-(4-bromo-phenyl)- 1-cyclopropyl-ethyl]-5-(l H-pyrazoi-4-yl)[ 1,2,4]oxadiazole
To a sealed tube is added lH-pyrazole-4-carboxylic acid (484 mg, 4.2 mmol) in 1,4dioxane (8 ml), followed by the addition of Ι,Γ-carbonyldiimidazole (679 mg, 4.2 mmol). The reaction mixture is stirred at 55 °C for 30 minutes. Then 1-17 (1.1 g, 4.0 mmol) in 1,4-dioxane (5 ml) is added to the above mixture. The reaction mixture is 15 stirred at 120 °C for 18 hours. The reaction mixture is concentrated in vacuo. The residue is diluted with EtOAc, washed with water, brine, dried under anhy. Na2SO4, filtered and
123 concentrated. The residue is purified by flash chromatography (SiO2, 0-5%
MeOH/CH2Cl2) to afford the title intermediate (1.3 g); m/z 359.0, 361.0 [M, M+2HJ.
Synthesîs of 2-(4-{3-[l-(4-bromo-phenyI)-l-cyclopropyl-ethyl]-[1,2,4]oxadiazol-5-yl} pyrazol-l-yl)-N,N-dimethyl-acetamide
To a solution of 1-59 (6.9 g, 19 mmol) in DMF (80 mL) are added K2CO3 (5.3 g, 38 mmol) and 2-chloro-N,N-dimethylacetamide (2.9 g, 28 mmol) at room température. The mixture is stirred at the same température for 24 hours. Water (200 mL) is added and the mixture is extacted with EtOAc (300 mL). The combined organic layer is dried with MgSO* and filtered. The filtrate is concentrated and the remaining residue was purified via silica gel flash column chromatography with 8% MeOH in CH2C12 as the eluent to afford the tîtle intermediate (8.3 g); m/z 444.2, 446.2 [M, M+2J.
The following intermediates are synthesized in similar fashion from the appropriate reagents:
Intermediate
Structure m/z [M/M+2H]
124
1-63 | nrV'o AJ B< Ά , Z x 0 | 444.2/446.2 |
I-64a | J VN V OH | 431.2/433.2 |
I-65b | P /—z VA CD | 415.1/417.1 |
a) The reaction mixtures îs stirred at 80°C for 48 hours
b) The reaction is run startîng from the corresponding iodide and the mixture is stirred at
80°C ovemîght
Synthesis of 3-[(R)-l-(4-bromo-phenyI)-l-cyclopropyl-ethyl]-5-(l-methyl-lH5 pyrazol-4-yl)-[l,2,4]oxadiazole z
125
To a vial îs added 1-61 (550 mg, 1.531 mmol), iodomethane (0.191 mL, 3.062 mmol) and K2CO3 (423 mg, 3.062 mmol) in 6 ml of DMF. The reation mixture is stirred at room température for 2 hrs, then poured into water and brine, and extracted with EtOAc (4x25ml). The combined organic fractions are dried with sodium sulfate, filtered, and concentrated in vacuo to afford the title intermediate (516 mgs); m/z 374.0, 376.0 [M/M+2]
The following intermediates are synthesîzed in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M/M+2H] |
1-68 | /Y J NA/0 Br Ά b r' ^-0 | 417.2/419.2 |
Synthesis of 2-[4-(3-{l-cyclopropyl-l-(4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2· ν1)-ρΗ6ΐιν1|-εΐ1ινΙ}-|1,2,41οχαάΪΜζ.ο1-5-ν1)-ργΓίΐζο1-1-ν1|-Ν,Ν-0ΐηΐ6ί1ιν1-3€€ΐ3ΐηΐά€ /
126
To a solution of 1-62 (2.6 g, 5.9 mmol) in 1,4-dioxane (20 mL) in a pressure vial are added bis(pinacolato)diboron (2.2 g, 8.8 mmol), KOAc (2.3 g, 23 mmol) and tetrakis (triphenylphosphine)palladium (0) (481 mg, 0.6 mmol). The reaction mixture is stirred 5 under Ar at 100°C for 4 hours. The mixture is cooled down and is concentrated in vacuo.
The residue is diluted with EtOAc (100 mL) and is passed through a plug of Celite and is rinsed thoroughly with EtOAc (20 mL). The filtrate is dried with magnésium sulfate and is filtere to afford the title intermediate (1.9 g); m/z 492.3 (M+H)
The following intermediates were synthesîzed in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M+H] |
I-70a | [i ï 1 ° FJ I / vn o | 492.4 |
127
I-71a | γχχ i vn T | 479.5 |
I-72a | A^x yN | 421.5 |
I-73b | crv-o yX y Vl | 463.3 |
I-74b | ίχΧχ y V V—.o< | 465.3 |
I-75b | .Αν AJ X, | 421.3 |
a) l,r-bis(diphenylphosphino) ferrocenedichlaropalladium(II) dichloromethane S
128 is used instead
b) l,r-bis(dîphenylphosphino) ferrocenedichloropalladium(II) dichloromethane is used instead and the reaction mixture is stirred at 100°C ovemight
Synthesis of Boc-piperidine intermediates.
Synthesis of 5'-(3-{l-[4-(2-amino-pvrin)idin-5-yl)-phenyl|-i cyclopropyl-ethyl}[l,2,4|oxadiazol-5-yl)-2,3,5,6-tetrahydr()-|1,2,|bipyrazinyl-4-carboxylic acid tertbutyl ester
A 250ml RB flask is charged with R-7 (5.4 g, 28.99 mmol) in 100 mL of NMP. R-8 (5.00 g, 28.99 mmol) is added followed by triethylamine (4.85 ml, 34.79 mmol). The reaction is heated to 60 °C under nitrogen ovemight. The reaction is cooled to room température, Z
129 poured into ice water and the precipitated 1-76 (8.60 g) is isolated by filtration; m/z 323.4 [M+H]
To a stirred suspension of 1-76 (8,60 g, 26.68 mmol) in éthanol (250 ml) is added 5M NaOH (26.68 ml, 133.39 mmol) at room température. The mixture becomes homogenous before a persisting precipitate forms and becomes a solid mass. Water (200 ml) is added and the mixture is stirred for 4 h after which time the reaction appears complété. The light brown sludge is poured into a beaker and treated with water. AcOH îs added to reach acidic pH and the product is extracted into DCM (2x). The combined organics are dried over anhydrous MgSO4, filtered and concentrated to give the product as a solid which is suspended in heptanes. The solid is collected via filtration and washed with heptanes to give 1-77 (7.90 g); m/z 309.4 [M+H].
To a suspension of 1-77 (3.0 g, 9.71 mmol) in THF (40 ml) is added 1,1'carbonyldiimidazole (1.6 g, 9.71 mmol) at room température. The mixture is stirred at 50° C for 30 minutes. After this time 1-16 (2.5 g, 8.83 mmol) is added and the resultîng mixture is heated at 80°C for 3 hours. The mixture is cooled down and treated with AcOH (8ml). The mixture is warmed to 80°C and stirred over nîght. Upon cooling toroom température, the reaction îs concentrated and diiuted with water. The product is extracted into DCM (2x). The combined organics are washed with brine and dried over anhydrous MgSO4. The mixture is filtered and concentrated. The remaining crude is purified via flash chromatography (silica gel, 0-5% MeOH/DCM) to afford 1-78 (2.2 g). In a microwave reaction vessel îs added 1-78 (0.50 g, 0.90 mmol) în 15ml of DMF, followed by the addition of 2-aminopyrimidine-5-boronic acid pinacol ester (0.30 g, 1.35 mmol), tetrakis(triphenylphosphine)palladium(0) (105 mg, 0.09 mmol) and aq. Ni^CCf (2.0M, 1.8 ml). The reaction mixture is stirred at 85 °C for 16 hours. After this time the reaction mixture is poured into brine and extracted with EtOAc (3x). The combined organic fractions are dried over anhydrous MgSO4, filtered, then concentrated in vacuo to give the crude material. Purification via flash chromatography (silica gel, 0-5% MeOH/DCM) affords the title intermediate (150 mg); m/z 570.4 [M+H] /
130
The following intermediates are synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M+H] |
1-80 | N j N=^ O '—N T0./ 0 A | 569.4 |
1-81 | A, /yU A AJ c > O K ° A | 569.4 |
1-82 | sa A N=Z O | 570.4 |
131
Synthesis of 5'-(3-{(S)-l-[4-(5-amino-pyrazin-2-yl)-phenyl]-l-cyclopropyl-ethyl}]l,2,4|oxadiazol-5-yl)-2,3,5,6-ietrahydro-|1.2'|bipyraziny]-4-carboxylic acid tertbutyl ester
To a suspension of 1-77 (1.0 g, 3.53 mmol) in THF (20 ml) is added 1,1*carbonyldiimidazole (0.63 g, 3.88 mmol) at room température. The mixture is stirred at 50° C for 30 minutes. After this time 1-19 (1.2 g, 3.88 mmol) is added as a THF solution
132 ( 15 ml) and the resulting mixture is heated at 80°C for 3 hours. The mixture is cooled and treated with AcOH (8 ml) then warmed to 80°C and stirred over night. After this time the reaction is cooled to room température, concentrated and diluted with water. Extracted the product into DCM (2x). The combined organics are washed with brine and dried (MgSO4). Filtered and concentrated. The remaining crude is purified via flash chromatography (silica gel, 0-5% MeOH/DCM) to afford 1-84 (1.2 g).
In a 5 ml microwave reaction vessel are combined 5-amino-2-bromopyrazine (60 mg, 0.34 mmol) and hexamethyldîstannane (120 mg, 0.38 mmol) în toluene (2 ml). The mixture is degassed using argon after which tetrakîs(triphenylphosphine) palladium (0) (40 mg, 0.03 mmol) is added. The reaction is degassed once more, capped and warmed to 115°C for lh. Upon cooling to ambient température, 1-84 (270 mg, 0.48 mmol) is introduced along with teÎrakis(triphenylphosphine) palladium (0) (30 mg, 0.05 mmol). The vessel is capped and warmed to 115°C over night. After this time the reaction is cooled and concentrated. The crude îs suspended in DCM/MeOH, treated with silica gel and concentrated. The resulting solid is purified via flash chromatography (silica gel, 010% MeOH/DCM) to afford the title intermediate (100 mg).
Synthesîs of 4-fluoro-pyrimidin-2-ylamine
To a suspension of R-9 (100 mg, 0.77 mmol) in CH3CN (10 mL) is added HF in Et3N (0.26 mL, 1.5 mmol) at room température. The solution is heated to 80 °C for 48 hours. The solution is cooled down and water (10 mL) is added. The solution is extracted with EtOAc (20 mL) and H2O (5 mL). The combined organic layer is dried with MgSO4 and is filtered. The filtrate is concentrated to afford 1-86 (25 mg); m/z 113.9 [M+H].
133
The following intermediates are synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M+H] |
I-86bis | nv+Q F | 127.9 |
Synthesis of 5-bromo-4-fluoro-pyrimidin-2-yIamine
To a solution of 1-86 (280 mg, 2.5 mmol) in ClfCN (20 mL) is addedN10 bromosuccinimide (881 mg, 4.9 mmol) at room température. The solution is stirred at the same température for 12 hours. The solid that precipiates out from the solution is collected and is dried to afford the title intermediate (250 mg); m/z 191.9, 193.9 [M, M+2H]
The following intermediates are synthesized în similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M/M+2+H] |
I-87bis | A H2N—(Z V- Br N=( F | 205.9/207.9 |
134
Synthesis of 5-bronio-3-trifluoroinethyl-pyridin-2-ylainine
NBS
To a stirred solution of R-IO (2.70 g, 16.66 mmol) in DMF (15 ml) is added Nbromosuccinimide (3.00 g, 16.85 mmol) as a DMF solution (15 ml, dropwise). After 4 h the réaction is poured onto ice. The resulting precipitate is collected via filtration to give the product as an off-white solid. Dissolved into DCM and washed with brine. The layers are separated and the organic phase is dried (MgSO4), filtered and concentrated to give the title intermediate (3.8 g); m/z 241.2/243.2 [M/M+2H].
Synthesis of 5-bromo-3-fluoro-pyridin-2-ylamine
NBS
To a round bottom flask is added R-l 1 (500 mg, 4.46 mmol) in CH3CN (120 ml) at 0 °C, followed by the addition of N-bromosuccinimide (397 mg, 2.23 mmol). The réaction mixture is stirred (protected from light) vigorously for 15 minutes, then at room température for 1 hour. The additional portion of N-bromosuccinimide (397 mg, 2.23 mmol) is added at 0 °C, then the reaction mixture is stirred at room température for 2 hours. The réaction mixture is concentrated in vacuo. The residue is dissolved in EtOAc, washed with sat Na?S2O3 (20 ml), brine, dried over anhy. Na2SO.i. filtered and concentrated. The residue is purifîed by flash chromatography (S1O2, 0-20% EtOAc/heptane) to afford the title intermediate (772 mg); m/z 190.89/192.86 [M/M+2HJ. Z
135
The following intermediates are synthesîzed in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M/M+2H] |
1-90 | C( 1 Ar h/J | 207.9/209.9 |
Synthesis of (5-bromo-pyrimidin-2-yl)-tert-butyl-amine
Λ7 - R-12 | /Br H 1-91 |
To a vîal is added R-12 (200 mg, 1.13 mmol) in DMF (5 ml), followed by the addition of
K2CO3 (312 mg, 2.26 mmol) and isopropylamine (134 mg, 2.27 mmol). The reaction mixture is stirred at 70 °C for 3 hours. The reaction mixture îs concentrated in vacuo. The residue is dissolved in EtOAc, washed with water, brine, dried under anhy. Na2SO4, fitered and concentrated to afford the title intermediate (221 mg); m/z 216.0/218.0 [M/M+2HJ.
The following intermediates are synthesîzed in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M/M+2H] |
1-92 | N^YBr H | 202.2/204.2 |
136
Synthesis of 3-BenzyIoxy-5-bromo-pyridine
I-94
To a vîal is added 3-bromo-5-hydroxypyridine (200 mg, 1.15 mmol), benzyl alcohol (137 mg, 1.27 mmol) and triphenylphosphine (332 mg, 1.27 mmol) in THF (5 ml) at 0 °C, followed by the addition of dîisopropyl azodicarboxylate (256 mg, 1.27 mmol). The reaction mixture is stirred at room température for 18 hours. The reaction mixture is concentrated in vacuo. The residue is diluted with EtOAc, washed with sat NaHCOj, water, brine, dried under anhy. Na2SO4, filtered and concentrated. The residue is purified 10 by flash chromatography (S1O2, 0-5% MeOH/C^CL) to afford title compound (97 mg);
m/z 264.0, 266.0 [Μ, M+2H]
Synthesis of 5-Bromo-3-trifluoromethyl-pyrazin-2-ylamine
To a solution of 2-amino-5-bromopyrazine (174 mg, 1 mmol) in DMSO (3ml) stirring under Ar is added ferrocene (56 mg, 0.3 mmol) and degassed for 5 minutes with Ar. 2ml '
137 of IN H2SO4 in DMSO is added, followed by CF3I (0.276 ml, 3 mmol) in DMSO (2 ml), giving a slight yellow solution. 0.2ml of 30% H2O2 is added slowly, causing the reaction to go from yellow to dark green in color. The reaction was heated to 50 °C for 2 hours under Ar. After cooling to room température, the reaction mixture is poured into brine, and product is extracted with EtOAc (4x20ml). The combined organic fractions are dried with magnésium sulfate, filtered, then concentrated in vacuo. The crude material was purified by flash chromatography (SiO2, Biotage SNAP 10g, 0-50% EtOAc/hept) which yields 70 mg of title compound; m/z 242.0, 244.0 (Μ, M+2H)
Synthesis of 4-benzyIoxy-5-bronio-pyrÎmidin-2-y)amine
1-96
1-90
A 20 ml microwave reaction vessel îs charged with benzyl alcohol (7.0 ml) and sodium (145 mg, 6.33 mmol). The vessel is capped and stirred at ambient température until the sodium is consumed. After this time, 1-90 (1.10 g, 5.28 mmol) is added and the reaction is warmed to 130°C for 2h. Upon cooling to room température the reaction mixture is concentrated to low volume. The remaining residue is diluted with water. The water is decanted and the remaining oil is treated with méthanol. The precipîtated solid is collected via filtration and washed with méthanol to give the title intennedîate (0.86 g); m/z 282.0 [M+H].
Synthesis of (5-bromo-pyridin-2-yl)-methyl-amine
138
H l-96bis
A 20 ml microwave reaction vessel is charged with 2,5-Dibromo-pyridine (2.00 g, 8.44 mmol) and treated with methylamine (10.45 ml of a 33% solution in éthanol, 84.43 mmol) and warmed to 80°C for 3 days. After this time the reaction is concentrated and the remaining solid is treated with IM HCl (50 ml) and DCM. The layers are separated and the aqueous phase is basified using IN NaOH (to pH-11). The product was extracted into DCM (2x) and the combined organics were dried (MgSO4), filtered and concentrated to give the desired product I-96bis (1.20 g). lH-NMR (400MHz, DMSOd6): 2.75 ppm (d, 3H), 6.44 ppm (d, IH), 6.72 ppm (bs, IH), 7.51 ppm (dd, IH), 8.05 ppm (s, 1 H)
Synthesis of 2-[4-(3-Î(R)-l-[4-(2-AmÎno-4-benzyIoxy-pyrimidin-5-yl)-phenylJ-l-cyclo propybethvlHL2,4|oxadiazoI-5-yl)-pyrazol-l-yl|-N,N-dimethyl-acetamide
1-97 is prepared following Method 26 (using Palladium tetrakis, 2M Na2COÎ5 and DMF at 85°C for 16h); m/z 565.0 [M+H].
Synthesis of 2-{2-[4-(3-{(R)-l-[4-(2-Amino-pyriïnidin-5-yl)-phenyl]-l-cyclopropyl-et hyI}-[l,2,41oxadiazol-5-yl)-pyrazoH-ylJ-ethyI}-isoindole-l,3-dione /
139
Example 48 (100 mg, 0.266 mmol) is treated with DMF (2.5 mL), 2-(2-Bromo-ethyl)isoindole-l,3-dione (101 mg, 0.399 mmol), and CS2CO3 (83.0 mg, 0.599 mmol) and the reaction is stirred ovemight. The resulting mixture is diluted with water and ethyl acetate and the phases separated. The organic phase is washed with water and brine, dried over Na2SO4, filtered, and concentrated in vacuo. The resulting residue is purified by flash chromatography over silica eluting 0-10% methanol/CH2Cl2 to give 1-98 (120 mg).
Synthesis of Final Compounds
Method 1
Synthesis of 2-(3-{2-[4-(5-methoxypyridin-3-yl)phenyl]-3-methylbutan-2-yI}-l,2,4oxadiazoI-5-yl)pyrazine (Example 1, table 1)
Hunig’s base
DMF
To a solution of 1-27 (200 mg, 0.64 mmol) in DMF (5 mL) is added Hunig’s base (0.3 mL, 1.6 mmol) followed by pyrazine-2-carbonyl chloride (110 mg, 0.80 mmol). The reaction mixture is heated at 120 ’C for 2 h then volatiles are removed in vacuo. The residue is purified by flash chromatography (SiO2, heptane to 60% EtOAc in heptane) to give the title compound (165 mg). Z
140
The following compounds were synthesized in similar fashîon from the appropriate intermediates:
Examples 2-5, table 1
Example 7, table 1
Examples 117-118, table 1
Example 120, tablel
Method 2
Synthesis of [2-amino-5-(4-[3-methyi-2-[5-(pyridin-3-yl)-l,2,4-oxadiazol-3-yl]butan
2-yl}phenyl)pyridin-3-yl] methanol (Example 6, table 1)
1-58 1-99
Example 6
1-58 (0.450 g, 1.21 mmol) is suspended in 1,4-dioxane (3.0 mL). Bis(pinacolato)diborane (0.364 g, 1.43 mmol), potassium acetate (0.500 g, 5.09 mmol) and 1,1'bis(diphenylphosphino)ferrocenedichloropalladium(ll) dichloromethane complex (0.100 g, 0.122 mmol) is added. This reaction mixture is de-gassed and heated under argon at 100 °C for 4 h. The mixtue is cooled to room température then diluted with EtOAc and washed with water. The organics are collected and concentrated in vacuo to afford a residue that is purifed by flash chromatography (SiO2, hexane to 30% EtOAc in hexane) to give 1-99 (0.362 g); m/z 420.61 [M+1]
1-99 (0.100 g, 0.238 mmol) is dissolved in DMF (2.0 mL) and treated with 2-amino-5bormo-3(hydroxymethyl)pyridine (0.051 g, 0.25 mmol),
141 tetrakis(triiphenylphosphine)palladium(0) (0.029 g, 0.025 mmol), and aqueous Na2CO3 (2.0 Μ, l .0 mL, 1.0 mmol). This reaction mixture is de-gassed and heated under argon at 100 °C for 4 h. The mixtue is cooled to room température then diluted with EtOAc and washed with water. The organics are collected and concentrated in vacuo to afford a residue that is purifed by flash chromatography (SiO2, 0-10% MeOH in CH2C12) to give the title compound (0.025g).
Method 3
Synthesis of 5-(4-(2- [5-(6-methoxypyridin-3-yl)-l,2,4-oxadiazol-3-yl]-3-methylbutan-
2-yl}phenyl)pyrimidin-2-amine (Example 8, table 1)
Example 7 (35 mg, 0.083 mmol) is dissoved in MeOH (2.0 mL). A 25% (w/w) NaOMe solution in MeOH (50 pL) is added. The reaction mixture is heated at 70 °C for 6 h then volatiles are removed in vacuo. The residue is purified by flash chromatography (SiO2, 0-10% MeOH in CH2C12) to give the title compound (26 mg).
The following compounds are synthesized in similar fashion from the appropriate intermediates:
Example 9, table 1
Method 4
Synthesis of 3-(3-{2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methylbutan-2-yl}-l,2,4oxadiazol-5-yl)pyridin-2(lH)-one (Example 12, table 1) χ
142
Cl
1-21 (100 mg, 0.255 mmol) îs dissoved in l-methyl-2-pyirolidinone (1 mL). Ethyldiisopropylamine (0.3 mL, 1.6 mmol) is added followed by 2 chloro-nîcotinyl chloride (62 mg, 0.35 mmol). The reaction mixture is heated at 120 °C for 1 h then cooled to room température and partioned between CH2CI2 and water. The organics are collected and volatiles are removed in vacuo. The residue is purified by flash chromatogrophy (S1O2, 0-100% ethyl aceatate in heptane) to afford 1-100 (78 mg); m/z 421.48 [M+1]
1-100 (35 mg, 0.083 mmol) is dissoved in 1,4-dioxane (2.0 mL). A 10% (w/w) aqueous LiOH solution (50 pL) is added. The reaction mixture is heated at 70 °C for 2 h. The solvent is removed in vacuo and the residue is suspended in water (2.0 mL). The precipetate is collected by filtration, washed with water, and air-dried. The solid is furhter purified by flash chromatography (S1O2, 0-10%MeOH in CH2CI2) to give the title compound (28 mg).
The following compounds are synthesized in similar fashion from the appropriate intermediates:
Example 10, table 1
Method 5 z
143
Synthesis of 5-(4-{2-[5-(4-methoxypyridin-3-yl)-l,2,4-oxadiazol-3-yl]-3-methylbutan-
2-yl}phenyl)pyrimidin-2-amine (Example 11, table 1)
4-Methoxy-nicotînic acid (54 mg, 0.35 mmol) is dissoved in l-methyl-2-pyrrolidinone (1 mL) and carbonyldiimidazole (57 mg, 0.35 mmol) is added. The mixuture is stirred for 15 minutes then 1-21 (100 mg, 0.255 mmol) is added. This reaction mixture îs heated at 120 °C for 1 h then cooled to room température and diluted with water. The solid is collected by filtration and purified by flash chromatogrophy (S1O2, 0-100% EtOAc in heptane) to give the title compound (19 mg).
The following compounds were synthesized in similar fashion from the appropriate intermediates:
Examples 13-15, table 1
Examples 18-22, table 1
Examples 25-29, table 1
Examples 33-34, table l
Example 37, table 1
Example 58, table 1
Examples 67-69, table 1
Example 119, table 1
Synthesis of 5-(4-{(R)-l-cyel{>propyl-l-|5-(lll-pvrazoL4-yl)-|L2,4]oxadiazol-3-vl]ethyl}-phenyI)-pyrimidin-2-yIamme (Example 48, Table 1)
144
To a suspension of IH-pyrazole-4-carboxylic acid (7.1 g, 0.063 mol) in THF (200 mL) is added Ι,Γ-carbonyldfimidazole (10.2 g, 0.063 mol) at room température. The mixture is stirred at 50 °C for 30 minutes. A suspension of 1-29 (12.5 g, 0.042 mol) in THF (100 5 mL) is added to the above mixture and the resulting mixture is heated under reflux for 24 hours. The mixture is cooled down and the solid is collected by means of filtration. The solid is then suspended in AcOH (150 mL) at room température. The mixture is heated to 90 °C for 2 hours. The solution is cooled down and is concentrated under vaccuum.
The residue is dissolved in EtOAc (100 mL) and the solution is washed with H2O (200 10 mL) and saturated NaHCO3 solution (200 mL). The organic layer is concentrated to afford the title compound (14.7 g, 0.040 mol).
Method 6
Synthesis of 4-(3-{l-[4-(2-Amino-pyrimidin-5-yI)-phenyl]-l,2-dimethyl-propyl}- l,2,4-oxadiazol-5-yI)-piperidine-l-carboxylic acid tert-butyl ester (Example 109, table 1) and 5-(4-{3-methyl-2-[5-(piperidin-4-yl)-l,2,4-oxadiazol-3-yI]butan-2- yl}phenyl)pyrimidin-2-amine (Example 110, table 1) s
145
To a suspension of 7V-Boc-isonipocotic acid (115 mg, 0.50 mmol) in THF (1 mL) is added carbonyldiimîdazole (81 mg, 0.50 mmol). The mixture is heated at 55 °C for 20 min then treated with 1-21 (100 mg, 0.33 mmol). The reaction mixture is heated at 55 ’C for 17 h then heated in microwave at 150 °C for 20 min. The mixture is cooled to room température then directly purified by flash chromatography (SiCh, 15-100% EtOAc in heptane) to give Example 109 (89 mg).
Example 109 (83 mg, 0.17 mmol) is dissolved in CH2CI2 (1 mL) and treated with a solution of HCl in 1,4-dioxane (4.0 M, 0.4 mL). The mixture is stirred at room température for 3.5 h then resulting solid is filtered, washed with CH2CI2, collected, and dried to afford the title compound (63 mg).
The following compounds are synthesized in similar fashion from the appropriate intermediates:
Examples 111-114, table 1
Method 7
Synthesîs of 5-(4-{3-methyl-2-[5-(lH-pyrazol-4-yl)-l,2,4-oxadiazol-3-yl]butan-2yl}phenyl)pyrimidin-2-amîne (Example 146, table 1)
146
PdCI2(PPh3)z
2M aq Na2CO3
DMF
A mixture of 1-47 (70 mg, 0.19 mmol), 2-aminopyrimidine-5-boronic acid pinacol ester (51 mg, 0.23 mmol) and 2M aqueous Na2CO3 (0.2 mL) in DMF (1 mL) is degassed under N2 for 5 minutes. To this mixture is added PdCl2(PPhs)2 (14 mg, 0.02 mmol). The mixture is stirred at 80 °C for 18 h then partitioned between EtOAc and water. The organics are washed with water, dried with Na2SO4, filtered, and concentrated in vacuo. The residue is purified by préparative HPLC to give the title compound (13 mg).
The following compounds are synthesized in similar fashion from the appropriate intermediates:
Examples 125, table 1 - upon reaction of 1-38 with -aminopyrimîdine-5-boronic acid , PdCl2dppf (0.05eq) and dppf (0.05eq) only Example 125 is formed instead of Example 128
Example 126-133, table 1
Example 139, table 1
Example 143, table 1
Examples 146-157, table 1
Method 8
Synthesis of 5-[4-(3-methyl-2-Î5-[6-(trifluoromethyl)pyridin-3-yl]-l,2,4-oxadiazol-3yl}butan-2-yl)phenyl]pyrimidm-2-amine (Example 136, table 1)
147
OH Ν·^γ-ΒΟΗ
H,
PdCI2(dppf)
Na2CO3 EtOH: toluene (4:1)
To a suspension of 1-33 (156 mg, 0.35 mmol), 2-ammopyrimîdine-5-boronic acid (58 mg,
0.42 mmol) and 2M aqueous NaiCOj (0.53 mL) in ethanol:toluene (4:1, 2 ml) in a pressure tube is added [l,r-bis(diphenylphosphino)-ferrocene]dichloro palladium (II) 5 (25 mg, 0.030mmol) and l,r-bis(diphenylphosphino)fenOcene (15 mg, 0.02 mmol). The reaction mixture is stirred at 90 °C for 2 h. The reaction mixture îs filtered through a pad of Celite, washed with EtOAc and CH2CI2. The collected filtrate is concentrated in vacuo. Purification by préparative HPLC gives the title compound (72 mg).
The following compounds are synthesized in similar fashion from the appropriate intermediates:
Example 135-138, table 1
Examples 140-141, table 1
Method 9
Synthesis of 2-[4-(3-( l-[4-(2-aminopyrimidin-5-yl)phenyl]-l-cyclopropylethyl}-l,2,4oxadiazol-5-yl)-lH-pyrazol-l-yl]-N,N-dimethylacetamide (Example 59, table 1)
-NA-CI I
K.?CO, DMF
148
To a solution of example 21 (350 mg, 0.94 mmol) in DMF (1 mL) is added K-CO; (260 mg, 1.9 mmol) and 2-chior<)-.V,/V-dimethylacetamidu (0.19 mL, 1.9 mmol). The reaction mixture is stirred for 20 h at room température then directly purified by prepartive HPLC (10-60% CH3CN in water containing 0.1%TFA) to give the title compound (200 mg).
The following intermédiares are synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M+H] |
I-100bisa | AA A+ Ao' | 446.4 |
a) The reaction mixture is heated at 50°C
The following compounds are synthesized in similar fashion from the appropriate intermediates:
Example 30, table 1
Example 43, table 1
Example 60, table lExample 75-76, table 1
Example 79, table 1
Examples 97-99, table 1
Example 106, table 1
Example 271, table 1 - the reaction is performed at 130l’C for 48 hours starting from the corresponding bromide /
149
Synthesis of 2—[4-(3-{(R)-l-[4-(2-amino-pyriniidin-5-yl)-phenyl]-l-cyclopropylethyl}-[l,2,4]oxadiazol-5-yl)-pyrazol-l-yl]-N,N-dimethyl-acetamide (Example 115. table 1)
To a solution of Example 48 (14.7 g, 0.040 mol) in DMF (150 mL) are added 2-chloroN,N-dimethylacetamide (6.1 mL, 0.059 mol) and K-CO3 (10.9 g, 0.079 mol) at room température. The mixture is stirred at the same température for 2 hours. Water (100 mL) is added and the mixture is extacted with EtOAc (200 mL). The combined organic layer is dried with VlgSO4 (20 g) and is filtered. The filtrate is concentrated and the remaining solid is re-suspended in small amount of acetonitrile (30 mL) for 10 minutes. The solid is collected by filtration and is washed with cold acetonitrile. The resulting solid is dried under vaccuum and is confirmed to be the title compound (10 g).
The title compound îs further purified, if desired, by recrystallization from éthanol, methanol or THF. Alternatively, the title compound is converted to its hydrochloride sait by dissolving the free base in éthanol or isopropyl alcohol followed by addition of aqueous hydrochloric acid to the solution.
Method 10
Synthesis of 2-[(3-{2-f4-(2-aminopyriniidin-5-yl)phenyl]-3-niethyibutan-2-yl}-l,2,4oxadiazol-5-yl)amino] éthanol (Example 80, table 1) /
150
To a solution of I-2l (900 mg, 3.0 mmol) in toluene (35 mL) is added trichloroacetic anhydride (0.69 mL, 3.6 mmol). The reaction mixture is heated at reflux for 2.5 h then cooled to room température. The mixture is diluted with EtOAc, washed with saturated aqueous NaHCXL, dried with Na-SCL, filtered and concentrated to afford 1-101 (1.25 g); m/z 426.31/428.22 [M/M+2H].
To a solution of 1-101 (80 mg, 0.19 mmol) and KOH (19 mg, 0.28 mmol) in DMSO (1 mL) is added ethanolamine (20 μL, 0.28 mmol). The reaction mixture is stirred at room température for 1 h then treated with water. The mixture is extracted with EtOAc, washed with brine, dried with Na?SO4, filtered, and concentrated. The residue is purifîed by flash chromatography (SiO2, 0-10%MeOH in CH?CL) to yield the title compound (45 mg).
The following compounds are synthesized in simîlar fashion from the appropriate intermediates:
Examples 81-83, table 1
Example 84, table 1 - sideproduct isoiated from the reaction performed to form Example 83
Example 86, table 1 - the intended amine dérivative is not isoiated and the amide sideproduct is the only one that is isoiated
Example 87, table 1
Examples 89, table 1 x
151
Example 90, table l - sideproduct isolated from the reaction performed to form Example
Example 91, table 1 - the intended amine dérivative is not isolated and the amide sideproduct is the only one that is isolated
Example 134, table 1
Example 171, table 1
Method 11
Synthesis of l-{ [5-(3-(1-[4-(2-aminopy rimidin-5-yl)phenyl]-l-cyclopropylethyl}10 l,2,4-oxadiazol-5-yl)pyrazin-2-y]]amino}-2-methylpropan-2-ol (Example 44, table 1)
To a solution of 5-chIoro-pyrazine-2-carboxylic acid (490 mg, 3.1 mmol) in NMP (3 mL) is added carbonyldiimidazole (500 mg, 3.1 mmol). The mixture is stirred at 50 for 0.5 h then treated with 1-23 (830 mg, 2.8 mmol) and heated at 110 °C for 2 h. The mixture is 15 cooled to room température, treated with water, and stirred for 18 h. The resulting solid is filtered, dried, and collected to give 1-102 (1.0 g). 1H NMR (DMSO-J6) Ô ppm 9.40 (1H, s), 9.20 (1H, s), 8.75 (1H, s), 8.55 (2H, s), 8.10 (1H, s), 7.60 (2H, d), 7.40 (2H, d), 7.20 (1H, s), 6.75 (2H, s), 1.65-1.75 (1H, m), 1.55 (3H, s), 0.3-0.75 (4H, m).
1-102 (300 mg, 0.66 mmol) is dissolved in 1-amino-2-methyl-propan-2-ol (1.5 mL) and 20 heated at 80 °C for 4 h. The mixture is cooled to room température and treated with
152 water. The resulting solid îs filtered, collected, and further purified by recrystallization from CH3CN to give the title compound (l 55 mg).
The following compounds are synthesized in similar fashion from the appropriate 5 intermediates:
Example 42, table 1
Example 45, table 1
Examples 35-36, table 1
Examples 73-74, table 1
Examples 162-163, table 1
Method 12
Synthesis of 5-{4-|l-cyc!opropyl-l-(5-{6-|(2-inethoxyethyl)amino]pyridin-3-yl [-1,2,4oxadiazol-3-yl)ethyi]phenyl}pyrimidin-2-amine (Example 38, table 1)
Example 38
To a solution of 6-chloronicotinîc acid (500 mg, 3.2 mmol) in NMP (7 mL) is added carbonyldiimidazole (520 mg, 2.9 mmol). The mixture is stirred at room température for 1 h then treated with 1-23 (860 mg, 2.8 mmol) and heated at 130 °C for 2 h. The mixture
153 îs cooled to room température and treated with water. The resulting solid is filtered, dried, and collected to give 1-103 (350 mg); m/z 419.33 [M+H]
1-103 (150 mg, 0.36 mmol) is dissolved in 2-methoxyethylamine (0.5 mL) and heated at 80 °C for 2 h. The mixture îs cooled to room température and treated with water to afford a residue. The water is decanted and the residue is purified by préparative HPLC (1060% CH-,CN în water containing 0.1%TFA) to give the title compound (98 mg).
The following compounds are synthesized in similar fashion from the appropriate intermediates:
Example 39-41, table 1
Examples 70-72, table 1
Method 13
Synthesis of l-[4-(3-{2-[4-(2-aminopyrimidin-5-yl)phenyI]-3-methylbutan-2-yl}l,2,4-oxadiazoI-5-yl)-lH-pyrazol-l-yl]-2-methylpropan-2-ol (Example 159, table 1)
To a suspension of 1-47 (336 mg, 0.93 mmol) and potassium carbonate (154 mg, 1.12 mmol) în DMF (6 mL) is added l-chloro-2-methyl-propan-2-ol (100 pL, 0.98 mmol). The reaction mixture is stirred at 80 °C for 16 h then concentrated in vacuo. The residue îs extracted with CH2C12, washed with saturated aqueous N'H.RT, dried with Na2SCU, filtered and concentrated in vacuo to afford 1-104 (365 mg); m/z 434 [M+H].
The following intermediates are synthesized in similar fashion from the appropriate reagents: /
154
Intermediate | Structure | m/z [M/M+2H] |
1-104 A | YVo BrAJ N< Ua- H | 432.0/434.0 |
I-104B | ryV'o V | 474.0/476.0 |
I-104C | ifjA) | 419.0/421.0 |
I-104D | ryVo 'n'NVo | 417.0/419.0 |
A mixture of 1-104 (365 mg, 0.84 mmol), 2-aminopyrimidine-5-boronic acid pinacol ester (279 mg, 1.26 mmol) and 2M aqueous Na2COî (0,85 mL) in DMF (4 mL) is degassed under N2 for 5 minutes. To this mixture is added bis(triphenylphosphine)palladium(II)chloride (59 mg, 0.08 mmol). The mixture is stirred /
155 i
î at 80 °C for 18 h then concentrated in vacuo. The residue is extracted with CH2Cl2, i
î washed with saturated aqueous NaHCOi, dried with filtered, and concentrated in vacuo. The residue îs purified by flash chromatography (S1O2, 0-5% MeOH in CH2CI2) to J give the title compound (268 mg).
; The following compounds are synthesized in similar fashîon from the appropriate intermediates:
Example 142, table 1
Example 144, table 1
Example 158, table 1
Example 161, table 1
Method 14
Synthesis of l-(3-{2-[4-(2-aminopyrimidin-5-yl)phenyl]-3-methyJbutan-2-yl}-l,2,415 oxadiazol-5-yl)cyclopropanecarboxylic acid (Example 95, table 1)
1-21 1-105
Example 95
To a solution 1-21 (189 mg, 0.63 mmol) in DMF (1 mL) is added a solution of 1chlorocarbonyl-l-cyclopropanecarboxylic acid methyl ester (113 mg, 0.69 mmol) in 20 DMF (1 mL). The reaction mixture is stirred at room température for 15 min then heated at 120 °C for 2 h. The mixture is cooled then treated wîth water and extracted with
EtOAc, washed with brine, dried with Na2SO4, filtered, and concentrated in vacuo. The
156 residue is purified by falsh chromatography (SiO2, 0-10% MeOH în CH2C12) to give I105 (30 mg); m/z 408 [M+H],
To a solution of 1-105 (30 mg, 0.074 mmol) in MeOH (0.5 mL·) is added an aqueous solution of NaOH (4.0M, 90 pL). The reaction mixture is stirred at room température for 1 h then concentrated in vacuo. The residue is partioned between EtOAc and water then the aqueos layer was acidified to pli -4 with 1 M aqueous HCL The aqueous mixture is extracted with EtOAc and concentrated in vacuo to afford a residue that is purified by préparative HPLC to afford the title compound (20 mg).
Method 15
Synthesis of l-(3-{2-[4-(2-aminopyriinidin-5-yl)phcnyi|-3-methylbutan-2-vl}-l,2,4oxadiazoI-5-yl)cycIohexanecarboxylic acid (Example 145, table 1)
1-107 Example 145
A mixture of cyclohexane-1,1-dicarboxylic acid monoethyl ester (142 mg, 0.50 mmol), HATU (199 mg, 0.52 mmol) and triethylamîne (80 pL, 0.55 mmol) in DMF (2.5 mL) is stirred for 5 min then 1-14 (100 mg, 0.50 mmol ) is added. The mixture is stirred at room température for 2 h then at 90 °C for 18 h then concentrated in vacuo. The résultant residue is partitioned between 1 M aqueous HCl and EtOAc. The organics are washed with brine, dried over MgSO4, fîltered and concentrated in vacuo. The residue îs purified by flash chromatography (SiO2, 15% EtOAc in cyclohexane) to give 1-106 (251 mg); m/z 449/451 [M/M+2H]. /
157
A mixture of 1-106 (223 mg, 0.50 mmol), 2-aminopyrimidine-5-boronic acid pinacol ester (121 mg, 0.55 mmol) and 2M aqueous Na?C()3 (1.9 mL) in DMF (5 mL) is degassed under N2 for 5 minutes. To this mixture is added bis(triphenylphosphine)palladium(ll)chloride (35 mg, 0.05 mmol). The mixture is stirred at 80 °C for 1 h then concentrated in vacuo. The residue is extracted with EtOAc, washed with saturated aqueous NaHCXh, dried with Na2SO4, filtered, and concentrated in vacuo. The residue îs purified by flash chromatography (SiO2, 0-20% EtOAc in cyclohexane) to give 1-107 (182 mg); m/z 464 [M+H].
To a solution of 1-107 (175 mg, 0.38 mmol) in 1:1 THF:water (3 mL) is added LiOHH2O (17 mg, 0.40 mmol). The reaction mixture is stirred at room température for 2 d then THF is removed in vacuo. The aqueous mixture is washed with EtOAc then acidified with saturated aqueous NH4CI. The aqueous mixture is extracted with EtOAc, washed with brine, dried with MgSÛ4, filtered, and concentrated in vacuo. The résultant solid is triturated with Et2O then filtered, collected and dried to yield the title compound (88 mg).
Method 16
Synthesis of 3-[4-(3-{2-[4-(2-aminopyrîmidin-5-yI)phenyIl-3-methylbutan-2-yl}- l,2,4-oxadiazol-5-yl)-lH-pyraz.ol-l-yl|-2,2-dimethylpropanoic acid (Example 164,
O
table 1)
CSjCO,
TBAI
Example 164
To a mixture of 1-47 (407 mg, 1.13 mmol) and 3-chloro-2,2-dimethyl propionic acid ethyl ester (557 mg, 3.38 mmol) in DMF (8 mL) is added CS2CO3 (734 mg, 2.25 mmol) and
158 tetrabutylammonium iodide (832 mg, 2.25 mmol). The mixture is stirred at 80 °C for 36 h then concentrated in vacuo. The residue is partitioned between CH2C12 and saturated aqueous NalICOj. The organics are dried with Na^SCU, filtered and concentrated in vacuo. The residue is purified by flash chromatography (S1O2, 10% EtOAc in cyclohexane) to give 1-108 (299 mg); m/z 489/491 [M/M+2HJ.
The following intermediate is synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M+2H] |
I-108bisa | AAAn /=n 0 | 463.0 |
a) The reaction is run at 80°C for 8 hours using K2CO;( in DMF
A mixture of 1-108 (290 mg, 0.46 mmol), 2-aminopyrimîdine-5-boronic acid pinacol ester (307 mg, 1.39 mmol) and 2M aqueous Na2CO3 (0.46 mL) in DMF (6 mL) is degassed under N2 for 5 minutes. To this mixture is added bis(triphenylphosphine)palladium(H)chloride (65 mg, 0.09 mmol). The mixture is stirred at 80 °C for 3 h then concentrated in vacuo. The residue is extracted with EtOAc, washed with saturated aqueous NaHCO3, dried withNa2SO4, filtered, and concentrated in vacuo. The residue is purified by flash chromatography (S1O2, 0-1% MeOH in CH2CI2) to give ΙΙΟ? (171 mg); m/z 504.90 [M+H].
The following intermediate is synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M+H] |
159
A mixture of 1-109 (171 mg, 0.282 mmol), LiOH.H2O (12 mg, 0.286 mmol), methanol (2.5 mL), THF (2.5 mL) and water (1.3 mL) is heated at 40 °C for 8 h then concentrated in vacuo. The residue is purified by préparative HPLC to give the title compound (33 mg).
The following compound is synthesized in similar fashion from the appropriate intermediates:
Example 160, table 1
Method 17
Synthesis of 6-(3-{2-[4-(2-aminopyriinidin-5-yl)phcnyl|-.3-inethylbutan-2-yl}-l,2.4oxadiazoI-5-yl)-l-methyIpyridin-2(lH)-one (Example 165, table 1)
9¼
PdCl2(PPh3)2
2M aq Na2CO3
DMF
To a solution of 2-carboxylic acid-6-oxo-pyridîne (161 mg, 1.16 mmol) in DMF (3 mL) is added carbonyldiimidazole (188 mg, 1.16 mmol). The mixture is stirred for 20 min at A
160 °C then treated with I-14 (300 mg, 1.05 mmol) and stirred at 110 “C for 3 h. The mixture is concentrated in vacuo and the residue is extracted with EtOAc, washed with saturated aqueous NaHCO3, dried with MgSO4, filtered, and concentrated. The residue is purifîed by flash chromatography (SiO2, 2% MeOH in CH2CI2) to give 1-110 (223 mg); m/z 389.95 [M+1].
The following intermediates are synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M/M+2H] |
I-11 Obis | Ao 0 | 392.0/394.0 |
To a solution of 1-110 (223 mg, 0.41 mmol) in THF (3 mL) is added K2CO3 (68 mg, 0.49 mmol) and Meï (30 jiL. 0.49 mmol). The mixture is stirred at 40 °C for 20 h and is treated with additional Meï (30 pL, 0.49 mmol) at 3 h and 15 h. The mixture is treated with saturated aqueous ammonia and MeOH then volatiles are removed in vacuo. The residue is extracted with EtOAc, washed with saturated aqueous NaHCO3, water, brine, dried with MgSO4) filtered, and concentrated. Purification of the crude by flash chromatography (SiO2, 0-10% EtOAc in cyclohexane) yields 1-111 (80 mg); m/z 403.85 [M+1].
The following intermediates are synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M/M+2H] |
161
A mixture of I-l 11 (80 mg, 0.19 mmol), 2-aminopyrimidine-5-boronic acid pinacol ester (124 mg, 0.56 mmol) and 2M aqueous Na2CO3 (0.20 mL) in DMF (2 mL) îs degassed under N2 for 5 minutes. To this mixture is added PdCl2(PPh3)2 (26 mg, 0.094mmol). The mixture is stirred at 80 °C for 3 h then concentrated in vacuo. The residue is extracted with EtOAc, washed with saturated aqueous NaHCOj, dried wîth Na2SO4, filtered, and concentrated in vacuo. The residue is purified by flash chromatography (SiO2, 0-1% MeOH în CH2C12) to give the tîtle compound (30 mg).
The following compounds are synthesized in similar fashion from the appropriate intermediates:
Example 166-167, table 1 — the reaction is run starting from a mixture of 1-1 lObis and I11 Ibis. Silica gel column chromatography affords Example 166 and 167.
Method 18
Synthesis of 2-[4-(3-{(lR)-l-[4-(2-aminopyrimidin-5-yI)phenyl]-l-cyclopropylethyl} l,2,4-oxadiazol-5-yI)-lH-pyrazol-l-yll-N,N-dimethyiacetamide (Example 115) and 2 [4-(3-{(lS)-l-f4-(2-aminopyriinidin-5-yl)phenyl]-l-cyclopropylethyl}-l,2,4oxadiazol-5-yI)-lH-pyrazol-l-yl]-N,N-dimethyIacetainide (Example 116, table 1)
162
Enantiomers 115 and 116 are prepared by resolution of example 59 (100 mg) on a Chiralpak® AD-H (avaîlable form Chiral Technologies, Inc., Exton, PA) semipreparative (250 x 20 mm) HPLC column (eluting with 95% EtOH in heptane containing 0.1%diethylamine). The faster eluting enantiomer 115 having a rétention time of ~ 35 min and the slower eluting enantiomer 116 having a rétention time of — 73 min. The eluants are concentrated to provide Example 115 (32 mg) and Example 116 (27 mg).
The following compounds are synthesized in similar fashion from the appropriate intermediates:
Examples 23-24, table 1
Examples 31-32, table 1 - eluting with 70%EtOH with 0.1% diethylamine/heptane
Examples 61-62, table 1
Examples 65-66, table 1
Examples 77-78, table 1
Examples 102-103, table 1
Example 104-105, table 1 - 95% EtOH in heptanes +0.05% diethylamine at 8ml/min
40°C
Examples 107-108, table 1
Example 115-116, table 1 - 95% EtOH in heptanes +0.05% diethylamine at 55ml/min
Examples 121-122, table 1 - 95% EtOH in heptanes +0.4% diethylamine at 55ml/min
Examples 123-124, table 1
Example 227-228, table 1
Example 230-231, table 1
Example 233-234, table 1
Example 254-255, table 1
Example 257-258, table 1
Example 282-283, table 1 /
163
Method 19
Préparation of 5-(4-{(2R)-3-methyl-2-[5-(l-methyl-lH-pyrazol-4-yl)-l,2,4-oxadiazol· 3-yl]butan-2-yl}phenyI)pyrimidin-2-amine (Example 46) and 5-(4-{(2S)-3-methyl-2[5-(l-methyl-lH-pyrazol-4-yl)-l,2,4-oxadiazoI-3-yl|butan-2-yl}phenyl)pyrimidin-2amine (Example 47, table 1)
Enantiomers 46 and 47 are prepared by resolution of example 15 (50 mg) on a Chiralpak® AD-H (available form Chiral Technologies, Inc., Exton, PA) semipreparative (250 x 30 mm) HPLC column (eluting with 70% MeOH in CO?) at 250 bar. The faster eluting enantiomer 46 having a rétention time of --5 min (Chiralpak® AD-H analytical HPLC column 4.6 x 100 mm) and the slower eluting enantiomer 47 having a rétention time of -13 min. The eluants are concentrated to provide Example 46 (12 mg) and Example 47 (15 mg).
The following compounds are resolved in similar fashion:
Examples 16-17, table 1
Examples 48-49, table 1
Method 20
Préparation of 2- {[5-(3- {(IR)- l-[4-(2-aminopyrimidiii-5-yl)phenyl] -1cyclopropylethyl}-l,2,4-oxadiazol-5-yl)pyrazin-2-yl]amino}-2-methylpropan-l-ol (Example 56, table 1) and 2-{[5-(3-{(lS)-l-[4-(2-aminopyrimidin-5-yl)phenyII-lcyclopropylethyI}-l,2,4-oxadiazoi-5-yi)pyrazin-2-yl]amîno}-2-methylpropan-l-oI (Example 57, table 1) z
164
Enantiomers 56 and 57 are prepared by resolution of Example 45 (89 mg) on a RegisPak (available form Chiral Technologies, Inc., Exton, PA) semi-preparative (250 x 30 mm) HPLC column (eluting with 70% MeOH in CO?) at 250 bar. The f'aster eluting enantîomer 56 having a rétention time of ~5 min (Chiralpak® AD-H analytical HPLC column 4.6 x 100 mm) and the slower eluting enantîomer 57 having a rétention time of —13 min. The eluants were concentrated to provide Example 56 (12 mg) and Example 57 (15 mg).
The following compounds are resolved in similar fashion:
Examples 50-51, table 1 - eluting with 55% MeOH in CO2
Examples 52-53, table 1 - eluting with 45% of 3/1/0.1
MeOH/isopropanol/isopropylamine in CO2
Examples 54-55, table 1 eluting with 55% EtOH in CO2
Examples 56-57, table 1 - eluting with 45% 1/1 methanol/ispropanol
Example 100-101, table 1 - eluting with 40% co-solvent of 1:1 methanoliisopropanol with 0.5% isopropylamine at 150 bar
Example 63-64, table 1
Method 21
Synthesis of 5-(4-{3-methyI-2-[5-(4-methylpiperazin-l-yl)-l,2,4-oxadiazol-3yl]butan-2-yl}phenyl)pyrimidin-2-amine (Example 96, table 1) X
165
To a mixture of 1-14 (1.029 g, 3.61 mmol) and carbonyldiimidazole (702 mg, 7.33 mmol) is added acetonitrile (20 mL). The reaction mixture is heated at 75 °C for 18 hours. After this time, the reaction mixture is concentrated in vacuo and purified by flash 5 chromatography (SiO2, 12-100% EtOAc in heptane) to give 1-112 (373 mg); m/z 311.2/313.2 [M/M+2H].
To a solution of 1-112 (163 mg, 0.523 mmol) in pyridine (0.5 mL) is added POC13 (0.479 mL, 5.23 mmol). The reaction mixture is heated at 90 °C for 18 hours. The reaction mixture is cooled to room température and carefully poured into ice water and then 10 extracted with EtOAc twice. The organcis are combined and washed with brine, dried over NapSOi- filtered and concentrated in vacuo. The residue is purified by flash chromatography (SiO2, 12-100% EtOAc in heptane) to give 1-113 (59 mg); IH- NMR (DMSO-ί/ό) Ô ppm 7.50 (2H, d), 7.35 (2H, d), 2.62 (IH, m), 1.60 (3H, s), 0.83 (3H, d), 0.6 (3H, d).
To a solution of 1-113 (44 mg, 0.133 mmol) in DMSO (1 mL) is added 1methylpiperazine (0.148 mL, 1.33 mmol) and the reaction mixture is stirred at room température for 1.5 hours. The reaction mixture is quenched with water and extracted with EtOAc twice. The organics are combined and washed with water then brine, dried over Na?SOi, filtered and concentrated in vacuo. The residue is purified by flash 20 chromatography (SiO2, 10-100% MeOH in CH2C12) to give 1-114 (45 mg); m/z 393.0/395.0 [M/M+2H]. Z
166
The following intermediates are synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M/M+2H] |
1-115b | rANo N-:( Ao O X | 450.2/452.2 |
I-116a | Q | 428.2/430.2 |
1-117a | fKc βΛ N«< D V 0 | 421.2/423.2 |
1-118b | A bA X O '—N ..s— oô | 457.2/459.2 |
1-119a | fA bF'·^ n,:< O ? OH | 423.2/425.2 |
167
I-I20b | pY B,A NX O '—N Ao h2n | 422.2/424.2 |
I-I21b | ÂYo b/> Νχ HO | 436.4/438.4 |
I-!22b | ίγΑ'ο bA NX Ν-χ < Ko H | 393.2/395.4 |
I-I23b | ΓγΑο A Νχ OH | 366.2/368.2 |
I-I24b | BrA> N==( NH S | 408.4/410.4 |
I-125b | ryKo bA Νχ (A A \ | 407.1/409.1 |
168
I-126b | S Q .s00 | 456.2/458.2 |
I-127b | ÂVo q HO | 408.2/410.2 |
I-128b | A BrXJ N.X 9 OH | 422.3/424.2 |
I-I29b | A 0ΓΛ> N-( X. h2n | 421.2/423.2 |
I-130b | 0 N/ | 421.2/423.2 |
I-13lb | ΓγΑο V Ah o N—/ / | 407.4/409.4 |
169
I-132b | 00% N*< NH 0 HO | 408.2/410.1 |
I-133b | 00% xM N=( N-- S --N | 395.4/397.4 |
I-134b | ίΥΛ O A | 435.4/437.4 |
I-135b | 00% bXX n=( Q OH | 394.4/396.2 |
I-I36b | 00% V | 421.4/423.4 |
I-137c | 00% O V | 419.4/421.2 |
170
I-138b | A Br+X N=( D -N Y | 450.4/452.4 |
I-139b | jA O z° | 408.2/410.2 |
1-140 | nbo BrAA N-=< N-Λ U OH | 420.4/422.4 |
I-140bis | jCjbN'° Ν-λ Q P-+ -H A | 507.3/509.3 |
I-140tris | ryXo ΒγΛΧ n-( Q hN~V H o | 493.3/495.3 |
a) 1.2 equ. of amine and 1.2 equ. of diisopropylethylamine are used.
b) 1.2 equ. of amine (either as free base or hydrochloride sait) and 2.5 equ. of diisopropylethylamine are used. /
171 ί ί ί
c) 1.2 equ. of amine as di-hydrochloride sait and 5 equ. of diisopropylethylamine are used.
The mixture of 1-114 (45.000 mg, 0.114 mmol), 2-aminopyrîmidine-5-boronic acid pinacol ester ¢30.286 mg, 0.137 mmol) and tetrakis (triphenylphosphine)palladium (0) (13.173 mg, 0.011 mmol) in a vial is evacuated and back filled with Ar 3 times. Then THF (1 mL) and sat. Na^CO. aqueous solution are added and the mixture is heated to 65 °C for 18 hours. After this time, the reaction mixture is quenched with water and extracted with EtOAc twîce. The organcis are combined and washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue is purified by flash chromatography (SiO2, 12-100% EtOAc in heptane) to give Example 96 (12 mg).
The following intermediates are synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M+H] |
I-141a | A II J Ν-Λ h-nA < ) o-4/H \ 0 | 522.4 |
I-142a | AzAn. (Ύ r o J! J hjAnJ < ) ( oZ H 0 | 508.4 |
172
I-143a
465.4
a) The reaction has been performed in the microwave oven at 110°C for 45 minutes.
The following compounds are synthesized in similar fashion from the appropriate intermediates:
Examples 168, table 1
Example 169, table 1 - the last step has been performed in the microwave oven at 110°C for one hour
Example 170, table 1 - the last step has been performed in the microwave oven at 110°C for 45 minutes
Examples 186, table 1- the last step has been performed in the microwave oven at 110°C for 45 minutes
Examples 192, table 1
Exemples 198-202, table 1- the last step has been performed in the microwave oven at 110°C for 45 minutes
Examples 208-209, table 1- the last step has been performed in the microwave oven at 110°C for 45 minutes
Examples 212-213, table 1 - the last step has been performed în the microwave oven at 110°C for 45 minutes
Examples 218, table 1- the last step has been performed in the microwave oven at 110°C for 45 minutes
Exampe 235, table 1 - the last step has been performed in the microwave oven at 100°C for two hours
Examples 236-237, table 1- the last step has been performed in the microwave oven at 110°C for 45 minutes
Examples 260, table 1 S
173 f
Examples 261-262, table 1- the last step has been performed in the microwave oven at 110°C for 45 minutes
Examples 264, table 1 - the last step has been performed in the microwave oven at 110°C 5 for 45 minutes
Exemples 266, table 1- the last step has been performed in the microwave oven at 110°C for 45 minutes
Examples 269-270, table 1- the last step has been performed in the microwave oven at 110°C for 45 minutes
Method 22
Synthesis of 4-(3-{2-|4-(2-aminopyrimidin-5-yI)plienyl|-3-metIiyIbutan-2-yI}-l,2.4oxadiazol-5-yl)-2,2-dimethylbutanoic acid (Example 85, tablel)
[.21 Example 85
To a solution of 1-21 (100 mg, 0.334 mmol) in DMF (1 mL) is added 2,2dimethylglutaric anhydride (52 mg, 0.367 mmol). The reaction mixture is heated to 120 °C for 2.5 hours. After this time, the reaction mixture is quenched with water and extracted with EtOAc twice. The organics are combined and washed with water then 20 brine, dried over Na2SÛ4, filtered and concentrated in vacuo. The residue is purified by flash chromatography (SiO2, 10-100% MeOH in CH2C12) then triturated in hot MeOH to give Example 85 (40 mg).
The following compounds are synthesized in similar fashion from the appropriate 25 intermediates:
Example 92-94, Table 1 x
174
I s i
i i
Method 23
Synthesis of: 5-(4-{(R)-l-Cyclopropyl-l-[5-(3,4,5,6-tetrahydro-2H-[l,2’]bipyrazinyl5 *-yl)-[ 1,2,4] oxadiazoI-3-yl]-ethyl]-phenyl)-pyraziii-2-y lamine (Example 195, tablel)
To cold (0°C) méthanol (20 ml) is added 1 ml of acetyl chloride (dropwise). Upon 10 complété addition, 1-83 (350 mg, 0.61 mmol) is added as a méthanol solution (5 ml).
Allow to gradually warm to RT and stir over night. After this time the reaction is basified using 7N ammonia and concentrated to dryness. The remaining residue is purifîed via flash chromatography (silica gel, 0-10% MeOH/DCM) to give 1-135.
The following intermediates are synthesized in similar fashion from the appropriate 15 reagents:
Intermediate | Structure | m/z [M+H] |
I-143tris | ΓγΑο A J AN HJsAbf f > N=( O H | Not available |
175
I ί i r
I i
i
The following compounds are synthesized in a similar fashion from the appropriate intermedîates:
Example 214, Table I - the crude is purified via flash chromatography (silica gel, ΟΙ 00% MeOH/DCM)
Example 267, Table 1
Example 268, Table 1 - the crude is concentrated to dryness and purified the crude via flash chromatography (silica gel, 0-10% MeOH/DCM, with 0.5% NH4OH)
Step2:
I-I43bis
Example 195 Ά
176
Chiral resolution of 1-135 was performed using a ChiralPak® AD-H column (3.0 x 25.0 cm, available from Chiral Technologies, West Chester PA). Eluting with methanol/IPA (1:3) with 1% isopropylamîne at 150 bar afforded Example 195 (6 mg).
The following compounds are synthesized in a similar fashion from the appropriate intermediates:
Example 196, Table 1- the chiral resolution is performed at 125 psi
Example 210, Table 1- the chiral resolution is performed at 125 psi, with no ispropylamine in the eluent
Method 24
Synthesîs of 1-(3- (1-(4-(2- Amino-pyrimidin-5-yI)-phenyl]-l, 2-dimethyl-propyl}[l,2,4]oxadiazol-5-yl)-2-methyI-propan-2-ol (Example 225, table 1)
To a suspension of R-13 (118 mg, 1.0 mmol) in THF 10 ml) is added 1,1’carbonyldîimidazole (162 mg, 1.0 mmol) at room température. The mixture is stirred at 50 °C for 30 minutes. After this time 1-21 (200 mg, 0.67 mmol) is added and the resulting mixture is heated under reflux for 3 hours. After this time the reaction is cooled 20 to RT, treated with HOAc (1 ml) and warmed to 80°C. After stirring for 3 days the mixture is cooled to RT and concentrated. The remaining residue is purified via flash chromatography (silica gel, 0-8% MeOH/DCM) to afford the title compound (80 mg).
The following compounds are synthesized in a similar fashion from the appropriate intermediates:
Example 229, Table 1- no AcOH is added in the reaction mixture s
177
Example 232, Table I- no AcOH is added in the reaction mixture
Method 25
Synthesis of 5-(4-{l-Cyclopropyl-l-[5-(3-oxetan-3-yl-3H-imidazol-4-yl)5 [l,2,4]oxadiazol-3-ylJ-ethyl}-pbenyl)-pyrimidin-2-ylaniÎne (Example 206, table 1)
Synthesis of 5-(4-{l-Cyclopropyl-l-[5-(l-oxetan-3-yl-lH-imidazol-4-yl)·
11,2,4]oxadiazol-3-yl|-ethyl}-ph<.’nyl)-pyriinidin-2-ylamine (Example 207, table 1)
Example 206 Example 207
To a suspension of l-trityl-lH-imidazole-4-carboxylic acid (893 mg, 2.5 mmol) in THF (10 mL) is added Ι,Γ-carbonyldiimidazole (409 mg, 2.5 mmol) at room température.
The mixture is stirred at 50 °C for 30 minutes. A suspension of 1-23 (500 mg, 1.7 mmol) in THF (5 mL) is added to the above mixture and the resulting mixture is heated at 130 °C in a microwave reactor for 2 hours. The mixture is cooled down and is concentrated under vaccuum. The residue is extracted with H2O (10 mL) and EtOAc (20 mL). The combined organic layer is dried with MgSO.1 and is filtered. The filtrate is concentrated and the residue is purified by silica gel flash column chromatography with 10% MeOH in CH2CI2 as the eluent to afford 1-144 (150 mg); m/z 374 [M-trityl group].
To a solution of 1-144 (80 mg, 0.13 mmol) in CH2CI2 (10 mL) is added TFA (0.015 mL,
0.19 mmol) at room température. The solution is stirred at the same température for 24 /
178 hours. The solution is concentrated under vaccuum to afford 1-145 (48 mg); m/z 374 [M+H],
To a round bottom flask is added 1-145 (100 mg, 0.27 mmol), 3-iodooxetane (98 mg, 0.54 mmol) and K2CO3 (111 mg, 0.8 mmol) in DMF (10 mL). The reation mixture is stirred at 5 80 °C for 12 hours. The reaction is cooled down and water (10 mL) is added. The solution is extracted with EtOAc (20 mL) and H2O (10 mL). The combined organic layer is dried with MgSO4 and is filtered. The fïltrate is concentrated and the residue is purified by silica gel flash cloumn chromatography with 10% MeOH in TB ME as the elunet to afford the title compounds (Example 206: 8 mg; Example 207: 10 mg).
Method 26
Synthesis of 2-[4-(3-{l-[4-(2-Ammo-4-fluoro-pyrimidin-5-yl)-phenylJ-l-cyclopropylethyl}-[l,2,41oxadiazoI-5-yl)-pyrazol-l-yl]-N,N-dimethyl-acetamide (Example 275, table 1)
To a solution of 1-69 (300 mg, 0.6 mmol) in DMF (10 mL) are added 1-87 (140 mg, 0.7 mmol), tetrakis (triphenylphosphine)palladium (0) (70 mg, 0.06 mmol) and 2M Na2CO3 (1.5 mL, 3.0 mmol). The mixture is heated to 100 °C for 1 hour in a microwave reactor. The mixture is cooled down and is extracted with H2O (20 mL) and EtOAc (30 mL). The 20 combined organic layer is dried with MgSO4 and is filtered. The fïltrate is concentrated and the residue is purified by silica gel flash column chromatography with 10% MeOH in CH2C12 as the eluent to afford the title compound (200 mg).
The following compounds are synthesized in a similar fashion from the appropriate intermediates: /
179
J i
t
Example 175, Table 1 - the reaction is run at 120°C
Example 176-180, Table 1 — the reaction is run at 120°C
Example 184-185, Table 1 — the reaction is run at I2O°C j Example 187-189, Table 1 - the reaction is run at 120°C
Example 191, Table 1 - the reaction is run at 120°C
Example 239-243, Table 1 - the reaction is run for 6 hours at 100°C in an oil bath
Example 244-246, Table 1
Example 247, Table 1 — the reaction is run for 6 hours at 100°C in an oil bath
Exemple 249-250, Table 1 — the reaction is run for 6 hours at 100°C in an oil bath
Example 251, Table 1- the reaction is run at 85°C overnight
Example 253, Table 1 - the reaction is run for 6 hours at 100°C in an oil bath
Example 256, Table 1 — the reaction is run for 6 hours at 100°C in an oil bath
Example 265, Table 1 - the reaction is run for 6 hours at 100°C in an oil bath
Example 273, Table l - the reaction is run for 6 hours at 100°C in an oil bath
Example 275, Table 1
Example 279, Table 1
Example 280-281, Table 1 - the reaction is run for 48 hours at 80°C
Example 284-286, Table 1
Example 289-291, Table 1
Example 292, Table 1- the reaction is run for 16 hours at 85ÛC
Example 293-294, Table 1
Example 298, Table 1
Method 27
2-[4-(3-{(R)-l-[4-(6-Amino-pyridin-3-yI)-phenyl]-l-cyclopropyI-ethyI}- [l,2,4]oxadiazol-5-yl)-pyrazol-l-yl|-N,N-dimethyI-acetamide (Example 172, table 1) y
180
Το a micro wave vial is added 1-63 (lOOmg, 0.225 mmol) in DMF (2 ml), followed by the addition of 2-aminopyridine-5-boronic acid pinacol ester (55 mg, 0.25 mmol), tetrakis(triphenylphosphine)palladium(0) (26 mg, 0.023 mmol) and 2 M aq. Na2CO3 (0.4 5 ml, 0.8 mmol). The reaction mixture is stirred in microwave reactor at 120 °C for 1 hour.
The residue is diluted with EtOAc, washed with water, brine, dried under anhy. Na2SO4, filtered and concentrated. The residue is purified by flash chromatography (SiO2, 0-5% MeOH/CH2Cl2) to afford the title compound (39 mg).
The following compounds are synthesized in a similar fashion from the appropriate intermediates:
Example 173-174, Table 1
Example 181, Table 1
Example 183, Table 1
Example 263, Table 1 - the reaction is run at 80°C overnight
Method 28
Synthesis of5-(4-{l,2-Dimethyl-l-[5-(4-methylamÎno-piperidin-l-yl)- [l,2,4]oxadiazol-3-yI]-propyI}-phenyl)-pyrimidin-2-ylamine (Example 217, table 1)
181
1-141 (138 mg, 0.265 mmol) îs dissolved in DCM (2 mL) and 4N HCl in 1,4-dioxane (0.663 mL, 2.65 mmol) is added and the reaction mixture is stirred at room température for 3 hours. After this time, the reaction mixture is concentrated in vacuo and the residue is dissolved in MeOH and passed through a PL-HCOj MP-resin column to free base the product. The filtrate is concentrated in vacuo and the crude is purified by préparative TLC using 10% MeOH/DCM as solvent mixtures to afford the title compound (71 mg); m/z 422.4 [M+1].
The following compounds are synthesized in a similar fashion from the appropriate intermediates:
Example 222, Table 1
Method 29
Synthesis of 2-[4-(3-( 1-(4-(2-Amitio-pvrirnidin-5-yl)-phenvl|-l,2-diinetliyl-propyl}[l,2,4]oxadiazol-5-yI)-piperazin-l-yl]-N,N-dimethyl-acetamide (Example 193, table
182
Synthesis of 2-[4-(3-{l-[4-(2-Amino-pyrimidin-5-yl)-phenyl]-l,2-dimethyl-propyl}- [l,2,4]oxadiazol-5-yI)-pîperazin-l-yl]-N,N-dimethyl-acetainide
Synthesis is performed in similar conditions used in Method 9 using the appropriate reagents.
The following intermedîates are synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M+H] |
1-146 | ί η r o NA JL J < ) Vf o- | 466.0 |
The following compounds are synthesized in a similar fashion from the appropriate intermedîates:
Example 211, Table 1
Method 30
Synthesis of l-(3-{l-|4-(2-Amino-pyriinidin-5-yl)-phenyl]-l,2-diniethyl-propyl}- [l,2,4]oxadiazol-5-yl)-piperidine-4-carboxyIic acid (Example 219, table 1)
183 i
I
Synthesis is similar to conditions used in Method 14 Step 2 using the appropriate reagents; m/z 437.4 [M+1]. Compound is purified by trituation from hot MeOH.
The following compounds are synthesized in a similar fashion from the appropriate intermediates:
Example 272, Table 1
Method 31
Synthesis of l-(3-{l-[4-(2-Amino-pyrimidin-5-yl)-phenyl]-l,2-dimethyl-propyl}10 [1,2,4] oxadiazol-5-yl)-3-methyl-azetidin-3-ol (Example 203, table 1)
Step!
MeMgCl THF
Step 2
Synthesis of l-{3-[l-(4-Bromo-phenyl)-l,2-diinethyl-propyI]-[l,2,4]oxadiazol-5-yl}azetidin-3-one
Synthesis is performed in similar conditions used in Method 21 Step 3 using the appropriate reagents; m/z 364 [M+H]. S
184
The following intermediates are synthesized în similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M/M+2H] |
I-147bis | Q O | 392.2/394.2 |
I-147tris | .M» Q O | 390.1/392.1 |
I-147quadris | .A 7 O | 362.2/364.0 |
Synthesis of l-{3-[l-(4-Bromo-phenyl>l,2-dimethyl-propyi]-[l,2,4]oxadiazol-5-yl}-3methyl-azetidin-3-ol
To a cooled solution of 1-147 (132.6 mg, 0.364 mmol) in THF (1 mL) at -78°C is added 3M methyl magnésium chloride in THF (0.485 mL, 1.456 mmol). The reaction mixture is 10 stirred at -78°C for 10 minutes then at room température for 20 minutes. After this time, the reaction mixture is quenched with water and extracted with EtOAc twice. The organcis are combined and washed with brine, dried over NajSO.·, filtered and concentrated in vacuo to afford the title compound (122 mg); m/z 380 [M+H], Z
185
The following intermediates are synthesized in similar fashion from the appropriate reagents:
Intermediate | Structure | m/z [M/M+2H] |
M48bis | A'S βΓΛ> N=( Q V°H | 408.4/410.4 |
I-148tris | iWO X N=< V | 406.1/408.1 |
I-148quadris | A- | 378.2/380.2 |
Synthesis of l-(3-{l-[4-(2-Amino-pyrimidin-5-yl)-phenyl]-l,2-diniethyl-propyl} [ 1,2,4] oxadiazoI-5-yi)-3-methyl-azetidin-3-oi
Synthesis is performed in similar conditions used in Method 21 Step 4 using the appropriate reagents.
The following compounds are synthesized in a similar fashion from the appropriate intermediates;
Example 216, Table 1
Example 238, Table l
Example 276, Table 1 /
186
Method 32
Synthesis of 2-[4-(3-{l-[4-(2-Amino-pyrimidin-5-yI)-phenyi]-l-cyclopropyl-ethyl}[l,2,4]oxadiazol-5-yI)-piperazin-l-yl]-ethanol (Exampie 252, tablel)
OH
Synthesis of 3-[l-(4-Bromo-phenyl)-l-cyclopropyl-ethyl]-[l,2,4]oxadiazol-5“Ol
Synthesis is performed in similar conditions used in Method 21, Step 1 using the appropriate reagents; m/z 307 [M+H].
Synthesis of 3-(l-(4-Bromo-phenyl)-l-cyclopropyl-ethyl]-5-chloro-Jl,2,4]oxadiazole To a solution of 1-149 (847 mg, 2.74 mmol) in DCM (8 mL) in a microwave vial is added POCI3 (0.401 mL, 4.384 mmol) andpyridine (1.107 mL, 13.7 mmol). The reaction mixture is heated in microwave oven at 120°C for 1 hour. After this time, the reaction mixture is quenched with water and extracted with CH2CI2 twice. The organcis are combined and washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude is purified by flash chromatography (SiO2, 6-50% EA/Hep) to afford the title intermediate (694 mg). 1H-NMR: (DMSO-J6) Ô ppm 7.5 (2H, d), 7.3 (IH, d), 1.5 (IH, m), 1.4 (3H, s), 0.6 (IH, m), 0.5 (IH, m), 0.4 (IH, m), 0.3 (IH, m).
187
Synthesis of 2-(4-{3-[l-(4-Bromo-phenyl)-l-cyclopropy]-ethyl]-[l,2}4]oxadiazol-5yl}-piperazin-l-yl)-ethanol
Synthesis is similar to conditions used in Method 21, Step 3 using the appropriate reagents; m/z 421/423[M/M+2H].
Synthesis of 2-[4-(3-{l-[4-(2-Amino-pyrimidin-5-yl)-phenyl]-l-cyclopropyl-ethyl}- [1.2.4] oxadiazol-5-yl)-piperazin-l-yl]-ethanol
To a mixture of 1-151 (193 mg, 0.458 mmol) and Pd(PPh3)4 (53 mg, 0.046 mmol) in a microwave vîai is added the DMF (5 mL) solution of 2-aminopyrimidine-5-boronic acid pinacol ester (121.6 mg, 0.55 mmol) and 2M Na2CO3 aqueous solution (0.92 mL). The reaction mixture is purged with Ar and then heated in microwave oven at 110°C for 45 minutes. After this time, the reaction mixture is quenched with water and extracted with EtOAc twice. The organics are combined and washed with brine, dried over Na>SOi, filtered and concentrated in vacuo. The crude is purified by flash chromatography (SiO2,
1.2-10% MeOH/DCM) to afford the tîtle compound (83 mg).
The following compounds are synthesîzed in a similar fashion from the appropriate intermediates:
Example 204-205, Table 1
Example 248, Table 1
Example 252, Table 1 Example 259, Table 1 Example 274, Table 1 Example 287-288, Table 1 Example 297, table 1
Method 33
Synthesis of l-(3-{(R)-l-[4-(2-Ainino-pyriniidin-5-yl)-phenyl]-],2-dimethyl-propyl}- [1.2.4] oxadiazol-5-yI)-piperidin-4-ol (Example 223, table 1) and l-(3-{(S)-l-[4-(2Amino-pyrimidin-5-yl)-phenyl]-l,2-dimethyl-propyl}-[l,2,4]oxadiazol-5-yI)piperidin-4-oI (Example 224, table 1) y
188
Example 223 and Example 224 are prepared by resolution of Example 262 (90.3 mg) on a RegisPak (available from Regis Technologies, Morton Grove, IL) semi-preparative (30*250 mm) HPLC column (eluting with 35% 1:1 MeOH in Isopropanol containing 0.1% isopropylamine in CO2) at 100 bar. The faster eluting enantiomer Example 223 having a rétention time of 2.07 min (RegisPack 4.6* 100 mm, available from Regis Technologies, Morton Grove, IL) and the slower eluting enantiomer Example 224 having a rétention time of 2.68 min. The eluents are concentrated to provide Example 223 (36 mg) and Example 224 (34 mg).
Method 34:
Synthesis of 5-I4-((R)-l-Cyclopropyl-l-{5-[l-(2-dimethylamino-ethyl)-lH-pyrazol-4yl]-[l,2,41oxadiazol—yl}-ethyl)-phenyI]-pyrimidin-2-ylamine (Example 182, table 1)
N/
CIH
Example 48 (75.0 mg, 0.201 mmol) is treated with (2-Chloro-ethyl)-dimethyl-amine hydrochloride (43.4 mg, 0.301 mmol), Cs2CO3(147 mg, 0.452 mmol), and DMF (1.5 mL) and the resulting mixture is stirred at 60 °C for 1 hour. At this time the mixture is treated with (2-Chloro-ethyl)-dimethyl-amine hydrochloride (14.5 mg, 0.100 mmol), Cs2CO3 (32.7 mg, 0.100 mmol) and stirred for 1 hour longer. The reaction is then purified directly by flash chromatography over C-18 silica eluting 10-60% s
189 acetonitrile/water/0.1% trîfluoroacetic acid. The resulting semi-pure material is treated with CH2C12 and saturated aqueous NaHCOî and the phases are separated. The resulting aqueous phase is extracted 5 additional times with CH2C12 and the combined organic phases are dried over Na2SO4, filtered, and concentrated in vacuo to give a residue that is further purified by préparative TLC eluting 8% methanol/ CH2C12 to give the title compound (35.0 mg).
The following compound is synthesized in a similar fashion from the appropriate intermediates:
Example 215, table 1
Method 35:
Synthesis of2-[4-(3-{(R)-l-|4-(2-Ammo-pyrimidin-5-yl)-phenyl]-l-cyclopropylethyl}-[l,2,4]oxadiazoI-5-yl)-pyrazol-l-yl]-l-((R)-3-methoxy-pyrrolidin-l-yl)ethanone (Example 220, table 1).
o \
Synthesis of [4-(3-{(R>-1-(4-(2-Amino-pyrimidin-5-yl)-phenyl]-l-cyclopropyl-ethyl}- [l,2,4]oxadiazol-5-yl)-pyrazol-l-yl]-acetic acid ethyl ester
Example 48 is alkylated according to Method 9; m/z 460 [M+H].
190 i ι
Synthesis of [4-(3-{(R)-l-[4-(2-Amino-pyrimidin-5-yl)-phenyl]-l-cyclopropyl-ethyl}[ 1,2,4]oxadiazol-5-yl)-pyrazol-l-yl]-acetic acid j
' 1-152 is hydrolyzed according to the final step of Method 16; m/z 432 [M+H].
1-153 (94.0 mg, 0.218 mmol) is treated with (R)-3-methoxy-pyrrolidine (33.1 mg, 0.327 mmol), HATU (125 mg, 0.327 mmol), DIEA (114 pL, 0.654 mmol), and DMF (1.50 mL) and the resulting mixture is stirred for 1 hour. The reaction is purified directly by reverse phase préparative HPLC eluting 30-70% acetonitriIe/water/0.1% formic acid to give the title compound (16.0 mg).
The following compounds aresynthesized in a similar fashion from the appropriate intermediates:
Example 194, table 1 Example 221, table 1
Method 36
Synthesis of 2-[4-(3-{(R)-l-[4-(2-amino-6-oxo-l,6-dihydro-pyrimidm-5-yl)-phenyI]l-cyclopropyl-ethyl}-[l,2,4]oxadiazol-5-yl)-pyrazoI-l-yl]-N,N-dimethyl-acetamide (Example 197, table 1)
1-97 (170 mg, 0.30 mmol) is dissolved in éthanol (10 ml) and treated with Pearlman's catalyst (Palladium hydroxîde, 35 mg, 50% wet, 0.12 mmol). The vessel is degassed and
191 placed under hydrogen (balloon). Upon complété conversion, the reaction is filtered through a pad of celite and the solids are washed with méthanol. The combined filtrâtes are concentrated and the remaining crude is purified via flash column chromatography (010% MeOH/DCM) to give the title compound (100 mg).
Method 37
Préparation of 5- [4-((R)-l-{5-1 l-(2-Amino-ethyl)-111-pvrazol-4-yl]-[ 1,2,4Joxadiazol-
3-yl}-l-cyclopropyI-ethyl)-phenyl|-pyrimidin-2-ylamine (Example 190, table 1).
Example 190
Intermédiare 1-98 (120 mg, 0.22 mmol) is treated with éthanol (2.7 mL) and THF (0.5 ml.) and hydrazîne (97 mg, 1.93 mmol) is then added. The resultingmixture is stirred at °C for 2 hours. The resulting mixture is filtered, rinsing with éthanol, diluted with ethyl acetate and water, and the phases separated. The organic phase is washed with brine dried over Na2SO4, filtered, and concentrated in vacuo. The residue îs purified by reverse-phase préparative HPLC eluting 10-80% acetonitrile/water/trifluoroacetic acid to | give the title compound (33.0 mg).| r I
Method 38I
J
Synthèses of 2-[4-(3-{l-[4-(2-Amino-6-fluoro-pyridin-3-yl)-phenyl]-l-cyclopropyl-| ethyl}-[l,2,4]oxadiazoI-5-yl)-pyrazoi-l-yl]-N,N-dimethyl-acetaniide (Example 277,j table 1) and 2-[4-(3-{l-[4-(6-Amino-2-fluoro-pyridÎn-3-yI)-phenyl]-l-cyclopropyl- S[ t
192 ethyl}-[l,2,4]oxadiazol-5-yI)-pyrazol-l-yl]-N,N-dimethyl-acetamide (Example 278, table 1)
Example 277 Example 278
To a mixture of 1-69 (300 mg, 0.68 mmol) in 1,4-dioxane (10 mL) are added 2,6difluoropyridin-3-boronic acid (128 mg, 0.81 mmol), PdC12(PPh3)2 (47 mg, 0.068 mmol) and 2 M NîitCO;, solution (2M aqueous solution)(l mL, 02 mmol). The mixture is heated to 100 °C for 1 hour in a microwave reactor. The solution is cooled down and is extracted with H2O and EtOAc. The combined organic layer is dried with \lg2SO4 and is 10 filtered. The filtrate is concentrated and the residue is purified by silica gel flash column chromatography with 10% MeOH in CH2CI2 as the eluent to afford 1-154 (200 mg) (m/z:
479.2 [M^+H]).
1-154 (150 mg, 0.31 mmol) is dissolved in NH3 in MeOH (2M solution)(10 mL) and the solution is heated to 100 °C for 72 hours. The solution îs cooled down and is 15 concentrated. The residue is purified by préparative silica gel TLC to obtain the title compounds (example 277: 10 mg; example 278: 14 mg) X
193
Method 39
Synthesis of 2-[4-(3-{l-[4-(5-Amino-3-cyano-pyrazin-2-yl)-phenyl]-l-cyclopropylethyl}-[1,2,4] oxadiazoI-5-yl)-pyrazol-l-yl]-N,N-dimethyl-acetamide (Example 295, table 1)
1-155 Example 295
To a solution of 1-69 (100 mg, 0.2 mmol) in DMF are added 2-amino-5-bromo-6chloropyrazîne (51 mg, 0.24 mmol), Tetrakis (triphenylphosphine)palladium (0) (24 mg, 0.02 mmol) and 2M Na2CO3 solution (2M aqueous)(0.5 mL, 1 mmol). The mixture is heated to 100 °C for 1 hour in a microwave reactor. The mixture is cooled down and is extracted with H2O and EtOAc. The combined organic layer is dried with MgSO4 and is filtered. The filtrate is concentrated and the residue is purified by silica gel flash column chromatography with 10% MeOH in CH2CI2 as the eluent to afford 1-155 (86 mg) (m/z:
493.2 [M^+H]).
In a microwave reaction vessel is dissolved 1-155 (80 mg, 0.16 mmol) in DMF (8 mL). Zinc cyanide (23 mg, 0.19 mmol) and Pd(PPh3)4 (18 mg, 0.016 mmol) are added and the solution is heated to 120oC in a microwave for 2 hours. The solution is cooled down and îs poured into water and extracted the product into EtOAc. The combined organics are dried with MgSO4, filtered and concentrated. The residue is purified by silica gel flash column chromatography with 10% MeOH in CH2C12 as the eluent to afford the title compound (38 mg).
Method 40 /
194
Synthesis of 2- [4-(3-(1- [4-(6-Amino-2-cyano-pyridin-3-yl)-phenyl]-l-cyclopropylethyl}-l,2,4]oxadiazo]-5-yl)-pyrazol-l-yl]-N,N-dimethyl-acetamide (Example 296, table 1)
Example 296
To a solution of 2-bromo-6-aminopyridine (200 mg, 1.2 mmol) in DMF (10 mL) are added Zn(CN)2 (163 mg, 1.4 mmol) and Pd(PPh3)4 (134 mg, 0.12 mmol) at room température. The solution is heated at 120 °C in a microwave reactor for 2 hours. The solution is cooled down and water is added. The solution îs extracted with EtOAc and the combined organic layer was dried with MgSO4 and is filtered. The filtrate is concentrated and the residue is purified by silica gel flash column chromatography with 10% MeOH in CH2CI2 as the eluent to afford 1-156 (54 mg) (m/z: 119.9 [M+]).
To a solution of 1-156 (54 mg, 0.46 mmol) in CH3CN (10 mL) is added NBS (162 mg, 0.9 mmol) at room température. The solution is stirred at the same température for 12 hours. The solution is concentrated and the residue îs purified by silica gel flash column chromatography with 10% MeOH in CH2CI2 as the eluent to afford 1-157 (35 mg) (m/z: 197.9 [M+]).
To a solution of 1-69 (50 mg, 0.1 mmol) in DMF (8 mL) are added 1-157 (24 mg, 0.12 mmol), Tetrakis (triphenylphosphine)palladium (0) (11 mg, 0.01 mmol) and 2M Na2CO3 (0.25 mL, 0.51 mmol). The mixture is heated to 100 °C for 1 hour in a microwave reactor. The mixture is cooled down and is extracted with H2O and EtOAc. The Z
195 combined organic layer is dried with MgSO4 and is filtered. The filtrate is concentrated and the residue is purified by silica gel flash column chromatography with 10% MeOH in CH2CI2 as the eluent to afford the title compound (26 mg).
Method 41:
Synthesis of 3-{l-[4-(2-Amino-pyrimidin-5-yl)-phenyil-l,2-dimethyl-propyl] [1,2,4] oxadîazol-5-ol (Example 88, table 1)
To a suspension of morpholine-4-carbonyl chloride (32.907 mg, 0.220 mmol) in DMF (1 ml) is added 1-21 (60.000 mg, 0.200 mmol). The reation mixture is stirred at room température for 20 mîns then Hunig’s base (0.038 mL, 0.22 mmol) is added and the reaction mixture is heated at 55°C for 1 hour then heated in microwave oven at 150°C for 30 mins. After this time, the reaction mixture is concentrated in vacuo. Purification of the crude by flash chromatography (SiO2, 0-10% MeOH in DCM) then pre-TLC (10% MeOH in DCM) yields Example 88 (23 mg) as a white solid; m/z 326.0 [M+H].
Final Compounds; Table 3
Example | Structure | Method | Rétention time (min) | m/z [M+ H]+ | LCMS meth od |
196
l | dd 1 ifji > XX a N fj> | 1 | 7.4 | 402.6 | A |
2 | dd M* :.^XX n=/ «A \X | 1 | 8.23 | 386.6 | A |
3 | AA NpX^ =/ Η,Ν^Χ ^A N^/ | 1 | 7.32 | 387.6 | A |
4 | ίΓ^τ^Γ^Νχ° d x N=/ | 1 | 7.66 | 401.2 | A |
5 | îTaVnx η-λι^α —d x N=/ | 1 | 7.51 | 401.6 | A |
197
6 | ΗΟ'^'Υ· Η/Γ | x y Ν | A | A Ν:=^/ | 2 | 6 | 416.6 | A |
αα | Y -Ν y s ι 0 | |||||||
7 | Ν' | Ύγ | AU | Ν=Υ | 1 | 7.98 | 421.5 | A |
II Η,ΓΤ | A Ν | Ο | ||||||
Ν-’-’/ | ||||||||
Cf | ||||||||
AT | χ yy χ I ° | |||||||
8 | Χγ'' | N==V | 3 | 8.04 | 417.6 | A | ||
A Ν | ο | |||||||
Ν=/ | ||||||||
ο— | ||||||||
ΓΤ | X. -Ν I /° | |||||||
9 | τΓ | γγ- | ΑΑ | Ν=/ | 3 | 6.55 | 403.5 | A |
II ΗΖΝ | y) Ν | Ο | ||||||
ν—y Η V | ||||||||
0 | ||||||||
Af | ||||||||
ΙΟ | ν' | γγ- | A | | ο Ν^Υ | 4 | 7.82 | 417.6 | A |
η3ν^ | yfi Ν | Αι | ||||||
Ν=/ |
198
11 | A J h2n n | o | Xi, y r X N=A °-b | 5 | 6.75 | 417.6 | A |
12 | 17 h2n n | o | XX -N 'rp' x l ° °=Q N-JZ H | 4 | 6.37 | 403.5 | A |
13 | AV | o | XA^\ l ° nX | 5 | 7.55 | 417.5 | A |
AJ H2N N | 0 | ||||||
—o | |||||||
14 | A | AX r x 1 0 1 N=A | 5 | 5.87 | 390.6 | A | |
H2N N | A N / | ||||||
15 | AV A J h2n n | Ό | XX^N X nX XA VN 1 | 5 | 5.74 | 390.6 | A |
199
16 | Λ J η2ν ν | U | À-^N\ y P Ν-·=/ N / | 19 | 1.6 | 390.7 | B |
17 | Ν’ΧΑγχ AJ η2ν ν | J:. O | A^\ 1 0 N==/ o N / | 19 | 1.6 | 390.7 | B |
18 | Ν’Χ<Υτχ | A a A X 1 ° | 5 | 6.36 | 390.6 | A | |
Λ A η2ν ν | -A J N | ||||||
19 | A A X 1 0 N=/ | 5 | 5.46 | 376.6 | A | ||
JL A η2ν N | HN\ <J w | ||||||
20 | XT | A ^-N A x [ 0 N^y | 5 | 4.82 | 376.6 | A | |
Jj A h2n n | HN A |
200
21 | h2n' | n Λ | Tr | \A 1 0 Nx/ X \ /-N N H | 5 | 5.03 | 374.6 | A | |
'Tr A 'N | UxJ | ||||||||
Tr | 1 ° | ||||||||
22 | N I | Τγ | Λχ | A | 5 | 5.37 | 388.6 | A | |
H2n' | II | A 'N | X VN 1 | ||||||
χ | |||||||||
AT | |||||||||
23 | Nz II | Τγ | XJ | 1 θ NA/' | 18 | 5.48 | 376.6 | A | |
hX | II | A 'N | hn, u | ||||||
N' | |||||||||
J. | |||||||||
/4/ | ζγ | ||||||||
24 | N' [| | Τγ | XJ | l 0 «A | 18 | 5.48 | 376.6 | A | |
hX | II | A 'N | HN J | ||||||
N | |||||||||
25 | bT il | Τγ | \ /-N x 1 0 | 5 | 5.13 | 374.6 | A | ||
hX | II | . A N | O N H |
201
26 | J HaN | 7 | -G | X. ,-N ><> I 0 n=x A N I | 5 | 5.5 | 388.6 | A |
Aï | ||||||||
27 | Nx t | V | kj | I 0 nJ | 5 | 5.98 | 388.6 | A |
II h2n'^' | J 'N | ---N [ \ J N | ||||||
Πτ | JC __-N \x x l 0 | |||||||
28 | n' | VA | Μι/ | 5 | 4.8 | 388.6 | A | |
4 h2n | h N I | |||||||
JY | JC ^.n | 0 | |||||||
29 | H | AA | N-J | 5 | 5.78 | 399.6 | A | |
II | J ‘N | o | ||||||
N=J | ||||||||
Hr | JC -N x I 0 | |||||||
30 | J | Ά/ | “k | 9 | 2.32 | 432.2 | B | |
h2n^^ | J N | a N J | ||||||
/ |
202
203
36 | yyJyo X S/NH —-o | 11 | 2.61 | 473.4 | C |
37 | aXa [ ΪΓ T p -u./Az NM N \ h2n'^^'n<^ ξ \ | 5 | 2.31 | 373.2 | C |
38 | AifL N/yAJ h2nJ^X N—/ N—. L o \ | 12 | 5.42 | 458.4 | A |
39 | yyyNY nay/x/ η,ν-AJ y N—/ N—Λ , Ύ HO | 12 | 2.29 | 472.2 | C |
204
40 | KnA N—y N—, H \ HO | 12 | 2.15 | 458.2 | C |
41 | /-N \ n 'o hX^X À N—7 N—. A °^ / X ο X | 12 | 5.34 | 506.4 | A |
42 | Η/Γ N vJ N—-, H λ X | 11 | 2.33 | 459.4 | C |
43 | .AA. N J | 9 | 5.32 | 430.4 | A |
205
44 | Αχ tyr νγ N—, OH | 11 | 5.26 | 473.4 | A |
45 | /AU U U h U 'OH | 11 | 5.57 | 473.4 | A |
46 | itA b h2n n < H N / | 19 | 2.45 | 390.4 | C |
47 | Χζ /xJ\U n^:< X~Jn N / | 19 | 2.45 | 390.4 | C |
48 | 111° η2ν^Α θ N H | 19 | 2.01 | 374.4 | C |
206
49 | A. z n \ y A N Y< H,N \A \ A 2 X N N H | 19 | 2.01 | 374.4 | C |
50 | lÎlV'o b HjN'b'b N=/ NH A | 20 | 5.26 | 473.4 | A |
51 | A, _ rx°u NH Æ0H | 20 | 5.26 | 473.4 | A |
52 | fijr o *ύ η3ν^Α An NX I | 20 | 5.55 | 432.4 | A |
207
53 | 4 , .νΑ Ç1 | 20 | 5.55 | 432.4 | A |
54 | ΓΥ Ύ ο zX/ÎJ Μ;=/ n +q ν. | 20 | 5.32 | 430.4 | A |
55 | 4, ιΓΥιΥ= Ν-yM Νΐ< hF+ | 20 | 5.32 | 430.4 | A |
56 | /Χ,Α/Ν ιΤ +ύ ϊ+ s [il ] ο pAJ À Il A Λ—N Η,Ν'^'Ν'^ N==/ NH Aœ | 20 | 5.57 | 473.5 | A |
57 | 4 . ryv> /xAJ N=/ il J YN H2N N \ y N=J NH A-o„ | 20 | 5.57 | 473.5 | A |
208
58 | A Λ J HaN N | \^N yA x 1 0 N^=/ A A / | 5 | 5.9 | 390.3 | A |
59 | AA N/VJ y nK-V f çN Ar1 o | 9 | 4.97 | 459.6 | A | |
60 | Αλ» n^VaJ y h.n^n'' <o H f O | 9 | 4.74 | 445.5 | A | |
61 | 11° Va A aJ K H.N N < J, N / | 18 | 5.36 | 388.3 | A |
209
62 | A , | 18 | 5.36 | 388.3 | A | ||
A J η2ν n | U | ° N^/ \ _.-N N / | |||||
63 | AJ η2ν n | --'x c> U | ..N Ά l 0 N=s=/ X N < | 20 | 5.91 | 434.4 | A |
? °\ | |||||||
64 | Ν^ΑΖ A J h2n n | Z cJ | \ A l ° N^/ <n VN J | 20 | 5.91 | 434.4 | A |
r | |||||||
65 | A J h2n n | u | 1 ° n=A X VN / | 18 | 5.89 | 390.3 | A |
210
66 | Η2Ν· | V | A | 18 | 5.89 | 390.3 | A | ||
Άγ A ’Ν | £ | Ζ\χΝ ι ν' χ° J ν=Α VN ! | |||||||
ΑΑ | Γ χ | ||||||||
67 | Ν' I | Άγ | AJ | 1 θ | 5 | 2.27 | 376.4 | C | |
η2ν | II | Ν | Ρ VN 1 | ||||||
η | \ | ο | ||||||||
68 | ν' II | a | ΑζΑ | ν=Α | 5 | 1.16 | 362.4 | D | |
η2ν' | II | A Ν | )α Αα I | ||||||
Π | ΑΑν^Ν\ ι Τ ° | ||||||||
69 | π | Αγ | t'A | 5 | 1.08 | 346.4 | D | ||
Η,Ν' | Η | A Ν | A | ||||||
Ν Η | |||||||||
£ύ | ΑΓ Μ χΧ χ 1 /° | ||||||||
Νι | a | Αα | Ν=7 | ||||||
70 | η2ν^^ | A Ν | Ο | 12 | 1.19 | 446.4 | D | ||
Ν=/ | |||||||||
ΝΗ 0 | |||||||||
A |
211
71 | ,ΑγΖ -=Ζ «Y-b (Λ y 0=s οΑ | 12 | 1.15 | 480.4 | D |
72 | r ri ν'χ N/AU -Ζ Af θ ΝΗ X ΗΟ | 12 | 1.24 | 446.4 | D |
73 | fYpo νΑ Ν \ Η^Χ'-ΙΤ ξ Ν=/ ΝΗ V HO X | 11 | 1.18 | 447.4 | D |
74 | a N \__ ξ N=Z NH HO | 11 | 1.22 | 447.4 | D |
212
75 | ΑίΓγ^ο k /fl N y HO | 9 | 1.17 | 420.4 | D |
76 | A |J yyA/ nV H,rk^V \ 2 \ N | 9 | 1.19 | 406.4 | D |
77 | fi x 1 o NfJ =/ H/VZ θ N H | 18 | 1.21 | 376.4 | D |
78 | NV H N/Z^'N v^ Π2 M \ ^N N H | 18 | 1.21 | 376.4 | D |
213
79 | r 11 χο ζγ/Χζ νΑ η3ν'χ^Α x~^L 1 X ^Ν Ν Y ._--ΝΗ | 9 | 1.06 | 419.4 | D |
80 | /AXA Η ί ] Ύ V\ Ν^ΑΧΧ --Λ Λ J Η,Ν Ν | 10 | 1.28 | 369.4 | D |
81 | XX ΖΝ Η fYï Ά\ M-^yXX ν-ο \ | 10 | 1.4 | 383.4 | D |
82 | jlj^Vvv Λ J HjN Ν | 10 | 1.37 | 397.4 | D |
83 | N^Otrv7H Λ J η2ν Ν | 10 | 1.11 | 394.4 | D |
84 | ΑΧΧν AU Χ° Λ J Χ° HjN Ν y--Ν Ν---ζ Η | 10 | 1.12 | 422.4 | D |
214
85 | Η-,νΆ^ ' HO— O | 22 | 1.46 | 424.4 | D |
86 | pVrO-f HJ1 N | 10 | 1.37 | 478.5 | D |
87 | i T I V\ n^VaAa n-o \ VJ Y | 10 | 1.29 | 431.4 | D |
88 | 1 ï 1 o naJJ A A J °h h2n n | 41 | 1.26 | 326.4 | D |
89 | aAaA-n. f \ ffj\i An\7° Az^ N-— n ' n >r ° A J h2n n | 10 | 1.59 | 395.4 | D |
90 | Aj” v/A A n-X h2n'^xn^ \—o | 10 | 1.43 | 423.4 | D |
215 ί I
I j i j
91 | o a A J Ύ H2N N /--N N--' | 10 | 1.12 | 436.4 | D |
92 | AA A A A x N^AA »v A A>0H 0 | 22 | 1.43 | 410.4 | D |
93 | <VvN'' ^OAa h2n n \ Y°H 0 | 22 | 1.43 | 410.4 | D |
94 | ιτγγ\ Ν^γΜ nA Η,Ν^^Α ' \ 2—OH oz | 22 | 1.32 | 382.4 | D |
95 | rAA» nAa a H^'N^ H°~X\ O | 14 | 1.39 | 394.4 | D |
96 | 21 | 0.64 | 408.4 | D |
216
217
I ,!
218
104 | v v ' „γν- nX H00 * X N V -Nx | 18 | 2.3 | 473.4 | C |
105 | □ ^A'o /x/k/ NA jX 01 * X N V | 18 | 2.3 | 473.4 | C |
106 | /zzk/ N‘'r;-'/ fifi h ΙΨ V | 9 | 2.24 | 461.4 | C |
107 | /4Ax /=n XrA „.z7 Λη | 18 | 1.29 | 448.4 | D |
108 | z, A J Aoh H2N N | 18 | 1.29 | 448.4 | D |
219
109 | LA ^-N 1 Ο Y A ML Ο + '> 0 X | 6 | 1.67 | 493.4 | Ε |
110 | Αα ίΑ X η2ν ν ( \ '—Ν \ Η | 6 | 1.09 | 393.4 | Ε |
111 | /Μ/\Α MU 4 νΖ/Αθ Ο X | 6 | 1.68 | 493.4 | Ε |
112 | LA» Π I ι Ρ <λ Χμ ÀA HjN Ν \ / / | 6 | 1.72 | 493.4 | Ε |
113 | ΑαΑα 1 ι ο AJ X η2ν ν ( νη | 6 | 1.13 | 393.4 | Ε |
220
ll4 | α£ | 6 | 1.13 | 393.4 | E |
115 | r; ίΑ o n/AA hAa a N 1 1 | 18 | 4.97 | 459.4 | A |
116 | 4 ,/¾. AC ^-N iï ν' xo m=a n Λ h2n h' 4 J N 1 | 18 | 4.97 | 459.4 | A |
117 | .,a£ | 1 | 1.69 | 392.4 | D |
118 | Ai | 1 | 1.58 | 364.4 | D |
221
119 | ιΤνν' I T ο jûi ν5α η2ν ν ( \ | 5 | 1.68 | 392.4 | D |
120 | Π Τ Τ ° η2ν ν ( \ | 1 | 1.73 | 406.4 | D |
121 | ζ^κ/kJ ΝΑ η£ν'/^ν^ \~3ν Ν ! | 18 | 2.5 | 402.4 | C |
122 | □,. Xd -ν \ Ιι χ ο /Αν νΑ η2ν^Α 4~Λ Ν ! | 18 | 2.5 | 402.4 | C |
222
P ! i Ί .1 i i
123 | y>^ JA. Λ (y Tr zvU A I J A hAA J N=/ NH < | 18 | 1.33 | 461.4 | D |
124 | na° A J A H2N N ξ 2 n-=7 NH $ | 18 | 1.33 | 461.4 | D |
125 | yOiA>-CA Λ J HjN N | 7 | 4.03 | 430.1 | F |
126 | jXyA NyA/ nA n | 7 | 3.47 | 376.1 | F |
127 | îaXaO NyA> Y A\ A J V h2n n | 7 | 4.92 | 437.1 | F |
223
128 | Λ J H.N N | 7 | 4.54 | 412.1 | F |
129 | rAvO N-0 η2ν'^''Ά | 7 | 4.02 | 388.1 | F |
130 | Au N +γ | 7 | 4.92 | 393.1 | F |
131 | rruMX “X -'' | 7 | 4.6 | 407.1 | F |
132 | n%-o N X | 7 | 4.07 | 377.1 | F |
133 | .A'yXX.- /Ύ ni « y^v«H N(/^a> “-v y | 7 | 4.13 | 404.2 | F |
134 | ί T IK- jCjJ h2n n | 10 | 3.94 | 353.2 | F |
224
135 | JT | 8 | 4.65 | 472.1 | F |
136 | îPjy J N-J F Aï | 8 | 4.87 | 455 | F |
137 | ήχο AÏ HjN N | 8 | 3.74 | 388.1 | F |
138 | rrVy-O xu «v AÏ k2n n | 8 | 4.26 | 394.1 | F |
139 | N A A J h2n n | 7 | 4.36 | 393.1 | F |
140 | Χχζχ /°1 r T Ύ y-O Xk -ο γ A J H;N M | 8 | 4.3 | 391.1 | F |
141 | iyVvb XyA/1 nA s | 8 | 4.59 | 407.1 | F |
225
142 | N^JU Α^Άτ aJ Η/Γ Ν | 13 | 3.62 | 447.1 | F |
143 | ^\Αχγ-Ν /=Ν „ -γΜ ζΚ-Γ | 7 | 4.85 | 387.1 | F |
144 | / JA /VN r ît τ v/ i '' / \<^n za >w N-o A J Η,Ν N | 13 | 3.06 | 489.3 | F |
145 | A/ A—oh ^-N / ΠτΥνΑ n/a JU n^o | 15 | 4.35 | 436.2 | F |
146 | Av n^az «g hAA | 7 | 3.73 | 376.1 | F |
147 | V-o JA | 7 | 3.87 | 388.1 | F |
148 | y fïVvO N | 7 | 4.37 | 464.1 | F |
226
149 | 7 | 4.28 | 464.1 | F | |
150 | Υχ aJ HZN N | 7 | 2.92 | 407.2 | F |
151 | A) H.N N | 7 | 3.57 | 402.2 | F |
152 | nJy-O /yU < V N | 7 | 4.23 | 402.2 | F |
153 | aY AV | 7 | 4.72 | 421.1 | F |
154 | A'jFaCV0 AJ Ά A A J H,N n | 7 | 3.02 | 404.1 | F |
155 | iyJyCH jCj H,N N | 7 | 4.33 | 418.1 | F |
227
156 | fAz «n H2N'X^'A | 7 | 4.41 | 350.2 | F |
157 | / HO A - A Λ J HZI< N | 7 | 3.65 | 417.2 | F |
158 | nrVo naJU h2n^Z C°x | 13 | 5.91 | 434.4 | A |
159 | /xJZ/N /SSN αΛ*Α A J Ah H2N N | 13 | 4.06 | 448.3 | F |
160 | A Tr x o Xîj à vu O'^'OH | 16 | 3.93 | 462.2 | F |
161 | ii+y-Cl.__ A -· l-ÇN N | 13 | 3.91 | 432.2 | F |
228
162 | ί-'''AsAAzj Γι τ>- ' Λ Π 1 Το ν^/ ηΧγΤ \\ ν=Α Ν—, Η \ ν~Ό \ | 11 | 4.06 | 461.3 | F |
163 | ώ Nb ΗΖ \-χ Q \ | 11 | 3.12 | 486.3 | F |
164 | Νζ/0 Λ J Y Η,Ν N Α. ι ' // ηΧΝ~Ν ηοΑο | 16 | 4.04 | 476.2 | F |
165 | rfYy-Q ° /Α Η2Ν'^ΧΝΧ | 17 | 3.97 | 417.2 | F |
166 | X/ r ° ΗΖΝ Ν | 17 | 3.79 | 421.1 | F |
229
167 | (Xybb N-y H,nA-nA | 17 | 3.6 | 407.1 | F |
168 | J! J A xV / Γ° 0 | 21 | 1.37 | 443.4 | E |
169 | bb fYY \ «AJ γ —N yo | 21 | 1.39 | 436.4 | E |
170 | bX^ .XX j \ 0=r 0 | 21 | 1.42 | 472.4 | E |
171 | Abx h γ ύ ύ y-\ n-oz x—-\ JA /' | 10 | 1.1 | 396.4 | E |
230
172 | XX HjN N | -U | X NX/ > | 27 | 1.06 | 458.4 | H | |
ΧΎ | X. -N | |||||||
173 | XX HfN N | ÂJ | NA^/ A A-, A | X0H | 27 | 0.66 | 445.3 | G |
174 | Xb H?N N | £r | A CX A | '—'OH | 27 | 0.82 | 446.4 | G |
175 | ÎJ hLN N | XX | ^XfAN\ U/ H N A | ^OH | 26 | 0.86 | 446.4 | G |
176 | .N £ΐ HjN N | A | À A X K N Ί | 26 | 0.78 | 459.4 | G | |
A- 0 | r |
23!
232
182 | fl T i x° /V/\A N5=y V h N k< | 34 | 1 | 445.4 | H |
183 | A ?r A s 1 « 0 ' A 1 | 27 | 0.68 | 432.4 | G |
184 | xkV HX N A ,.tJ_. N | 26 | 0.85 | 389.5 | G |
185 | z\ Xk /-N X Ar rri x Vf H,N N A N | 26 | 0.69 | 401.6 | G |
186 | vC V i|j \ /v h2n / \ ’N ? OH | 21 | 1.1 | 438.4 | E |
233
187 | 1 ' 0 'γΝγ\ζ A N | 26 | 0.9 | 403.4 | G |
188 | JA Il ,,Xj o, Λ | 26 | 0.74 | 445.1 | G |
189 | \ 0 1 | 26 | 0.94 | 446.1 | G |
190 | aXa AJ nX «Α~'Ζ N J^-nh2 | 37 | 0.98 | 417.4 | H |
191 | ZX/V'1’ jCX j Hsrr n ,n. \ o 1 | 26 | 0.9 | 433.3 | G |
234
192 | _-N ιίΥΥ 'ο n==/ h/AA '----N Anhj 0 | 21 | 1.31 | 437.4 | E |
193 | jm A/V AJ HjN N | 29 | 1.15 | 479.4 | E |
194 | rA ZA y xJ h π2ν N < n N y '7 0 ! | 35 | 1.19 | 503.4 | H |
195 | Aj1 /—z zH X | 23 | 0.59 | 470.3 | G |
235
196 | h2n | Af | A. A AA x T /° nA C N=^ < | N \\ | 23 | 1 | 470.4 | D | |||
A x N | A/ | ||||||||||
N- A | ) N H | ||||||||||
0 | P | /A M \ 'v | x P | ||||||||
un'' | JA,--- | J Ni=: | ( | ||||||||
197 | H | y | 36 | 0.59 | 475.3 | G | |||||
Η,Ν | AA N | ( N | M | ||||||||
V | J | ||||||||||
II 0 | |||||||||||
ΓΎ | X A AA x 1 ° | ||||||||||
198 | A' | A | N- C | 21 | 1.49 | 451.4 | E | ||||
h2n | d N | γ> | V | ||||||||
A^x 1 P | |||||||||||
199 | jiA | A/ | JIJ | nsA | 21 | 1.29 | 408.4 | E | |||
h2n | A | A N | \ N— C | 3 N H | ~o |
236
200 | NX J | Αγ A 'N | Cr | Α,ν T ° t | OH | 21 | 1.29 | 381.4 | E |
Ay | A. ^-N Z-Z x | ||||||||
1 I | 1 o | ||||||||
201 | NX II | Aj | ££ | NH / | 21 | 1.42 | 423.4 | E | |
X> | |||||||||
hjA | VN | é | ) o | ||||||
A/ | zz\ | ||||||||
T | 1 0 | ||||||||
202 | rr | A | N===/ | 21 | 1.36 | 422.4 | E | ||
„ A | A | /A | |||||||
Η2Ν | N | W | =0 | ||||||
\ | |||||||||
ZA | Ά --n X x | ||||||||
il 1 | l ° | ||||||||
203 | Αγ- | ££ | 31 | 1.34 | 395.4 | E | |||
A | A | Λ | > | ||||||
h2n | 'N | $ | Ah | ||||||
A. ..n | |||||||||
ZA | |||||||||
1 I | T ° | ||||||||
204 | N | Αγ | W | 32 | 1.43 | 377.4 | E | ||
A | N- | -η | |||||||
H2N^ | 'N | < | 3 |
237
205 | λ. JA Υγ a χ o /AJ A A /nA HjN N / \ OH | 32 | 1.3 | 407.4 | E |
206 | na3*A p «z/ b N | 25 | 1.4 | 430.4 | D |
207 | ιγΑο ,A A A b N J | 25 | 1.3 | 430.2 | D |
208 | ζΥζΥ®Ν λ q 04~ ° o | 21 | 0.8 | 471.3 | G |
209 | HO | 21 | 0.82 | 423.3 | G |
238 i
ί i
I !
i
210 | x4 X X >r Ύ' x 1 o ( \) N^/ O '—N H | 23 | 0.85 | 469.4 | H |
211 | xOAVCxy- AJ N | 29 | 0.63 | 466.4 | G |
212 | N^Ay+Xz A^ /~\ H?N N ΐ \ OH | 21 | 0.87 | 437.4 | G |
213 | JC* HjN | 21 | 0.75 | 436.3 | G |
239
214 | A, z | 23 | 0.68 | 470.3 | G | |||
1 HaN | .n. y w | A | Xx AA \ 1 P nA Q | |||||
A | ||||||||
V H | ||||||||
L | ||||||||
va | /À \ o | |||||||
N K | Ά | AA | ||||||
215 | 11 Η,ΙΨ | x y> N | )a Vn / | 34 | 0.7 | 471.4 | J | |
0 | ||||||||
VY | X. γ+ \ l z° | |||||||
216 | Ν'* | ύζ | Ab | nY | 31 | 0.89 | 423.3 | G |
J Η.8Γ | N | Q | ||||||
[Ah | ||||||||
Ay h T | ZX yU \y x l 0 | |||||||
217 | N' A H?N | 'Άχ -A | Ab | Q | 28 | 0.7 | 422.4 | G |
NH / |
240
218 | II,M J— >>' ( ) N--- / | 21 | 1.14 | 436.4 | E |
219 | aaa /JU b „AJ q a°h o | 30 | 1.39 | 437.4 | E |
220 | \ H S° AJ A O N ν' n 0 \ | 35 | 1.17 | 515.4 | F |
241
221 | h2Z | I | -0 N | O | %x* >Ax\ p | 35 | 1.17 | 515.4 | F | |
N^X C Y' ZN ...o O \ | 1 | |||||||||
ΓΤ | XX \ l 0 | |||||||||
222 | NX | Αχ | N=z^ | 28 | 0.69 | 408.4 | G | |||
h2n'' | X N | C | ) hh2 | |||||||
Ύν | ||||||||||
ΓΤ | Z. N XX \ l ° | |||||||||
223 | Z | XZ | Αχ | 33 | 1.36 | 409.4 | E | |||
HjN | [I | X n | N — Y | > OH | ||||||
J..., | ||||||||||
ιΓΥ | XA l 0 | |||||||||
224 | Z | Xz | Ax | NY/^ | 33 | 1.36 | 409.4 | E | ||
h2n' | II | X N | N-— C | OH |
242
243
229 | AA AA -N \ Il xo AaA/ nF n Xf \ o / | 24 | 1.32 | 398.4 | D |
230 | ΓγΎο nAJ -A «AV o N Y NH | 18 | 1.29 | 445.4 | D |
231 | F< «Z nAA Λ h2An O Y ^-NH | 18 | 1.29 | 445.4 | D |
232 | z\zKa\ Γ iT ν' x° AxAU NF N AA \ h2n/^x‘n/ ξ 0 / | 24 | 1.3 | 368.4 | D |
244
233 | ίι ίΓ 'i Xz\j χ/ Λ J N-X G/ / V OH | 18 | 1.3 | 407.4 | E |
234 | a, vOa> A J J-a H;N'X*X'N / \ OH | 18 | 1.3 | 407.4 | E |
235 | [f^|ï N'o Q OH | 21 | 0.87 | 435.3 | G |
236 | X x X \ Il 1 l o N^JU X A J /H h2n n /r~~< N--' / | 21 | 1.11 | 422.4 | E |
245
237 | h2n' | aJ N | X | A A | AX -n ν' 19¾ c | \ 0 ( NH / | 21 | 1.33 | 423.4 | E |
/— HO | ||||||||||
238 | H A | N'UU xJ N | c | \A\ 1 ° ς | ) OH | 31 | 1.35 | 421.2 | E | |
f | Ά | O \ | ||||||||
239 | c N H | I XX N | A | N | V x-N\ Ί | 26 | 0.67 | 500.3 | G | |
χΧ CT | W 1 | |||||||||
240 | H/i | 1 i y J N | UX Y | X | 26 | 0.72 | 473.3 | G | ||
/ | M |
z
246
241 | rA Η | ο Ν | 0 | A V 1 CV | Y | 26 | 1.15 | 484 | Η |
ΑΎ | >C Αί> 1 ° | ||||||||
242 | Ζ Ν— Η | Ο Ν | ΛΑ | ΝΑ? Η 4 | 26 | 1.98 | 482.3 | Η | |
A | 1 | ||||||||
ιΓΎ | | ρ | ||||||||
243 | 1= | υ | ΛΑ | ~χ | 26 | 0.81 | 4763 | G | |
η/γ | A | ν\ | |||||||
b | 1 | ||||||||
ΑΧ | *C A 0 | ||||||||
244 | oc | ΑΑ | X | 26 | 1.01 | 472.2 | D | ||
Η/Γ | 43 Ί | ||||||||
X | 1 | ||||||||
ΑΎ | ___,Ν Ο | ||||||||
245 | J | ΟΧ | Αα | X | 26 | 1.16 | 473.4 | D | |
Η,Ν | VS | ||||||||
b | Αγ 1 |
247 i l i j I
J
246 | y fY ' '° N 1 OAZ | 26 | 1.38 | 526.2 | D |
247 | N-Q <cX 1 | 26 | 0.85 | 483.3 | G |
248 | XX0 A X h2n n / \ OH | 32 | 0.59 | 406.3 | G |
249 | h H VNz | 26 | 0.89 | 487.3 | G |
250 | aXa -=/ ArAi CL X 1 | 26 | 0.87 | 499.3 | G |
248
251 | ΗΓΓ 1 | X Ν 1 1 | 26 | 0.62 | 472.3 | D | ||
ίΧ Ν | υ | |||||||
ίΧη | JX _/-Ν ' X | |||||||
I | Ο | |||||||
χ·'.....Α | Ν^γ/ | 32 | ||||||
252 | ΛΑ | /-\ | 1.08 | 436.2 | Ε | |||
η2ν | Q ; | |||||||
< ΟΗ | ||||||||
υύ | ζΧ\ | |||||||
I | [ ζ° | |||||||
253 | Λ | Ά | AJ | 26 | 1.32 | 413.3 | Η | |
Ν' Η | Ν | ο | ||||||
τ | 1 Ζ° | |||||||
X | ||||||||
254 | L | A J | /X | 18 | 0.66 | 500.1 | G | |
Η | 4 Α Ν 1 | |||||||
A | ||||||||
UUA | \ | |||||||
1 T | 1 ο | |||||||
ΑΧ- | χχ | Ν^/ | ||||||
255 | c | A a | 18 | 0.66 | 500.3 | G | ||
η' Η | 'Ν'' | “ 1 0^../ |
249
J
256 | ΑΧ vk | 26 | 1.32 | 413.3 | H |
257 | /A n/LXJ «Y A CL 1 1 | 18 | 0.72 | 473.3 | G |
258 | 4 K ^-N’/ N 1 □>A 1 | 18 | 0.72 | 473.3 | G |
259 | /ΤγΑγ/Πχ Ju S j <”ΤΤ O | 32 | 1.32 | 469.2 | E |
260 | UC XXlz XX^ /A η/γΆ / \ / | 21 | 1.14 | 410.4 | E |
250
261 | .,ΛΖ '---N Z | 21 | 1.16 | 450.4 | E |
262 | OH | 21 | 1.37 | 409.4 | E |
263 | A^f HSN N | 27 | 1.34 | 429.3 | H |
264 | zAa\/N\ aA Z '---N λ~ | 21 | 1.16 | 436.4 | E |
265 | . Of HïN n VN-fX | 26 | 0.8 | 430.3 | G |
251
266 | A A2 / A J | 21 | 0.63 | 434.4 | G |
267 | A O '---N H | 23 | 0.61 | 470.4 | G |
268 | Pa jCa^ A\\ h2n n \ / N=/ O 1---N H | 23 | 0.53 | 469.4 | G |
269 | PP | 21 | 0.82 | 465.4 | G |
252
X | |||||||||
ΆΑ^ | γΧ X | ||||||||
fi | l 0 | ||||||||
270 | Y | 21 | 0.93 | 423.3 | G | ||||
A | A | /N-\ | |||||||
Η,Ν N | o | ||||||||
0—. | |||||||||
Fy | 1 .·'' XC X XX x | ||||||||
[ T | 1 0 | ||||||||
271 | N'' II | Ax | T | 9 | 0.87 | 414.4 | D | ||
II | X | F | 1 X | ||||||
h2n | Ή | \ N 4 | |||||||
AZ xn | Y-n | ||||||||
272 | JO | y y | — N yN \ | —OH | 30 | 0.61 | 452.3 | G | |
ν-Ύ | N-o | ||||||||
O | |||||||||
H.N N | |||||||||
AAA | A^n | ||||||||
1 T | 1 /° | ||||||||
273 | -N\/ | aJ | N=A | 26 | 2.02 | 412.3 | H | ||
FY | Y | ||||||||
SA H | XN N | ||||||||
X | |||||||||
JA X XX x | |||||||||
i I | 1 ° | ||||||||
274 | Αχ | -S.x:J | 32 | 1.23 | 379.4 | E | |||
jl | χ | ||||||||
X | 7 | ||||||||
h2n | n | Y | ( OH |
253 ί I ί | !
275 | vA-'J ç. ^γο | 26 | 1.38 | 477.4 | D |
276 | fÇV'o a η,ν^ν^ C? P OH | 31 | 0.71 | 393.2 | G |
277 | lirVo XV V F N NH2 < ,¾ ^γο -A | 38 | 0.93 | 476.3 | D |
278 | •aXa l ° JJ A ç> | 38 | 0.88 | 476.3 | D |
279 | Aq AAV h H V 1 ,Αγ | 26 | 0.97 | 501.3 | G |
254
280 | ί Ηϊ | Ύ- ’Ν | A | φ | 26 | 0.63 | 472.3 | D | ||
U | A N ’ A | |||||||||
ί F | |X | iï | < -h-N b^ x° | |||||||
281 | Γ I | X | A. | H | b | 26 | 0.97 | 526.6 | D | |
A | 4 A Ί | |||||||||
cr | V 1 | |||||||||
if | xy | X, _^N yX x l /° | ||||||||
282 | ιΡί | A | N^/ | 18 | 0.62 | 406.3 | G | |||
Η,Ν^ | A A N | C | > OH | |||||||
A | ||||||||||
if | γ | AA I o | ||||||||
283 | N ^/ | 18 | 0.62 | 406.3 | G | |||||
η2ν^ | A N | <: | OH | |||||||
j | I /° | |||||||||
284 | Ν' Η | o N | A. | A N 1 A | 26 | 1.28 | 484.3 | H |
255
285 | vx N1 | 26 | 0.76 | 473.3 | D |
286 | 1 ' /° M2=< CX N \ | 26 | 0.89 | 402.2 | G |
287 | j HO* | 32 | 1.31 | 407.2 | E |
288 | kVk'. o au a «A4 0 HO | 32 | 1.31 | 407.2 | E |
289 | v fFv> H,N^SZ ζ J N 1 | 26 | 2.35 | 527.2 | H |
290 | N - | 26 | 1.1 | 478.3 | G |
256
291 | Ν1 1 | 26 | 0.79 | 476.3 | G |
292 | ΖυΑ' Η,Ν Ν ' Ν 1 Αζ 1 | 26 | 0.64 | 472.3 | D |
293 | f Γγν·ο „W V η2Α< AJj Ν' Ύ | 26 | 0.83 | 477.3 | D |
294 | π2ν n <Ç?N -Νχ | 26 | 0.88 | 484.2 | D |
257 .ι i
J •f i ;
295 | ArY/0 o r | 39 | 0.83 | 484.2 | D |
296 | xr N1 -X | 40 | 0.85 | 483.3 | D |
297 | ZX JA. /N ίΐΊΓ Z ïr /O» h2n n \---/ | 32 | 0.82 | 435.3 | G |
298 | naaj a h2AAf a N £o X | 26 | 0.85 | 491.3 | D |
Assessment of Biological Properties
1. Binding Assay
Compounds are assessed for the ability to bind to FLAP in a binding assay that measures compound-specific displacement of an iodinated (,25I) FLAP inhibitor via a Scintillation
258
Proximity Assay format (adapted from S. Charleson et al., Mol. Pharmacol., 1992, 41, 873-879).
Cell pellets produced from sf9 insect cells expressing recombinant human FLAP protein are resuspended in buffer A [15 mM Tris-HCl (pH 7.5), 2 mM MgCl2, 0.3 mM EDTA, 1 mM PMSF]. The cells are lysed with a Dounce homogenizer and the material is centrifuged at 10,000 x g for 10 minutes. The supematant is then collected and centrifuged at 100,000 x g for 60 minutes. To préparé membrane protein for an assay, an alîquot of the 100,000 x g pellet is resuspended in 1 ml of buffer A, Dounce homogenized, and finally subjected to polytron mixing (30 seconds). Membrane protein (25 μΐ, 5 pg) is mixed with WGA SPA beads (Amersham) and stirred for lh. To an assay plate (Perkin Elmer FlexiPlate) is added 25 μΐ of test compound prepared în Binding buffer [100 mM Tris (pH 7.5), 140 mM NaCl, 5% glycerol, 2 mM EDTA, 0.5 mM TCEP, 0.05% Tween 20], 25 μΐ of [125I]L-691,831 (an iodinated analog of MK-591, Charleson étal. Mol, Pharmacol., 41, 873-879,1992) and finally 50 μΐ of the bead/protein mixture, (final concentrations: beads, 200 pg/well; protein, 5pg/well; [125I] probe, 0 08 nM/well(17 nCi/well). The plates are shaken for 2h before reading on a Microbeta plate reader. Non-specific binding îs determined by the addition of 10 μΜ cold L-691,831 compound.
In general, the preferred potency range (IC50) of compounds in the above assay is between 0.1 nM to 10 μΜ, the more preferred potency range is 0.1 nM to 1 μΜ, and the most preferred potency range is 0.1 nM to 100 nM.
2. Whole Blood Assay:
Compounds are additionally tested in a human whole blood assay to détermine their abîlîty to inhibit the synthesis of LTB4 in a cellular system. Compounds are combined with heparinized human whole blood and incubated for 15 minutes at 37°C. Calcimycin (20μΜ final, prepared in phosphate-buffered saline, pH 7.4) is then added and the mixture is incubated for another 30 minutes at 37°C. The samples are centrifuged for 5 S
259 min at low speed (1500 x g) and the plasma layer is removed. Plasma LTB4 concentrations are then measured using an antibody-based homogenous time-resolved fluorescence method (CisBio, Bedford, MA).
METHOD OF USE
The compounds of the invention are effective inhibitors of 5-lipoxygenase activating protein (FLAP) and thus suggest they inhibit leukotriene production. Therefore, in one embodiment of the invention, there is provided methods of treating leukotriene-mediated disorders using compounds of the invention or their pharmaceutically acceptable salts thereof. In another embodiment, there is provided methods of treating cardiovascular, inflammatory, allergie, pulmonary and fibrotic diseases, rénal dîseases and cancer using compounds of the invention or their pharmaceutically acceptable salts thereof.
Without wishing to be bound by theory, by inhibitîng the activity of FLAP, the compounds of the invention block the production of LTs resulting from the oxidation of arachidonic acid by 5-LO and subséquent metabolism. Thus, the inhibition of FLAP activity îs an attractive means for preventing and treating a variety of diseases mediated byLTs. These include:
Cardiovascular diseases including atherosclerosis, myocardial infarction, stroke, aortic aneurysm, sickle cell crisis, ischemia-reperfusion injury, pulmonary arterial hypertension and sepsis;
Allergie dîseases including asthma, allergie rhinitis, rhinosinusitis, atopie dermatitis and urticaria;
Fibrotic diseases including airway remodeling in asthma, idiopathic pulmonary fibrosis, scleroderma, asbestosis; /
260
Pulmonary syndromes including adult respiratory distress syndrome, viral bronchiolitis, obstructive sleep apnea, chronic obstructive pulmonary disease, cystic fibrosis, and bronchopulmonary dysplasia;
Inflammatory diseases including rheumatoid arthritis, osteoarthritis, goût, glomerulonephritis, interstitial cystitis, psoriasis, inflammatory bowel disease, inflammatory pain, multiple sclerosis, systemic lupus erythematosus, transplant rejection, inflammatory and allergie ocular diseases;
Cancer including solid tumors, leukemias and lymphomas; and
Rénal diseases such as glomerulonephritis.
For treatment of the above-described diseases and conditions, a therapeutically effective dose will generally be in the range from about 0.01 mg to about 100 mg/kg of body weight per dosage of a compound of the invention; preferably, from about 0.1 mg to about 20 mg/kg of body weight per dosage. For example, for administration to a 70 kg person, the dosage range would be from about 0.7 mg to about 7000 mg per dosage of a compound of the invention, preferably from about 7.0 mg to about 1400 mg per dosage. Some degree of routine dose optimization may be required to détermine an optimal dosing level and pattern. The active ingrédient may be administered from 1 to 6 times a day.
General Administration and Pharmaceutical Compositions
When used as pharmaceuticals, the compounds of the invention are typically administered in the form of a pharmaceutical composition. Such compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one compound of the invention. The compounds of the invention may also be administered alone or in combination with adjuvants that enhance stability of the compounds of the invention, facilitate administration of pharmaceutical compositions containing them in certain embodiments, provide increased dissolution or dispersion, increased antagonist activity, provide adjunct therapy, and the like. The compounds according to the invention may be used on their own or in conjunction with other active substances according to the invention, optionally also in conjunction with other /
261 pharmacologically active substances. In general, the compounds of this invention are administered in a therapeutically or pharmaceutically effective amount, but may be administered in lower amounts for diagnostic or other purposes.
Administration of the compounds of the invention, în pure form or in an appropriate pharmaceutical composition, can be carried out using any of the accepted modes of administration of pharmaceutical compositions. Thus, administration can be, for example, orally, buccally (e.g., sublingually), nasally, parenterally, topîcally, transdermally, vaginally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as, for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aérosols, or the like, preferably in unit dosage forms suitable for simple administration of précisé dosages. The pharmaceutical compositions will generally include a conventional pharmaceutical carrier or excipient and a compound of the invention as the/an active agent, and, in addition, may include other médicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, vehicles, or combinations thereof. Such pharmaceutically acceptable excipients, carriers, or additives as well as methods of making pharmaceutical compositions for various modes or administration are well-known to those of skill in the art. The state of the art is evidenced, e.g., by Remington: The Science and Practice of Pharmacy, 20th Edition, A. Gennaro (ed.), Lippincott Williams & Wilkins, 2000; Handbook of Pharmaceutical Additives, Michael & Irene Ash (eds.), Gower, 1995; Handbook of Pharmaceutical Excipients, A.H. Kibbe (ed.), American Pharmaceutical Ass’n, 2000; H.C. Ansel and N.G. Popovish, Pharmaceutical Dosage Forms andDrug Delivery Systems, 5th ed., Lea and Febiger, 1990; each of which is încorporated herein by reference in their entireties to better describe the state of the art.
As one of skill in the art would expect, the forms of the compounds of the invention utilized in a particular pharmaceutical formulation will be selected (e.g., salts) that possess suitable physical characteristics (e.g., water solubility) that are required for the formulation to be efficacious. P' *$ JAN 2013
262
CLA1MS
What is claîmed is:
Claims (16)
- What is claîmed is:wherein:R*and R2 are each independently hydrogen, C1.7 alkyl or C3.10 carbocycle, with the proviso that both R1 and R2 are not hydrogen;R3 is a 5-11 membered heteroaryl ring containing one to three heteroatoms selected from nitrogen, oxygen and sulfur, wherein the heteroaryl ring is optionally independently substituted with one to three groups selected from C1-5 alkyl optionally substituted with one to three halogen atoms, C1.5 alkoxy, Ci.3 hydroxy, halogen, hydroxy, -O-benzyl, oxo, cyano, amino, -NH-C3.6 carbocycle, Ci 6 alkylamino and C|<, dialkylamino;R4 îs hydrogen, C1.3 alkyl, halogen or nitrile;R5 is Ci_6 alkyl, C3.io carbocycle, 3-11 membered heterocycle, aryl, 5-11 membered heteroaryl, -C(O)-R6, hydroxy or -NR7R8, wherein each R5 is optionally independently substituted with one to three groups selected from R9, R10 and R*';R6 is C3_s heterocycle or NI 1-5-6 membered heterocycle, each optionally independently substituted with one to three groups selected from R9, Ri0 and R11 ; Z263R7and R8 are each independently hydrogen, 5-6 membered heterocycle optionally substituted with Ci_6 alkyl, C3.J0 carbocycle optionally substituted with hydroxy or Ci_6 alkyl;R9, Ri0 and R11 are independently selected from (a)-H, (b)-OH, (c) halogen, (d)-CN, (e)-CF (f) Ci /,alkyl optionally substituted with one to three -OH, -N(R12)(R13) , 3-6 membered heterocycle, Ci^alkoxy, Cj^alkoxy-O- C| 6alkyl, -CO2R12, -C(O)N(R12)(R13) or -S(O)nCi_6alkyl.(g) C; 6alkoxy, (h) -N(R12)(R13), (i) -SiO^Ct-ealkyl, (j) CO2R12, (k) -C(O)N(R12)(R13), (l) -S(O)2N(R12)(R13), (m) a 3-10 membered heterocyclic group optionally substituted with one to three Ci-e alkyl groups, (n’) oxo, (o) -C(O)-Ci_3 alkyl;R12 and R13 are each independently selected from -H, -Ci^alkyl, C(O)Ci_6aIkyl, and a 36 membered heterocyclic group, each of which is optionally independently substituted with one to three Ci.·,alkyl groups, -OH, Cj_6alkoxy, -C(O)N(R14)(R15), -S(O)nCi.6alkyl, CN, a 3-6 membered heterocyclic group, -OCi^alkyl, CF3, or; X264R12 and R13 taken together with the nitrogen ring to which they are attached form a heterocyclyl ring optionally substituted with one to three OH, CN, -OCi-6alkyl or oxo;R14 and R15 are each independently selected from -H and -Ci^alkyl;n is 0, 1 or 2;or a pharmaceutically acceptable sait thereof.
- 2. A compound according to claim 1, wherein:Rl and R2 are each independently hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert. butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl or cylohexyl, with the proviso that both R1 and R2 are not hydrogen;R3is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, thienyl, furanyl or thiazolyl, wherein each heteroaryl ring is optionally independently substituted with one to three groups selected from C1.3 alkyl optionally substituted with one to three halogen atoms, C1.3 alkoxy, Ci_3 hydroxy, halogen, hydroxy, -O-benzyl, oxo, cyano, amino, -NHC3^carbocycle, Ci/ alkylamino and C1.3 dialkylamino;orR3 is pyridooxazinyl, dihydro-pyridooxazinyl, dihydro-pyrrolopyridinyl, pyrrolopyrîdinyl, pyrrolopyrazinyl, wherein each heteroaryl ring is optionally independently substituted with one to three groups selected from C1-3 alkyl optionally substituted with one to three halogen atoms, Cj_3 alkoxy, C].3 hydroxy, halogen, hydroxy, -O-benzyl, oxo, cyano, amino, -NH-C3^ carbocycle, C1.3 alkylamino and C1.3 dialkylamino;R4 is hydrogen, methyl or fluoro;R5 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, teri-butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azetidinyl, pyrrolidînyl, X265 tetrahydropyranyl, pyrrolyl, thienyl, furanyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, triazolyl, pyridinyl, pyrimidînyl, pyrazinyl, pyridazinyl, quinolinyl, isoquinolinyl, indolyl, pyrrolopyridinyl, pyrrolopyrimidinyl, -C(O)-RS, hydroxy or NR7R8, wherein each R5 is optionally independently substituted with one to three groups selected from R9, R10 and R11;R6 is piperidinyl, pîperazinyl, tetrahydropyranyl, morpholinyl, tliiomorpholiny! or -NHpiperadinyl each optionally independently substituted with one to three groups selected from R9, R10 and R11;R7and R8 are each independently hydrogen, 5-6 membered heterocycle optionally substituted with methyl, CA, carbocycle optionally substituted with hydroxy, or C1-5 alkyl;R9, R10 and R11 are independently selected from (a)-H, (b)-OH, (c) halogen, (d)-CN, (e)-CF (f) C i_<,alkyl optionally substituted with one to three -OH, -N(R12)(R13) , 3-6 membered heterocycle, C|.(, alkoxy, C,.,,alkoxy-O- Ci.&alkyl, -CO2R12, -C(O)N(R,2)(R13) or -S(O)nCi^alkyl, (g) Ci.6alkoxy, (h) -N(R12)(R13), (i) -S(O)nCr6alkyI, (j) -CO2R12, (k) -C(O)N(R,2)(R13), (l) -S(O)2N(R12)(R13), (m) a 3-8 membered heterocyclic group optionally substituted with one to three C-i 6 alkyl groups, /266 ! ι ί I ί τ Î (η’) οχο, (ο) -C(O)-Ci_3 alkyl;R12 and R13 are each independently selected from -H, -Cj^alkyl, C(O)Ci-6alkyl, and a 3-6 membered heterocyclic group, each of which is optionally independently substituted with one to three Ci^alkyl groups, -OH, C|/alkoxy, -C(O)N(R,4)(R15), -S(O)nCi.6alkyl, ·CN, a 3-6 membered heterocyclic group, -OCi^alkyl, CF3; or,R12 and R13 taken together with the nitrogen ring to which they are attached can form a heterocyclyl ring optionally substituted with one to three -OH, CN, -OC; alkyl or oxo;R14 and R15 are each independently selected from -H and C 1.4alkyl;n is 1 or 2;or a pharmaceutically acceptable sait thereof.
- 3. A compound according to claim 1 or 2, wherein:R1 and R2 are each independently hydrogen, methyl, ethyl, propyl, isopropyl, tert-butyl,1 2 cyclopropyl or cyclobutyl, with the proviso that both R and R are not hydrogen;or a pharmaceutically acceptable sait thereof.
- 4. A compound according to any of the claims 1-3 wherein:R3 is pyridînyl, pyrazinyl, pyridazinyl or pyrimidinyl, wherein each heteroaryl ring is optionally independently substituted with one to two groups selected from Ci_3 alkyl optionally substituted with one to three halogen atoms, Ci_3 alkoxy, Ci.3 hydroxy, halogen, hydroxy, -O-benzyl, oxo, cyano, amino, -NH-C3.6 carbocycle, Ci.5 alkylamino and Ci_3 dîalkylamino; or /267R3 is pyridooxazinyl, dihydro-pyridooxazînyl, dihydro-pyrrolopyridinyl, pyrrolopyridinyl, pyrrolopyrazinyl;or a pharmaceutically acceptable sait thereof.
- 5. A compound according to any of the claims l-4, wherein:R5 is methyl, ethyl, propyl, îsopropyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, azetidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, thîazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, isoquinolinyl, -C(O)-piperizinyl, -C(O)piperidinyl, -C(O)-morpholinyl,-C(O)-NH-piperidinyl, hydroxy or -NR7R8, wherein each R5 is optionally independently substituted with one to three groups selected from R9, R10 and R11;R7and R8 are each independently hydrogen, 5-6 membered heterocycle optionally substituted with methyl, Cj.6 carbocycle optionally substituted with hydroxy or C1-C5 alkyl;R9, R10 and R11 are independently selected from (a)-H, (b)-OH, (c) halogen, (d)-CN, (e)-CF (f) Ci^alkyl optionally substituted with one to three -OH, -N(R12)(R13) , morpholinyl, piperazinyl, Cj^alkoxy, Ci.3alkoxy-O- Ci_3alkyl, -CO2R12 or -C(O)N(R12)(R13), (g) C[.3alkoxy, (h) -N(R12)(R13), (i) -S(O)nCMalkyl, (l) C()?R'2, Z268 (k) -C(O)N(R12)(R13), (l) -S(O)2N(R12)(R13), (m) morpholinyl, piperazinyl, piperidinyl or oxetanyl each optionally substituted with a methyl group, (n’) oxo, (o)-C(O)-CH3;R12 and R13 are each independently selected from -H and Ci alkyl, wherein the alkyl group is optionally substituted with one to three - OH, Ci^alkoxy, -C(O)N(R14)(R15) or S(O)nC[.6alkyl;R14 and R15are each independently selected from -H and -Ci^alkyl;nis 2;or a pharmaceutically acceptable sait thereof.
- 6. A compound according to claim 1 or 2, wherein:R1 and R2 are each independently hydrogen, methyl, ethyl, propyl, isopropyl, toY-butyl, cyclopropyl or cyclobutyl, with the proviso that both R1 and R2 are not hydrogen;R3 is pyridinyl, pyrazinyl, pyridazinyl or pyrimidinyl, wherein each heteroaryl ring is optionally independently substituted with one to two groups selected from methyl, methoxy,-CH2OH, trifluoromethyl, bromo, chloro, fluoro, hydroxy, -O-benzyl, oxo, cyano, amino, -NH-C 3-6 carbocycle, Cy alkylamino and C1-3 dialkylamîno; or R3 is pyridooxazinyl, dihydro-pyridooxazinyl, dihydro-pyrrolopyridinyl, pyrrolopyridinyl, pyrrolopyrazinyl;R4 is hydrogen;R5 is methyl, ethyl, propyl, isopropyl, butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, azetidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, pyrazinyl, A269 pyridazinyl, quînolinyl, isoquinolinyl, -C(O)-piperazinyl, -C(O)-morpholiny], piperidinyl, hydroxy or -NR7R8, wherein each R5 is optionally independently substituted with one to three groups selected from R9, R10 and R11;R7and R8 are each independently hydrogen, piperidinyl optionally substituted with a methyl group, cyclohexyl optionally substituted with a hydroxy group, methyl or ethyl;R9, R10 and R11 are independently selected from (a)-H, (b)-OH, (c) halogen, (d)-CN, (e)-CF (f) Ci-6alkyl optionally substituted with one to three -OH, -N(R12)(R13) , morpholinyl, piperazinyl, Ci^alkoxy, Ci-3alkoxy-O- Ci_3alkyl, -CO2H or -C(O)N(R12)(R13), (g) C i_3 alkoxy, (h) -N(R12)(R13), (i) -S(O)2Ck2alkyl,0) CO?R)?, (k) -C(O)N(R12)(R13), (l) -S(O)2N(R12)(R13), (m) morpholinyl, piperazinyl, or oxetanyl each optionally substituted with a methyl group, (n’) oxo, (o)-C(O)-CH3;R12 and R13 are each independently selected from -H and -Ci^alkyl, wherein the alkyl group is optionally independently substituted with one to three -OH, Ci.6alkoxy, C(O)N(R14)(R15), or -SiOhCï-ealkyl;R14 and R15are each independently selected from —H and -Ci^alkyl;270 | or a pharmaceutically acceptable sait thereof.iI
- 7. A compound according to claim 6 immediately above, wherein:R1 is methyl, j 5 R2 is selected from methyl, ethyl, isopropyl, tert-butyl, cyclopropyl and cyclobutyl;1 or a pharmaceutically acceptable sait thereof.i i
- 8. A compound according to claim 6, wherein: R3 is selected from or a pharmaceutically acceptable sait thereof.
- 9. A compound according to claim 6, wherein:R5 is pyrazolyl optionally independently substituted with one to three groups selected 15 from R9, R10 and R11 ;or a pharmaceutically acceptable sait thereof.
- 10. A compound according to claim 6, wherein:R1 îs methyl,20 R2 is selected from methyl, ethyl, isopropyl, terZ-butyl, cyclopropyl and cyclobutyl;R3 is selected fromΗ2Ν h2n ,and Z1HOR4 is hydrogen,R5 is selected from271 or pharmaceutically acceptable salts thereof.
- 11. A compound according to ciaim 10, wherein:R2 is cyclopropyl or cyclobutyl;or a pharmaceutically acceptable sait thereof.
- 12. A compound according to claim 10, wherein:R2 îs selected from methyl, ethyl, isopropyl and /iAbulyl; or a pharmaceutically acceptable sait thereof.
- 13. A compound according to claim 6, wherein:R3 is selected from or a pharmaceutically acceptable sait thereof.
- 14. A compound according to claim 6, wherein: R3 is selected from /272 or a pharmaceutically acceptable sait thereof.5
- 15. A compound according to claim 10, wherein:R1 is methyl,R2 îs cyclopropyl;R3 is selected fromR4 is hydrogen,273 or a pharmaceutically acceptable sait thereof.
- 16. A compound selected from a group consisting of:
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/373925 | 2010-08-16 | ||
US61/492176 | 2011-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16316A true OA16316A (en) | 2015-05-11 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2606045B1 (en) | Oxadiazole inhibitors of leukotriene production | |
JP6995067B2 (en) | [1,2,4] Triazolo [1,5-a] Pyridinyl-substituted indole compound | |
EP2651930B1 (en) | Biarylamide inhibitors of leukotriene production | |
TWI471326B (en) | Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cfms inhibitors | |
US9174980B2 (en) | Heterocyclic compounds as inhibitors of leukotriene production | |
EP2885285A1 (en) | Pyrazole derivatives which inhibit leukotriene production | |
MX2012005518A (en) | Tricyclic pyrazol amine derivatives. | |
EP2609092A1 (en) | Oxadiazole inhibitors of leukotriene production | |
KR20090034958A (en) | Pyrazole derivatives as cytochrome p450 inhibitors | |
HUE029594T2 (en) | Trpv4 antagonists | |
EP2619196B1 (en) | Oxadiazole inhibitors of leukotriene production | |
KR20150135458A (en) | Novel pyridine derivatives | |
JP2016518389A (en) | Aldosterone synthase inhibitor | |
EP2619197B1 (en) | Oxadiazole inhibitors of leukotriene production | |
EP2809321B1 (en) | Phenyl-c-oxadiazole derivatives as inhibitors of leukotriene production for use in combination therapy | |
OA16316A (en) | Oxadiazole inhibitors of leukotriene production | |
OA16344A (en) | Oxadiazole inhibitors of leukotriene production. |